<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="e">
		<monograph id="1" status="active">
			<mono_name>ecallantide</mono_name>
			<info>
				<pronunciation>(ee-kal′an-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x210">Kalbitor</tradename>
				</tradenames>
				<class type="func"> Hematological agents</class>
				<class type="chem"> Kallikrein inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x31">
				<sec_title>Action:</sec_title>
				<para>Selectively, reversibly inhibits kallikrein within the inflammatory pathways, preventing excess production of bradykinin</para>
			</section>
			<section type="uses" id="sidelem4x36">
				<sec_title>Uses:</sec_title>
				<para>Acute attacks of hereditary angioedema (≥16 yr)</para>
			</section>
			<section type="contra" id="sidelem4x41">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to the drug or its components</para>
				<para>
					<bbw>Anaphylaxis has occurred after administrations (usually within first hour after dosing); drug should be administered only by health care provider with medical support available to treat anaphylaxis and hereditary angioedema; monitor patient closely</bbw>
				</para>
				<section type="none" id="sidelem4x56">
					<section type="none" id="sidelem4x57">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, child &lt;16 yr</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x62">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x70">
					<label>•</label>
					<sec_title>Adult/adolescent ≥16 yr<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x70">
							<item>
								<label>•</label>
								<para> 30 mg given as three 10-mg injections; give additional 30-mg dose within 24 hours if attack persists</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x74">
					<section type="none" id="sidelem4x75">
						<sec_title>Available forms:</sec_title>
						<para> Solution 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x80">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x84">
								<item>
									<label>•</label>
									<para>Using aseptic technique, withdraw 1 ml (10 mg) using a large-bore needle; change the needle on the syringe to a needle suitable for subcut inj (27 gauge recommended)</para>
								</item>
								<item>
									<label>•</label>
									<para>Inject into the skin of the abdomen, thigh, or upper arm</para>
								</item>
								<item>
									<label>•</label>
									<para>Repeat the procedure for each of the three vials (30 mg total dose); the injection site for each of the three injections may be in the same or different anatomic location (abdomen, thigh, or upper arm); there is no need for site rotation; individual injections should be separated by at least 2 inches and away from the anatomical site of attack</para>
								</item>
								<item>
									<label>•</label>
									<para>The same directions for administration apply if an additional dose is required within 24 hr; different injection sites or the same anatomical location as used for the first dose may be used</para>
								</item>
								<item>
									<label>•</label>
									<para>Visually inspect parenteral products for particulate matter and discoloration before administration</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x110">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x113">
					<section type="none" id="sidelem4x114">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, fever, headache, flushing</para>
					</section>
					<section type="none" id="sidelem4x119">
						<sec_title>EENT:</sec_title>
						<para> Nasopharyngitis</para>
					</section>
					<section type="none" id="sidelem4x124">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, diarrhea, nausea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x129">
						<sec_title>CV:</sec_title>
						<para> Hypotension, chest pain</para>
					</section>
					<section type="none" id="sidelem4x134">
						<sec_title>INTEG:</sec_title>
						<para> Injection-site reactions, pruritus, rash, urticaria</para>
					</section>
					<section type="none" id="sidelem4x139">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory tract infection</para>
						<para>
							<bbw>Assess: anaphylaxis; usually within first hr after dosing</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x154">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x157">
					<section type="none" id="sidelem4x158">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x166">
							<label>•</label>
							<sec_title>
								<route>To immediately report wheezing, cough, chest tightness, trouble breathing, dizziness, fainting, throat tightness, itchiness, hives, and swelling of tongue or throat</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x172">
							<label>•</label>
							<sec_title>
								<route>Inform patient that drug must be given by health care provider in a health care setting in case serious allergic reaction occurs</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>econazole</mono_name>
			<info>
				<pronunciation>(ee-koe′na-zole)</pronunciation>
				<class type="func"> Topical antifungal</class>
				<class type="chem"> Imidazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x188">
				<sec_title>Action:</sec_title>
				<para>Antifungal activity results from inhibiting cell-wall permeability</para>
			</section>
			<section type="uses" id="sidelem4x193">
				<sec_title>Uses:</sec_title>
				<para>Tinea corporis, cruris, pedis, versicolor; cutaneous candidiasis</para>
			</section>
			<section type="contra" id="sidelem4x200">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x205">
					<section type="none" id="sidelem4x206">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x211">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x214">
					<section type="none" id="sidelem4x215">
						<sec_title>Tinea corporis, cruris, pedis, versicolor</sec_title>
						<section type="none" id="sidelem4x223">
							<label>•</label>
							<sec_title>Adult/child<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x223">
									<item>
										<label>•</label>
										<para> rub into affected areas daily × 2 wk, or × 4 wk (pedis)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x227">
						<sec_title>Cutaneous candidiasis</sec_title>
						<section type="none" id="sidelem4x235">
							<label>•</label>
							<sec_title>Adult/child</sec_title>
							<para>
								<list id="lidelem4x235">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/child:</emphasis> rub into affected areas bid × 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x239">
						<sec_title>Available forms:</sec_title>
						<para> Topical cream/foam 1%</para>
					</section>
					<section type="none" id="sidelem4x244">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x247">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x252">
									<item>
										<label>•</label>
										<para>Do not use products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x257">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x265">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x265">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> apply to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x269">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x272">
					<section type="none" id="sidelem4x273">
						<sec_title>INTEG:</sec_title>
						<para> Burning, rash, pruritus, erythema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x278">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x283">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x286">
					<section type="none" id="sidelem4x287">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x295">
							<label>•</label>
							<sec_title>
								<route>Allergic reaction</route>
							</sec_title>
							<para>
								<list id="lidelem4x295">
									<item>
										<label>•</label>
										<para>: assess for hypersensitivity, product might need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x302">
							<label>•</label>
							<sec_title>
								<route>Infection</route>
							</sec_title>
							<para>
								<list id="lidelem4x302">
									<item>
										<label>•</label>
										<para>: assess for itching, peeling</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x306">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x310">
								<item>
									<label>•</label>
									<para>Decreased itching, peeling</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x316">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x319">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x324">
									<item>
										<label>•</label>
										<para>That product is for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x329">
									<item>
										<label>•</label>
										<para>To wash hands before and after use; to wash affected area and gently pat dry</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x337">
								<label>•</label>
								<sec_title>Cream</sec_title>
								<para>
									<list id="lidelem4x337">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Cream:</emphasis> to apply a thin film to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>econazole topical</mono_name>
			<section type="none" id="sidelem4x345">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="4" status="active" ru="yes">
			<mono_name>edetate calcium disodium (Rx)</mono_name>
			<info>
				<pronunciation>(ee′de-tate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x3560">Calcium Disodium Versenate</tradename>
				</tradenames>
				<class type="func"> Heavy-metal antagonist (antidote)</class>
			</info>
			<section type="confusion" id="sidelem4x362">
				<para>
					<confusion>
						<tradename id="tnidelem4x3620">edetate calcium disodium</tradename>
						<drug type="generic" refid="idelem4x3620">edetate disodium</drug>
					</confusion>
				</para>
			</section>
			<section type="uses" id="sidelem4x366">
				<sec_title>Uses:</sec_title>
				<para>Lead poisoning, acute lead encephalopathy</para>
			</section>
			<section type="contra" id="sidelem4x371">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, anuria, poisoning of other metals, severe renal disease, hepatitis</para>
				<para>
					<bbw>Child &lt;3 yr</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x386">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x389">
					<section type="none" id="sidelem4x390">
						<sec_title>Lead mobilization test (lead toxicity 25-45 mcg/dl)</sec_title>
						<section type="none" id="sidelem4x398">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x398">
									<item>
										<label>•</label>
										<para> 500 mg/m<emphasis style="sup">2</emphasis> over 1 hr or </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x410">
							<label>•</label>
							<sec_title>Child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x410">
									<item>
										<label>•</label>
										<para> 500 mg/m<emphasis style="sup">2</emphasis> over 1 hr or  as single dose or 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x420">
						<sec_title>Acute lead encephalopathy (blood levels &gt;70 mcg/dl)</sec_title>
						<section type="none" id="sidelem4x428">
							<label>•</label>
							<sec_title>Adult/adolescent/child/infant<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x428">
									<item>
										<label>•</label>
										<para> 1500 mg/m<emphasis style="sup">2</emphasis> as  over 12-24 hr in combination with dimercaprol  give 1st dose ≥4 hr after initial dimercaprol, when urine flow established</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>efavirenz (Rx)</mono_name>
			<info>
				<pronunciation>(ef-ah-veer′enz)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x4460">Sustiva</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nonnucleoside reverse transcriptase inhibitor (NNRTI)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x456">
				<sec_title>Action:</sec_title>
				<para>Binds directly to reverse transcriptase and blocks RNA, DNA polymerase, thus causing a disruption of the enzyme’s site</para>
			</section>
			<section type="uses" id="sidelem4x461">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with at least 2 other antivirals</para>
				<section type="none" id="sidelem4x466">
					<section type="none" id="sidelem4x467">
						<sec_title>Unlabeled uses:</sec_title>
						<para> HIV prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x472">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, moderate/severe hepatic disease</para>
				<section type="none" id="sidelem4x477">
					<section type="none" id="sidelem4x478">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children &lt;3 yr, renal/hepatic disease, myelosuppression, depression, seizures</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x483">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x492">
					<label>•</label>
					<sec_title>Adult and child &gt;40 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x492">
							<item>
								<label>•</label>
								<para> 600 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x499">
					<label>•</label>
					<sec_title>Child ≥3 mo, 32.5-39.9 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x499">
							<item>
								<label>•</label>
								<para> 400 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x506">
					<label>•</label>
					<sec_title>Child ≥3 mo, 25-32.4 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x506">
							<item>
								<label>•</label>
								<para> 350 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x513">
					<label>•</label>
					<sec_title>Child ≥3 mo, 20-24.9 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x513">
							<item>
								<label>•</label>
								<para> 300 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x520">
					<label>•</label>
					<sec_title>Child ≥3 mo, 15-19.9 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x520">
							<item>
								<label>•</label>
								<para> 250 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x527">
					<label>•</label>
					<sec_title>Child ≥3 mo, 7.5-14.9 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x527">
							<item>
								<label>•</label>
								<para> 200 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x534">
					<label>•</label>
					<sec_title>Child ≥3 mo, 5-&lt;7.5 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x534">
							<item>
								<label>•</label>
								<para> 150 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x541">
					<label>•</label>
					<sec_title>Child 3.5-≤5 kg</sec_title>
					<para>
						<list id="lidelem4x541">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Child 3.5-≤5 kg:</emphasis> 100 mg/day at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x545">
					<section type="none" id="sidelem4x546">
						<sec_title>Available forms:</sec_title>
						<para> Caps 50, 200 mg; 600-mg tabs</para>
					</section>
					<section type="none" id="sidelem4x551">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x555">
								<item>
									<label>•</label>
									<para>Give on empty stomach; give at bedtime to decrease CNS side effects</para>
								</item>
								<item>
									<label>•</label>
									<para>Caps may be opened, added to grape jelly to disguise peppery taste, or sprinkled on food, do not cut/break tabs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x566">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x569">
					<section type="none" id="sidelem4x570">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, impaired cognition, insomnia, abnormal dreams, depression, headache, dizziness, anxiety, drowsiness, odd feeling, depersonalization</para>
					</section>
					<section type="none" id="sidelem4x575">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> abdominal pain, <emphasis style="italic">nausea,</emphasis> hyperlipidemia, constipation, increased LFTs, vomiting, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x588">
						<sec_title>GU:</sec_title>
						<para> Hematuria, kidney stones</para>
					</section>
					<section type="none" id="sidelem4x593">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x600">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-5 hr, well absorbed, metabolized by liver; terminal half-life 40-76 hr; &gt;99% protein binding, excreted in urine, feces; concentrations higher in females and those of African, Asian, and Hispanic descent</para>
			</section>
			<section type="interactions" id="sidelem4x605">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x610">
						<item>
							<label>•</label>
							<para>Avoid use with boceprevir, delavirdine, rilpivirine; dosage change may be needed if given with telaprevir</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x618">
					<label>•</label>
					<sec_title>
						<route>Do not give together with benzodiazepines, ergots, midazolam, triazolam, pimozide</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antidepressants, antihistamines, opioids</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of both products—ritonavir, estrogens, anticonvulsants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of warfarin, statins (except pravastatin, fluvastatin)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of indinavir, amprenavir, lopinavir, oral contraceptives, ketoconazole, itraconazole, posaconazole, voriconazole, saquinavir, cyclosporine, tacrolimus, sirolimus, bupropion, sertraline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> efavirenz metabolism—CYP3A4 inhibitors (conivaptan, ambrisentan, SORAfenib)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> efavirenz effect—CYP3A4 inducers (carBAMazepine, rifamycins)</para>
				<section type="none" id="sidelem4x645">
					<section type="none" id="sidelem4x646">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> efavirenz level—St. John’s wort; do not use together</para>
					</section>
					<section type="none" id="sidelem4x654">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> absorption—high-fat foods</para>
					</section>
					<section type="none" id="sidelem4x661">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> cannibinoids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x672">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x675">
					<section type="none" id="sidelem4x676">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x684">
							<label>•</label>
							<sec_title>Pregnancy<route> Rule out pregnancy (D) before starting treatment; a type of contraception is needed, oral/non-oral contraceptives are decreased, use barrier methods also</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x687">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, product should be discontinued; monitor hydration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x695">
							<label>•</label>
							<sec_title>Serious skin reactions<route> Stevens-Johnson syndrome, toxic epidermal necrolysis, usually occurs during first 2 wk, mild rash may resolve within 30 days; severe skin reactions including blistering, fever, product should be discontinued immediately and corticosteroids started</route></sec_title>
						</section>
						<section type="none" id="sidelem4x701">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x701">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> Monitor CBC, blood chemistry, plasma HIV RNA, absolute CD4+/CD8+ cell counts/%, serum β<emphasis style="inf">2</emphasis> microglobulin, serum ICD+24 antigen levels, cholesterol, hepatic enzymes</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x711">
							<label>•</label>
							<sec_title>Signs of toxicity<route> severe nausea/vomiting, maculopapular rash</route></sec_title>
						</section>
						<section type="none" id="sidelem4x717">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> LFTs in those with liver disease, hold if LFTs are moderately elevated; if severe or if LFTs increase after product is restarted, discontinue permanently</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x720">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x724">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CD4 cell counts; decreased viral load; slowing progression of HIV</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x730">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x735">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered; not to double dose; to take with water, juice; to take on empty stomach at bedtime</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x740">
								<item>
									<label>•</label>
									<para>To make sure health care provider knows all medications, supplements, OTC products taken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x748">
							<label>•</label>
							<sec_title>
								<route>That, if severe rash occurs, to notify health care provider; that adverse reactions (rash, dizziness, abnormal dreams, insomnia) lessen after 1 mo</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x754">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed or become pregnant if taking this product; to use nonhormonal contraception because serious birth defects have occurred (pregnancy [D]), use barrier method for ≥12 wk after last dose</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x757">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness, drowsiness occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x762">
								<item>
									<label>•</label>
									<para>That product does not cure disease but controls symptoms; that HIV can be transmitted to others even while taking this product; to continue with safe-sex practices</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>efinaconazole topical</mono_name>
			<section type="none" id="sidelem4x770">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>eletriptan (Rx)</mono_name>
			<info>
				<pronunciation>(el-ee-trip′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7790">Relpax</tradename>
				</tradenames>
				<class type="func"> Antimigraine agent, abortive</class>
				<class type="chem"> 5-HT-1B/1D receptor agonist, triptan</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x792">
				<sec_title>Action:</sec_title>
				<para>Binds selectively to the vascular 5-HT<emphasis style="inf">1</emphasis>-receptor subtype; causes vasoconstriction in cranial arteries</para>
			</section>
			<section type="uses" id="sidelem4x800">
				<sec_title>Uses:</sec_title>
				<para>Acute treatment of migraine with/without aura</para>
			</section>
			<section type="contra" id="sidelem4x805">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, coronary artery vasospasm, peripheral vascular disease, hemiplegic/basilar migraine, uncontrolled hypertension; ischemic bowel, heart disease; severe renal/hepatic disease, acute MI, stroke, angina, postmenopausal women, men &gt;40 yr; risk factors of CAD, MI, or other cardiac disease; hypercholesterolemia, obesity, diabetes</para>
				<section type="none" id="sidelem4x810">
					<section type="none" id="sidelem4x811">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, impaired renal/hepatic function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x816">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x824">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x824">
							<item>
								<label>•</label>
								<para> 20 or 40 mg, may increase if needed, max 40 mg (single dose); may repeat in 2 hr if headache improves but returns, max 80 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x830">
					<section type="none" id="sidelem4x831">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x836">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x840">
								<item>
									<label>•</label>
									<para>Swallow tabs whole; do not break, crush, or chew; use with 8 oz of water</para>
								</item>
								<item>
									<label>•</label>
									<para>At beginning of headache; if headache returns, repeat dose after 2 hr of 1st dose if 1st dose is ineffective; treat no more than 3 headaches per 30 days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x851">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x854">
					<section type="none" id="sidelem4x855">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> headache, anxiety, paresthesia, asthenia, somnolence, flushing, fatigue, hot/cold sensation, chills, vertigo, hypertonia, <emphasis style="bold">seizures, serotonin syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x865">
						<sec_title>CV:</sec_title>
						<para> Chest pain, palpitations, hypertension, <emphasis style="bold">MI, sinus tachycardia, stroke, ventricular fibrillation/tachycardia, atrial fibrillation, AV block, bradycardia,</emphasis> chest pressure syndrome, <emphasis style="bold">coronary vasospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x875">
						<sec_title>GI:</sec_title>
						<para> Nausea, dry mouth, vomiting</para>
					</section>
					<section type="none" id="sidelem4x880">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Weakness,</emphasis> back pain</para>
					</section>
					<section type="none" id="sidelem4x888">
						<sec_title>RESP:</sec_title>
						<para> Chest tightness, pressure</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x893">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset of pain relief <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr, peak 1<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-2 hr, half-life 4 hr, metabolized in the liver, 70% excreted in urine and feces</para>
			</section>
			<section type="interactions" id="sidelem4x910">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of eletriptan—CYP3A4 inhibitors (clarithromycin, erythromycin, itraconazole, ketoconazole, nelfinavir, ritonavir), propranolol, ergots, avoid use within 72 hr of these products</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—SSRIs, SNRIs, serotonin-receptor agonists</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: vasospastic reactions—ergots, ergot similar products, avoid use within 24 hr of these products</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x923">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x926">
					<section type="none" id="sidelem4x927">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x935">
							<label>•</label>
							<sec_title>Migraine</sec_title>
							<para>
								<list id="lidelem4x935">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Migraine:</emphasis> pain location, character, intensity, nausea, vomiting, aura; quiet, calm environment with decreased stimulation from noise, bright light, excessive talking</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x939">
								<item>
									<label>•</label>
									<para>B/P; signs, symptoms of coronary vasospasms, geriatric patients may be at higher risk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x944">
								<item>
									<label>•</label>
									<para>Tingling, hot sensation, burning, feeling of pressure, numbness, flushing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x949">
								<item>
									<label>•</label>
									<para>Stress level, activity, recreation, coping mechanisms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x954">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC, blurring vision, nausea, vomiting, tingling in extremities preceding headache</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x959">
								<item>
									<label>•</label>
									<para>Ingestion of tyramine foods (pickled products, beer, wine, aged cheese), food additives, preservatives, colorings, artificial sweeteners, chocolate, caffeine, which may precipitate these types of headaches</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x964">
								<item>
									<label>•</label>
									<para>Patients with CAD risk factors; 1st dose should be administered in prescriber’s office or medical facility</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x969">
								<item>
									<label>•</label>
									<para>Determine whether CYP3A4 inhibitors or other ergot-type products have been given</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x974">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x978">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in frequency, severity of migraine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x984">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x988">
								<item>
									<label>•</label>
									<para>To report any side effects to prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To use contraception while taking product; to inform prescriber if pregnant or intending to become pregnant</para>
								</item>
								<item>
									<label>•</label>
									<para>To provide dark, quiet environment</para>
								</item>
								<item>
									<label>•</label>
									<para>That product does not prevent or reduce number of migraine attacks</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active" ru="yes">
			<mono_name>elvitegravir/cobicistat/emtricitabine/tenofovir</mono_name>
			<info>
				<pronunciation>(el-vye-teg′gra-veer/koe-bik′-i-stat/em-tra-sye′ tah-ben/te-noe′ to-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10160"/>
				</tradenames>
				<class type="func"> Antiretrovirals</class>
			</info>
			<section type="uses" id="sidelem4x1026">
				<sec_title>Uses:</sec_title>
				<para>HIV in treatment-naïve patients</para>
			</section>
			<section type="contra" id="sidelem4x1031">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, CCr &lt;70 ml/min, severe hepatic disease</para>
			</section>
			<section type="doses" id="sidelem4x1036">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1044">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1044">
							<item>
								<label>•</label>
								<para> 1 Tab daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1049">
					<section type="none" id="sidelem4x1050">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x1058">
							<label>•</label>
							<sec_title>Adult<route> PO do not use in CCr &lt;50 ml/min</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ru="yes">
			<mono_name>eltrombopag</mono_name>
			<info>
				<pronunciation>(ell-trom-bow′pag)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10680">Promacta</tradename>
				</tradenames>
				<class type="func"> Hematopoietic</class>
			</info>
			<section type="uses" id="sidelem4x1074">
				<sec_title>Uses:</sec_title>
				<para>Thrombocytopenia in chronic immune thrombocytopenic purpura when unresponsive to other treatment, chronic hepatitis C–associated thrombocytopenia</para>
			</section>
			<section type="contra" id="sidelem4x1079">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Hepatotoxicity</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x1094">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1102">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1102">
							<item>
								<label>•</label>
								<para> 50 mg/day, adjust dosage to maintain platelets at ≥50 × 10<emphasis style="sup">9</emphasis>, max 75 mg/day; 25 mg/day chronic hepatitis C; East Asian descent reduce dose to 25 mg daily</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>emedastine ophthalmic</mono_name>
			<section type="none" id="sidelem4x1112">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>empagliflozin</mono_name>
			<info>
				<pronunciation>(em-pa-gli-floe′zin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x11210">Jardiance</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Sodium-glucose cotransporter 2 (SGLT2) inhibitors</class>
			</info>
			<section type="actions" id="sidelem4x1131">
				<sec_title>Action:</sec_title>
				<para> An inhibitor of sodium-glucose cotransporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the tubular lumen in the kidney</para>
			</section>
			<section type="uses" id="sidelem4x1136">
				<sec_title>Uses:</sec_title>
				<para> Type 2 diabetes mellitus with diet and exercise</para>
			</section>
			<section type="contra" id="sidelem4x1141">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity, dialysis, renal failure</para>
				<section type="none" id="sidelem4x1146">
					<section type="none" id="sidelem4x1147">
						<sec_title>Precautions:</sec_title>
						<para> Adrenal insufficiency, breastfeeding, children, dehydration, diabetic ketoacidosis, fever, geriatric patients, hypercholesterolemia, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypotension, hypothyroidism, hypovolemia, malnutrition, pituitary insufficiency, pregnancy, renal impairment, type 1 diabetes mellitus, vaginitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1152">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1160">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1160">
							<item>
								<label>•</label>
								<para> 10 mg daily, may increase to 25 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1164">
					<section type="none" id="sidelem4x1165">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25 mg</para>
					</section>
					<section type="none" id="sidelem4x1170">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1174">
								<item>
									<label>•</label>
									<para>Give every day without regard to food in the <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1182">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1185">
					<section type="none" id="sidelem4x1186">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x1191">
						<sec_title>ENDO:</sec_title>
						<para> Hypercholesterolemia, hyperlipidemia, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x1196">
						<sec_title>CV:</sec_title>
						<para> Hypotension, orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x1201">
						<sec_title>GU:</sec_title>
						<para> Increased urinary frequency, nocturia, polyuria, cystitis, dehydration, diuresis</para>
					</section>
					<section type="none" id="sidelem4x1206">
						<sec_title>GI:</sec_title>
						<para> Nausea</para>
					</section>
					<section type="none" id="sidelem4x1211">
						<sec_title>CNS:</sec_title>
						<para> Syncope</para>
					</section>
					<section type="none" id="sidelem4x1216">
						<sec_title>MISC:</sec_title>
						<para> Infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1221">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 82.6%, terminal elimination half-life 12.4 hr, peak 1.5 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1226">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1229">
					<section type="none" id="sidelem4x1230">
						<sec_title>Increase:</sec_title>
						<para> <emphasis style="bold">hypoglycemic effect—</emphasis> Angiotensin II receptor antagonists, angiotensin-converting enzyme (ACE) inhibitors, loop diuretics, thiazide diuretics, fluoxetine, olanzapine, β-blockers, octreotide, fibric acid derivatives, MAOIs type A</para>
					</section>
					<section type="none" id="sidelem4x1238">
						<sec_title>Increase/Decrease:</sec_title>
						<para> hypoglycemic effect—clonidine, androgens, bortezomib, lithium, alcohol, sulfonamides</para>
					</section>
					<section type="none" id="sidelem4x1243">
						<sec_title>Decrease:</sec_title>
						<para> <emphasis style="bold">hypoglycemic effect—</emphasis>phenothiazines, atypical antipsychotics, baclofen, carbonic anhydrase inhibitors, estrogens, progestins, oral contraceptives, dextrothyroxine, glucagon, corticosteroids, fenfluramine, dexfenfluramine, phenytoin, fosphenytoin, ethotoin, salicylates, cyclosporine, tacrolimus, tobacco</para>
						<para>Do not use with gatifloxacin, thyroid hormones</para>
					</section>
					<section type="none" id="sidelem4x1255">
						<sec_title>Drug/Herb/Supplements</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x1259">
						<sec_title>Increase:</sec_title>
						<para> hypoglycemia—chromium, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x1264">
						<sec_title>Increase/Decrease:</sec_title>
						<para> hypoglycemia—niacin</para>
					</section>
					<section type="none" id="sidelem4x1269">
						<sec_title>Decrease:</sec_title>
						<para> hypoglycemia—green tea</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1274">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1277">
					<section type="none" id="sidelem4x1278">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1286">
							<label>•</label>
							<sec_title>Diabetes</sec_title>
							<para>
								<list id="lidelem4x1286">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diabetes:</emphasis> Monitor blood glucose, glycosylated hemoglobin A1c (HbA1c), serum cholesterol profile, serum creatinine/BUN, assess for polydipsia, other products taken by patient</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1290">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1294">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing blood glucose, A1c</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1300">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1304">
								<item>
									<label>•</label>
									<para>How to check blood glucose, to continue with diet and exercise changes, to avoid smoking, alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>emtricitabine (Rx)</mono_name>
			<info>
				<pronunciation>(em-tri-sit′uh-bean)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x13200">Emtriva</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1330">
				<sec_title>Action:</sec_title>
				<para>A synthetic nucleoside analog of cytosine; inhibits replication of HIV virus by competing with the natural substrate and then becoming incorporated into cellular DNA by viral reverse transcriptase, thereby terminating cellular DNA chain</para>
			</section>
			<section type="uses" id="sidelem4x1335">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection with other antiretroviral</para>
				<section type="none" id="sidelem4x1340">
					<section type="none" id="sidelem4x1341">
						<sec_title>Unlabeled uses:</sec_title>
						<para> HBV (hepatitis B virus) infection with HIV, HIV prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1346">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Lactic acidosis</bbw>
				</para>
				<section type="none" id="sidelem4x1361">
					<section type="none" id="sidelem4x1362">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal disease</para>
						<para>
							<bbw>Hepatic insufficiency, chronic hepatitis B virus (HPV)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1377">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1387">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1387">
							<item>
								<label>•</label>
								<para> Caps 200 mg/day; oral sol 240 mg (24 ml)/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1394">
					<label>•</label>
					<sec_title>Adolescent/child &gt;33 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x1394">
							<item>
								<label>•</label>
								<para> Caps 200 mg/day; <emphasis style="bold">child 3 mo-17 yr:</emphasis> oral sol 6 mg/kg/day, max 240 mg (24 ml)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1404">
					<label>•</label>
					<sec_title>Infants &lt;3 mo<route> PO oral sol</route></sec_title>
					<para>
						<list id="lidelem4x1404">
							<item>
								<label>•</label>
								<para> 3 mg/kg daily, do not use caps</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1408">
					<section type="none" id="sidelem4x1409">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x1418">
							<label>•</label>
							<sec_title>Adult<route> PO Caps CCr 30-49 ml/min, 200 mg q48hr; oral sol 120 mg q24hr; caps CCr 15-29 ml/min, 200 mg q72hr; oral sol 80 mg q24hr; caps CCr &lt;15 ml/min, 200 mg q96hr; oral sol 60 mg q24hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1421">
						<sec_title>Available forms:</sec_title>
						<para> Cap 200 mg; oral sol 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1426">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1431">
								<item>
									<label>•</label>
									<para>Give without regard to meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1439">
							<label>•</label>
							<sec_title>
								<route>Oral cap and solution not interchangeable</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1442">
								<item>
									<label>•</label>
									<para>Store (caps) at 25° C (77° F); (oral sol) refrigerated, use within 3 mo</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1447">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1450">
					<section type="none" id="sidelem4x1451">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> abnormal dreams, <emphasis style="italic">depression,</emphasis> dizziness, <emphasis style="italic">insomnia,</emphasis> neuropathy, paresthesia, <emphasis style="italic">asthenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1467">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia, abdominal pain, dyspepsia,</emphasis><emphasis style="bold">hepatomegaly with steatosis (may be fatal)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1476">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> skin discolorization</para>
					</section>
					<section type="none" id="sidelem4x1484">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x1490">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1497">
						<sec_title>SYST:</sec_title>
						<para> Change in body fat distribution, <emphasis style="bold">lactic acidosis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1504">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly, extensively absorbed; peak 1-2 hr; protein binding &lt;4%; excreted unchanged in urine (86%), feces (14%); half-life 10 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1509">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1517">
					<label>•</label>
					<sec_title>
						<route>Do not use with efavirenz, tenofovir, lamiVUDine, treatment duplication</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Decrease:</emphasis> emtricitabine level—interferons<list id="lidelem4x1524">
						<item>
							<label>•</label>
							<para>Complex interactions—ribavirin, cautious use</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x1530">
					<section type="none" id="sidelem4x1531">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, glucose, amylase, bilirubin, CK, lipase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> neutrophils</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1542">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1545">
					<section type="none" id="sidelem4x1546">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1554">
							<para>
								<list id="lidelem4x1554">
									<item>
										<label>•</label>
										<para>Renal/hepatic function tests: AST, ALT, bilirubin, amylase, lipase, triglycerides periodically during treatment
<bbw>
												<emphasis alert="lifethreat">Lactic acidosis, severe hepatomegaly with steatosis;</emphasis> if lab reports confirm these conditions, discontinue treatment; may be fatal, more common in females or those who are overweight, monitor lactic acid levels, LFTs</bbw>

<bbw>
												<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> do not use in those with risk factors such as alcoholism, discontinue if hepatotoxicity occurs</bbw>

<bbw>Hepatitis B and HIV coinfection (unlabeled); perform HBV screening in any patient who has HIV to ensure appropriate treatment; avoid single-drug treatments in HBV</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1587">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1591">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased signs, symptoms of HIV; decreased viral load, increased CP4 counts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1597">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1602">
								<item>
									<label>•</label>
									<para>That GI complaints resolve after 3-4 wk of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1610">
							<label>•</label>
							<sec_title>
								<route>To report planned or suspected pregnancy; not to breastfeed while taking product</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1616">
							<label>•</label>
							<sec_title>
								<route>solution and cap are not interchangeable</route>
							</sec_title>
							<para>
								<list id="lidelem4x1616">
									<item>
										<label>•</label>
										<para>That product must be taken at same time of day to maintain blood level; </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1620">
								<item>
									<label>•</label>
									<para>That product will control symptoms but is not a cure for HIV; patient still infectious, may pass HIV virus on to others; that other products may be necessary to prevent other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1625">
								<item>
									<label>•</label>
									<para>That changes in body fat distribution may occur
<bbw>Lactic acidosis: to notify prescriber immediately if fatigue, muscle aches/pains, abdominal pain, difficulty breathing, nausea, vomiting, change in heart rhythm occur</bbw>

<bbw>Hepatotoxicity: to notify prescriber of dark urine, yellowing of skin/eyes, clay-colored stools, anorexia, nausea, vomiting</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>enalapril/enalaprilat (Rx)</mono_name>
			<info>
				<pronunciation>(e-nal′a-pril)/(e-nal′a-pril-at)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x16530">Vasotec</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme (ACE) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1663">
				<para>
					<confusion>
						<tradename id="tnidelem4x16630">enalapril</tradename>
						<drug type="generic" refid="idelem4x16630">ramipril/Anafranil/Eldepryl</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1667">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE; prevents conversion of angiotensin I to angiotensin II, dilation of arterial, venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x1672">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, CHF, left ventricular dysfunction</para>
				<section type="none" id="sidelem4x1677">
					<section type="none" id="sidelem4x1678">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diabetic nephropathy, hypertensive emergency/urgency, post-MI, proteinuria, renal crisis in scleroderma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1684">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, history of angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x1699">
					<section type="none" id="sidelem4x1700">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, renal disease, hyperkalemia, hepatic failure, dehydration, bilateral renal artery/aortic stenosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1705">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1708">
					<section type="none" id="sidelem4x1709">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x1717">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1717">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day, may increase or decrease to desired response, range 10-40 mg/day in 1-2 divided doses;  0.625-1.25 mg q6hr over 5 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1727">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1727">
									<item>
										<label>•</label>
										<para> 0.08 mg/kg/day in 1-2 divided doses, max 0.58 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1734">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1734">
									<item>
										<label>•</label>
										<para> 5-10 mcg/kg/dose q8-24hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1738">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x1746">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1746">
									<item>
										<label>•</label>
										<para> 2.5-20 mg/day in 2 divided doses, max 40 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1750">
						<sec_title>
							<emphasis style="bold">Renal disease</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x1759">
							<label>•</label>
							<sec_title>Adult<route> PO 2.5 mg/day (CCr &lt;30 ml/min), increase gradually; IV CCr &gt;30 ml/min, 1.25 mg q6hr; CCr &lt;30 ml/min, 0.625 mg as one-time dose, increase as per B/P</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1762">
						<sec_title>Hypertensive emergency/urgency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1770">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1770">
									<item>
										<label>•</label>
										<para> 1.25-5 mg q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1774">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Enalapril:</emphasis> tabs 2.5, 5, 10, 20 mg; <emphasis style="italic">enalaprilat:</emphasis> inj 1.25 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1785">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1788">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1792">
									<item>
										<label>•</label>
										<para>Tab may be crushed, given without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1798">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x1802">
									<item>
										<label>•</label>
										<para>Prepare in sterile environment using aseptic technique</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute each dose with ≤50 ml compatible sol</para>
									</item>
									<item>
										<label>•</label>
										<para>For 25 mcg/ml dilution often used for neonatal or pediatric patients, combine 1 ml enalaprilat 1.25 mg/ml and 49 ml compatible sol for IV</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1818">
							<sec_title>IV, Direct/Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1822">
									<item>
										<label>•</label>
										<para>Undiluted over ≥5 min, use diluent provided or 50 ml D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, 0.9% NaCl in D<emphasis style="inf">5</emphasis>W or LR, Isolyte E; give through <emphasis style="sans-serif">Y</emphasis>-tube of free-flowing infusion of 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, LR, Isolyte E</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alemtuzumab, alfentanil, allopurinol, amifostine, amikacin, aminophylline, amphotericin B liposome, anidulafungin, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, ceFAZolin, cefonicid, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, cisatracurium, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dextran 40, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposome, doxycycline, ePHEDrine, EPINEPHrine, epirubicin, epoetin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, indomethacin, insulin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamin injection, nafcillin, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, papaverine, PEMEtrexed, penicillin G potassium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, piperacillin-tazobactam, potassium chloride/phosphate, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxime, quinupristin-dalfopristin, ranitidine, remifentanil, ritodrine, riTUXimab, rocuronium, sodium acetate, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, tetracycline, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trastuzumab, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1846">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1849">
					<section type="none" id="sidelem4x1850">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, dizziness,</emphasis> paresthesias, headache, fatigue, anxiety</para>
					</section>
					<section type="none" id="sidelem4x1858">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> chest pain, tachycardia, <emphasis style="bold">dysrhythmias,</emphasis> syncope, angina, <emphasis style="bold">MI,</emphasis> orthostatic hypotension</para>
					</section>
					<section type="none" id="sidelem4x1872">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Tinnitus;</emphasis> visual changes; sore throat; double vision; dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x1880">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, colitis, cramps, diarrhea, constipation, flatulence, dry mouth, loss of taste, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1887">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria, renal failure,</emphasis> increased frequency of polyuria or oliguria</para>
					</section>
					<section type="none" id="sidelem4x1895">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1902">
						<sec_title>INTEG:</sec_title>
						<para> Rash, purpura, alopecia, hyperhidrosis, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x1907">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x1912">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, dry cough, crackles</para>
					</section>
					<section type="none" id="sidelem4x1917">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1924">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1927">
					<section type="none" id="sidelem4x1928">
						<sec_title>Enalapril: </sec_title>
						<para>
							<emphasis style="bold">PO:</emphasis> Onset 1 hr, peak 4-6 hr, duration ≥24 hr</para>
					</section>
					<section type="none" id="sidelem4x1935">
						<sec_title>Enalaprilat: </sec_title>
						<para>
							<emphasis style="bold">IV:</emphasis> Onset 5-15 min, peak up to 4 hr, duration 4-6 hr, half-life 35 hr, metabolized by liver to active metabolite, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1942">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypersensitivity—allopurinol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, phenothiazines, nitrates, acute alcohol ingestion, general anesthesia</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> potassium levels—salt substitutes, potassium-sparing diuretics, potassium supplements, cycloSPORINE, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of lithium, digoxin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of enalapril—antacids, rifampin</para>
				<section type="none" id="sidelem4x1965">
					<section type="none" id="sidelem4x1966">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, bilirubin, alk phos, glucose, uric acid, BUN, creatine</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> ANA titer</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1977">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1980">
					<section type="none" id="sidelem4x1981">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1989">
							<label>•</label>
							<sec_title>Bone marrow depression (rare)</sec_title>
							<para>
								<list id="lidelem4x1989">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bone marrow depression (rare):</emphasis> neutrophils, decreased platelets; WBC with differential baseline, q3mo; if neutrophils &lt;1000/mm<emphasis style="sup">3</emphasis>, discontinue treatment (recommended with collagen-vascular disease)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1999">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x1999">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, peak/trough level, orthostatic hypotension, syncope when used with diuretic, pulse q4hr; note rate, rhythm, quality</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2003">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins and 1 wk into therapy; electrolytes: potassium, sodium, chloride during 1st 2 wk of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2008">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status; edema in feet, legs daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2016">
							<label>•</label>
							<sec_title>Symptoms of CHF<route> edema, dyspnea, wet crackles, weight gain, jugular venous distension, difficulty breathing</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2019">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2023">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2029">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2034">
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, or allergy) products unless directed by prescriber; to avoid potassium, salt substitutes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2039">
								<item>
									<label>•</label>
									<para>To avoid sunlight or wear sunscreen for photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2044">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule even if feeling better</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2052">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pain, signs of angioedema</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2055">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in blood pressure; to consult prescriber if these occur, maintain adequate hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2062">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting; that light-headedness may occur during 1st few days of therapy, avoid activities requiring coordination</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2070">
							<label>•</label>
							<sec_title>
								<route>That product may cause skin rash, impaired perspiration or angioedema; to discontinue if angioedema occurs</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2073">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2078">
								<item>
									<label>•</label>
									<para>That CV adverse reactions may reoccur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2083">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension
<bbw>To notify prescriber if pregnancy is planned or suspected; to use contraception during treatment; pregnancy (D)</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>enfuvirtide (Rx)</mono_name>
			<info>
				<pronunciation>(en-fyoo′vir-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x21100">Fuzeon</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Fusion Inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x2120">
				<sec_title>Action:</sec_title>
				<para>Inhibitor of the fusion of HIV-1 with CD4+ cells</para>
			</section>
			<section type="uses" id="sidelem4x2125">
				<sec_title>Uses:</sec_title>
				<para>Treatment of HIV-1 infection in combination with other antiretrovirals</para>
				<section type="none" id="sidelem4x2130">
					<section type="none" id="sidelem4x2131">
						<sec_title>Unlabeled uses:</sec_title>
						<para> HIV prophylaxis after occupational exposure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2136">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x2141">
					<section type="none" id="sidelem4x2142">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>) (must be enrolled in the Antiretroviral Pregnancy Registry: 1-800-258-4263), children &lt;6 yr, liver disease, myelosuppression, infections</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2147">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2155">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x2155">
							<item>
								<label>•</label>
								<para> 90 mg (1 ml) bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2162">
					<label>•</label>
					<sec_title>Child 6-16 yr and &lt;42.6 kg<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x2162">
							<item>
								<label>•</label>
								<para> 2 mg/kg bid, max 90 mg bid; 11-15.5 kg 27 mg/0.3 ml bid; 15.6-20 kg 36 mg/0.4 ml bid; 20.1-24.5 kg 45 mg/0.5 ml bid; 24.6-29 kg 54 mg/0.6 ml bid; 29.1-33.5 kg 63 mg/0.7 ml bid; 33.6-38 kg 72 mg/0.8 ml bid; 38.1-42.5 kg 81 mg/0.9 ml bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2166">
					<section type="none" id="sidelem4x2167">
						<sec_title>HIV prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2175">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2175">
									<item>
										<label>•</label>
										<para> 90 mg bid added to PEP regimen</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2179">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj, lyophilized 108 mg (90 mg/ml when reconstituted)</para>
					</section>
					<section type="none" id="sidelem4x2184">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2187">
							<sec_title>SUBCUT route</sec_title>
							<section type="none" id="sidelem4x2195">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x2195">
										<item>
											<label>•</label>
											<para> vial with 1.1 ml sterile water for inj; tap and roll to mix; allow to stand until completely dissolved, may take up to 45 min; after dissolved, immediately  or refrigerate up to 24 hr</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2205">
								<label>•</label>
								<sec_title>
									<route>Do not mix with other medications</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x2208">
									<item>
										<label>•</label>
										<para>SUBCUT: give bid, rotate sites; preferred sites: upper arm, anterior thigh, abdomen</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2213">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2216">
					<section type="none" id="sidelem4x2217">
						<sec_title>CNS:</sec_title>
						<para> Anxiety, peripheral neuropathy, taste disturbance, <emphasis style="bold">Guillain-Barré syndrome,</emphasis> insomnia, depression</para>
					</section>
					<section type="none" id="sidelem4x2225">
						<sec_title>GI:</sec_title>
						<para> Nausea, abdominal pain, anorexia, constipation, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2232">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Glomerulonephritis, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2239">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2246">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Inj site reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2253">
						<sec_title>MISC:</sec_title>
						<para> Influenza, cough, conjunctivitis, lymphadenopathy, myalgia, hyperglycemia, <emphasis style="bold">pneumonia,</emphasis> rhinitis, fatigue, hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2261">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 8 hr, terminal half-life 3.8 hr, well absorbed, undergoes catabolism, 92% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x2266">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2269">
					<section type="none" id="sidelem4x2270">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, lipase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2282">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2285">
					<section type="none" id="sidelem4x2286">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2294">
							<label>•</label>
							<sec_title>
								<route>Signs of infection, inj site reactions, use analgesics; bacterial pneumonia may occur if blood counts are low, or viral load is high</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2300">
							<label>•</label>
							<sec_title>Glomerulonephritis/renal failure<route> BUN, creatinine, renal failure may occur</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2303">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain or constipation occurs, notify prescriber; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2308">
								<item>
									<label>•</label>
									<para>Skin eruptions, rash, urticaria, itching</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2313">
								<item>
									<label>•</label>
									<para>Allergies before treatment, reaction to each medication</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2321">
							<label>•</label>
							<sec_title>Immune reconstitution syndrome<route> with combination theory</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2327">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x2327">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> CBC, blood chemistry, plasma HIV RNA, absolute CD4+/CD8+ cell counts/%, serum β<emphasis style="inf">2</emphasis> microglobulin, serum ICD+24 antigen levels, cholesterol</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2334">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2338">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CD4 cell counts; decreased viral load; slowing progression of HIV-1 infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2344">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2352">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is suspected or if breastfeeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2358">
							<label>•</label>
							<sec_title>
								<route>That pneumonia may occur; to contact prescriber if cough, fever occur</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2364">
							<label>•</label>
							<sec_title>
								<route>That hypersensitive reactions may occur; rash, pruritus; to stop product, contact prescriber</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2367">
								<item>
									<label>•</label>
									<para>That product is not a cure for HIV-1 infection but controls symptoms; HIV-1 can still be transmitted to others; that product is to be used in combination only with other antiretrovirals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2372">
								<item>
									<label>•</label>
									<para>How to prepare and give using subcut inj, watch for site reactions, rotate sites</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name>enoxaparin (Rx)</mono_name>
			<info>
				<pronunciation>(ee-nox′a-par-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x23840">Lovenox</tradename>
				</tradenames>
				<class type="func"> Anticoagulant, antithrombotic</class>
				<class type="chem"> Low-molecular-weight heparin (LMWH)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x2394">
				<para>
					<confusion>
						<tradename id="tnidelem4x23940">enoxaparin</tradename>
						<drug type="generic" refid="idelem4x23940">enoxacin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2401">
				<sec_title>Action:</sec_title>
				<para>Binds to antithrombin III inactivating factors Xa/IIa, thereby resulting in a higher ratio of anti-factor Xa to IIa</para>
			</section>
			<section type="uses" id="sidelem4x2406">
				<sec_title>Uses:</sec_title>
				<para>Prevention of DVT (inpatient or outpatient), PE (inpatient) in hip and knee replacement, abdominal surgery at risk for thrombosis; unstable angina, acute MI, coronary artery thrombosis</para>
				<section type="none" id="sidelem4x2411">
					<section type="none" id="sidelem4x2412">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Antiphospholipid antibody syndrome, arterial thromboembolism prophylaxis, cerebral thromboembolism, percutaneous coronary intervention</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2417">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, heparin, pork; active major bleeding, hemophilia, leukemia with bleeding, thrombocytopenic purpura, heparin-induced thrombocytopenia</para>
				<section type="none" id="sidelem4x2422">
					<section type="none" id="sidelem4x2423">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, low weight men (&lt;57 kg), women (&lt;45 kg), severe renal/hepatic disease, severe hypertension, subacute bacterial endocarditis, acute nephritis, recent burn, spinal surgery, indwelling catheters, hypersensitivity to benzyl alcohol</para>
						<para>
							<bbw>Lumbar puncture, aneurysm, coagulopathy, epidural anesthesia, spinal anesthesia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2438">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2441">
					<section type="none" id="sidelem4x2442">
						<sec_title>DVT/PE prophylaxis</sec_title>
						<section type="none" id="sidelem4x2450">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x2450">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> (moderate risk—general surgery, nonsurgery 40-60 yr major surgery &lt;40 yr with no risk factors)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2457">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2457">
									<item>
										<label>•</label>
										<para> 20 mg daily; higher risk adults—abdominal surgery, geriatric—general surgery, major surgery &lt;40 yr no risk factors;  30 mg q12hr or 40 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2464">
						<sec_title>DVT prevention before hip or knee surgery</sec_title>
						<section type="none" id="sidelem4x2472">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2472">
									<item>
										<label>•</label>
										<para> 30 mg bid given 12-24 hr postop for 7-10 days until DVT risk is diminished</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2477">
						<sec_title>DVT prevention before hip replacement</sec_title>
						<section type="none" id="sidelem4x2485">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2485">
									<item>
										<label>•</label>
										<para> 40 mg/day started 9-15 hr preop or 30 mg q12hr started 12-24 hr postop, continued until DVT risk diminished or patient adequately on anticoagulant</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2489">
						<sec_title>DVT prophylaxis before abdominal surgery</sec_title>
						<section type="none" id="sidelem4x2497">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2497">
									<item>
										<label>•</label>
										<para> 40 mg/day starting 24 hr before surgery × 7-10 days to prevent thromboembolic complications</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2501">
						<sec_title>Treatment of DVT or PE</sec_title>
						<section type="none" id="sidelem4x2509">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x2509">
									<item>
										<label>•</label>
										<para> 1 mg/kg q12hr (without PE, outpatient); 1 mg/kg q12hr or 1.5 mg/kg/day (with or without PE, inpatient); warfarin should be started within 72 hr, continued ≥5 days until INR is 2-3 (at least 3 days)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2513">
						<sec_title>Prevention of ischemic complications in unstable angina or non–Q-wave MI/non-ST</sec_title>
						<section type="none" id="sidelem4x2521">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x2521">
									<item>
										<label>•</label>
										<para> 1 mg/kg q12hr until stable with aspirin 100-325 mg/day × ≥2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2525">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x2534">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT CCr &lt; 30 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2537">
						<sec_title>Available forms: </sec_title>
						<para>Prefilled syringes/inj 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml, 100 mg/1 ml, 120 mg/0.8 ml, 150 mg/ml; multidose vials 100 mg/ml (3 ml)</para>
					</section>
					<section type="none" id="sidelem4x2542">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2550">
							<label>•</label>
							<sec_title>
								<route>Only after screening patient for bleeding disorders</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x2556">
							<label>•</label>
							<sec_title>
								<route>Do not mix with other products or infusion fluids</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2560">
								<item>
									<para>
										<emphasis alert="nurse">Only this product when ordered; not interchangeable with heparin or other LMWHs</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2565">
								<item>
									<label>•</label>
									<para>At same time each day to maintain steady blood levels</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2570">
								<item>
									<label>•</label>
									<para>Avoid all IM inj that may cause bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2575">
								<item>
									<label>•</label>
									<para>Prepare in a sterile environment using aseptic technique</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2580">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x2585">
									<item>
										<label>•</label>
										<para>Do not give IM; begin 1 hr before surgery; do not aspirate; rotate sites; do not expel bubble from syringe before administration</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2590">
									<item>
										<label>•</label>
										<para>To recumbent patient, give SUBCUT; rotate inj sites (left/right anterolateral, left/right posterolateral abdominal wall)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2595">
									<item>
										<label>•</label>
										<para>Insert whole length of needle into skin fold held with thumb and forefinger</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2600">
									<item>
										<label>•</label>
										<para>If withdrawing from multidose vial, use TB syringe for proper measurement</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2605">
									<item>
										<label>•</label>
										<para>Prefilled syringes (30, 40 mg) not graduated; do not use for partial doses</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2613">
								<label>•</label>
								<sec_title>
									<route>do not use products with benzyl alcohol in pregnant women</route>
								</sec_title>
								<para>
									<list id="lidelem4x2613">
										<item>
											<label>•</label>
											<para>Do not administer if particulate is present, </para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x2617">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x2621">
									<item>
										<label>•</label>
										<para>Use multidose vial for IV administration; use TB syringe, other graduated syringe to measure dose; give IV BOL through IV line, flush after</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilution may be stored for up to 4 wk in glass vial at room temperature, up to 2 wk in TB syringes with rubber stoppers at room temperature or refrigerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2632">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2635">
					<section type="none" id="sidelem4x2636">
						<sec_title>CNS:</sec_title>
						<para> Fever, confusion</para>
					</section>
					<section type="none" id="sidelem4x2641">
						<sec_title>GI:</sec_title>
						<para> Nausea</para>
					</section>
					<section type="none" id="sidelem4x2646">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemorrhage from any site, hypochromic anemia, thrombocytopenia, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2653">
						<sec_title>INTEG:</sec_title>
						<para> Ecchymosis, inj site hematoma</para>
					</section>
					<section type="none" id="sidelem4x2658">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia in renal failure</para>
					</section>
					<section type="none" id="sidelem4x2663">
						<sec_title>MS:</sec_title>
						<para> Osteoporosis</para>
					</section>
					<section type="none" id="sidelem4x2668">
						<sec_title>SYST:</sec_title>
						<para> Edema, peripheral edema</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2673">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2676">
					<section type="none" id="sidelem4x2677">
						<sec_title>SUBCUT:</sec_title>
						<para> 90% absorbed, maximum antithrombin activity (3-5 hr), elimination half-life 4<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2688">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> enoxaparin action—anticoagulants, salicylates, NSAIDs, antiplatelets, thrombolytics, RU-486</para>
				<section type="none" id="sidelem4x2696">
					<section type="none" id="sidelem4x2697">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bleeding risk—feverfew, garlic, ginger, ginkgo, horse chestnut</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelet count</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2712">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2715">
					<section type="none" id="sidelem4x2716">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2724">
							<label>•</label>
							<sec_title>
								<route>Monitor anti-factor Xa activity in chronic therapy (renal disease)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2727">
								<item>
									<label>•</label>
									<para>Blood studies (Hct/Hgb, CBC, coagulation studies, platelets, occult blood in stools), anti-factor Xa (should be checked 4 hr after inj); thrombocytopenia may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2732">
								<item>
									<label>•</label>
									<para>Renal studies: BUN/creatinine baseline and periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2740">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
						</section>
						<section type="none" id="sidelem4x2748">
							<label>•</label>
							<sec_title>Hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x2748">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypersensitivity:</emphasis> rash, fever, chills, report to prescriber</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2755">
							<label>•</label>
							<sec_title>Neurologic status</sec_title>
							<para>
								<list id="lidelem4x2755">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Neurologic status:</emphasis> those with epidural catheters are at greater chance for impairments</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2759">
								<item>
									<label>•</label>
									<para>Injection-site reactions: inflammation, redness, hematomas
<bbw>Neurologic symptoms in patients who have received spinal anesthesia, may develop spinal hematoma, those who have had trauma, spinal surgery are at greater risk</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2773">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2777">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of DVT/PE</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2783">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2788">
								<item>
									<label>•</label>
									<para>To use soft-bristle toothbrush to avoid bleeding gums; to use electric razor</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2796">
							<label>•</label>
							<sec_title>To report any signs of bleeding<route> gums, under skin, urine, stools; do not rub injection site, easy bruising, dizziness, rash, breathing changes</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2799">
								<item>
									<label>•</label>
									<para>To avoid OTC products containing aspirin, NSAIDs unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>entacapone (Rx)</mono_name>
			<info>
				<pronunciation>(en′ta-kah-pone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x28140">Comtan</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> COMT inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2824">
				<sec_title>Action:</sec_title>
				<para>Inhibits COMT (catechol <emphasis style="italic">O</emphasis>-methyltransferase) and alters the plasma pharmacokinetics of levodopa; given with levodopa/carbidopa</para>
			</section>
			<section type="uses" id="sidelem4x2832">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s disease for those experiencing end of dose; decreased effect as adjunct to levodopa/carbidopa</para>
			</section>
			<section type="contra" id="sidelem4x2837">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2842">
					<section type="none" id="sidelem4x2843">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal/hepatic disease, affective disorders, psychosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2848">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2856">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2856">
							<item>
								<label>•</label>
								<para> 200 mg given with carbidopa/levodopa, max 1600 mg/day; may allow for 25% dosage reduction in levodopa therapy</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2860">
					<section type="none" id="sidelem4x2861">
						<sec_title>Available forms:</sec_title>
						<para> Tabs, film coated 200 mg</para>
					</section>
					<section type="none" id="sidelem4x2866">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2870">
								<item>
									<label>•</label>
									<para>Only after MAOIs have been discontinued for 2 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>Give with dose of levodopa/carbidopa; product has no effect on its own</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2881">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2884">
					<section type="none" id="sidelem4x2885">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Involuntary choreiform movements, hand tremors, fatigue, headache, anxiety, twitching, numbness, dyskinesia, hypokinesia, hyperkinesia, weakness, confusion, agitation, nightmares,</emphasis> psychosis, hallucination, hypomania, severe depression, dizziness, <emphasis style="bold">neuroleptic malignant syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2895">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2902">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal distress, dry mouth, flatulence, bitter taste, diarrhea, constipation, dyspepsia,</emphasis> gastritis, GI disorder</para>
					</section>
					<section type="none" id="sidelem4x2911">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x2916">
						<sec_title>MISC:</sec_title>
						<para> Dark urine and other body fluids, back pain, dyspnea, purpura, fatigue, asthenia, bacterial infection, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2923">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Duration up to 8 hr; excreted in urine, feces; well absorbed; protein binding 98%; metabolized in liver extensively; enters breast milk; half-life of levodopa extended, half-life 0.5 hr initial, 2.5 hr second</para>
			</section>
			<section type="interactions" id="sidelem4x2928">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2936">
					<label>•</label>
					<sec_title>
						<route>Prevents catecholamine metabolism—nonselective MAOIs; do not use together</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> B/P, tachycardia, dysrhythmias, avoid use—bitolterol, DOPamine, DOBUTamine, EPINEPHrine, methyldopa, isoetharine, norepinephrine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> excretion of entacapone—ampicillin, chloramphenicol, probenecid, erythromycin, rifampin</para>
				<section type="none" id="sidelem4x2947">
					<section type="none" id="sidelem4x2948">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> B/P—ma huang</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—kava</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2959">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2962">
					<section type="none" id="sidelem4x2963">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2969">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: high temperature, increased CPK, rigidity, change in LOC usually during rapid withdrawal</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2977">
							<label>•</label>
							<sec_title>Involuntary movements of Parkinson’s disease</sec_title>
							<para>
								<list id="lidelem4x2977">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Involuntary movements of Parkinson’s disease:</emphasis> akinesia, tremors, staggering gait, muscle rigidity, drooling when given with levodopa/carbidopa</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2981">
								<item>
									<label>•</label>
									<para>B/P, respirations during initial treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2986">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression; complete suicide assessment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2994">
							<label>•</label>
							<sec_title>Rhabdomyolysis<route> muscle pain, tenderness, weakness; swelling of affected muscles; may lead to decreased B/P, shock</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x2997">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3002">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3006">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in akathisia, increased mood when given with levodopa/carbidopa</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3012">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3017">
								<item>
									<label>•</label>
									<para>That hallucinations, mental changes, nausea, dyskinesia can occur; may mean patient is overmedicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3022">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension; not to drive, operate machinery until stabilized on medication and mental performance not affected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3027">
								<item>
									<label>•</label>
									<para>To use product exactly as prescribed; if dose is missed, to take as soon as remembered up to 2 hr before next dose; not to discontinue abruptly; to withdraw gradually</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3032">
								<item>
									<label>•</label>
									<para>That urine, sweat may darken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3040">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is suspected; if lactating, that product excreted in breast milk</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>entecavir (Rx)</mono_name>
			<info>
				<pronunciation>(en-te′ka-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x30480">Baraclude</tradename>
				</tradenames>
				<class type="func"> Antiretroviral nucleoside reverse transcriptase inhibitor (NRTIs)</class>
				<class type="chem"> Guanosine nucleoside analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3058">
				<sec_title>Action:</sec_title>
				<para>Inhibits hepatitis B virus DNA polymerase by competing with natural substrates and by causing DNA termination after its incorporation into viral DNA; causes viral DNA death</para>
			</section>
			<section type="uses" id="sidelem4x3063">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis B (HBV)</para>
			</section>
			<section type="contra" id="sidelem4x3068">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3073">
					<section type="none" id="sidelem4x3074">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, severe renal disease, liver transplant</para>
						<para>
							<bbw>Hepatic disease, hepatitis, HIV, lactic acidosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3089">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3092">
					<section type="none" id="sidelem4x3093">
						<sec_title>Chronic hepatitis B (nucleoside treatment naive)</sec_title>
						<section type="none" id="sidelem4x3101">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3101">
									<item>
										<label>•</label>
										<para> Tab 0.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3109">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3109">
									<item>
										<label>•</label>
										<para> (solution) 0.5 mg q day; <emphasis style="bold">Child/Adolescents ≥2 yr &gt;30 kg:</emphasis> 0.5 mg (10 ml) q day; <emphasis style="bold">Child ≥2 yr, 27 to 30 kg:</emphasis> 0.45 mg (9 ml) q day; <emphasis style="bold">Child ≥2 yr, 24 to 26 kg:</emphasis> 0.4 mg (8 ml) q day; <emphasis style="bold">Child ≥2 yr, 21 to 23 kg:</emphasis> 0.35 mg (7 ml) q day; <emphasis style="bold">Child ≥2 yr, 18 to 20 kg:</emphasis> 0.3 mg (6 ml) q day; <emphasis style="bold">Children ≥2 yr, 15 to 17 kg:</emphasis> 0.25 mg (5 ml) q day; <emphasis style="bold">Children 2 ≥yrs, 12 to 14 kg:</emphasis> 0.2 mg (4 ml) q day.;  0.15 mg (3 ml) q day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3137">
						<sec_title>Chronic hepatitis B with compensated liver disease and history of hepatitis B viremia while receiving lamiVUDine or known lamiVUDine/telbivudine-resistant mutations</sec_title>
						<section type="none" id="sidelem4x3145">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3145">
									<item>
										<label>•</label>
										<para> Tab 1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3152">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3152">
									<item>
										<label>•</label>
										<para> (solution) 1 mg q day; <emphasis style="bold">Child/ Adolescent ≥2 yr, &gt;30 kg:</emphasis> 1 mg (20 ml) q day; <emphasis style="bold">Children ≥2 yr, 27 to 30 kg:</emphasis> 0.9 mg (18 ml) q day; <emphasis style="bold">Children ≥2 yr, 24 to 26 kg:</emphasis> 0.8 mg (16 ml) q day; <emphasis style="bold">Children 2 years and older weighing 21 to 23 kg:</emphasis> 0.7 mg (14 ml); <emphasis style="bold">Child ≥2yr, 18 to 20 kg:</emphasis> 0.6 mg (12 ml) q day; <emphasis style="bold">Child ≥2 yr, 15 to 17 kg:</emphasis> 0.5 mg (10 ml) q day; <emphasis style="bold">Child ≥2 yr, 12 to 14 kg:</emphasis> 0.4 mg (8 ml) q day;  10 to 11 kg: 0.3 mg (6 ml) q day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3180">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3188">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≥50 ml/min, 0.5 mg/day; CCr 30-49 ml/min, 0.25 mg/day, 0.5 mg/day or 1 mg q48hr for lamiVUDine-refractory patient; CCr 10-29 ml/min, 0.15/day or 1 mg q72hr for lamiVUDine-refractory patient; CCr &lt;10 ml/min, 0.05 mg/day, 0.1 mg/day or 1 mg q7day for lamiVUDine-refractory patient</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3191">
						<sec_title>Available forms:</sec_title>
						<para> Tabs, film coated 0.5, 1 mg; oral sol 0.05 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x3196">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3201">
								<item>
									<label>•</label>
									<para>After hemodialysis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3206">
								<item>
									<label>•</label>
									<para>By mouth on empty stomach 2 hr before or after food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3211">
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3219">
							<label>•</label>
							<sec_title>Oral liquid</sec_title>
							<para>
								<list id="lidelem4x3219">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral liquid:</emphasis> use calibrated oral dosing spoon provided; may be used interchangeably with tabs, do not dilute</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3223">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3226">
					<section type="none" id="sidelem4x3227">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x3235">
						<sec_title>ENDO:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x3240">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dyspepsia,</emphasis> nausea, vomiting, diarrhea, elevated liver function enzymes</para>
					</section>
					<section type="none" id="sidelem4x3248">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, rash</para>
					</section>
					<section type="none" id="sidelem4x3253">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis, severe hepatomegaly with steatosis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3260">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 0.5-1.5 hr, steady state 6-10 days, 100% bioavailability, extensively distributed to tissues, protein binding 13%, terminal half-life 128-149 hr, excreted unchanged (62%-73%) via kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x3265">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x3268">
					<section type="none" id="sidelem4x3269">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—high-fat meal</para>
					</section>
					<section type="none" id="sidelem4x3276">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, total bilirubin, amylase, lipase, creatinine, blood glucose, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, albumin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3287">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3290">
					<section type="none" id="sidelem4x3291">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3299">
							<label>•</label>
							<sec_title>For nephrotoxicity</sec_title>
							<para>
								<list id="lidelem4x3299">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">For nephrotoxicity:</emphasis> increasing CCr, BUN
<bbw>For HIV before beginning treatment because HIV resistance may occur in chronic hepatitis B patients; monitor HIV RNA</bbw>

<bbw>For lactic acidosis and severe hepatomegaly with stenosis; increased serum lactate, increased hepatic enzymes, palpate line; discontinue if present, discontinue if signs occur</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3321">
								<item>
									<label>•</label>
									<para>Geriatric patients more carefully; may develop renal, cardiac symptoms more rapidly
<bbw>For exacerbations of hepatitis (jaundice, pruritus, fatigue), anorexia after discontinuing treatment, and for several months monitor LFTs</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3336">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3340">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of chronic hepatitis B, improving LFTs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3346">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3351">
								<item>
									<label>•</label>
									<para>Not to take with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3356">
								<item>
									<label>•</label>
									<para>To take exactly as prescribed, read the “Patient Information,” take missed dose when remembered unless close to time of next dose; compliance with dosage schedule is required; do not share product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3361">
								<item>
									<label>•</label>
									<para>Not to stop medication without approval of prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3366">
								<item>
									<label>•</label>
									<para>That optimal duration of treatment is unknown</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3371">
								<item>
									<label>•</label>
									<para>To avoid use with other medications, supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3376">
								<item>
									<label>•</label>
									<para>To notify prescriber of decreased urinary output, blood in urine
<bbw>Symptoms of lactic acidosis: muscle pain, severe tiredness, weakness, trouble breathing, stomach pain with nausea/vomiting, coldness in arms/legs, fast/irregular heartbeat, dizziness</bbw>

<bbw>Symptoms of hepatotoxicity: eyes/skin turning yellow, dark urine, light bowel movements, no appetite for days, nausea, stomach pain</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3399">
								<item>
									<label>•</label>
									<para>That product does not cure but lowers amount of HBV in body</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3404">
								<item>
									<label>•</label>
									<para>That product does not stop spread of HBV to others by sex, sharing needles, or being exposed to blood</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3412">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed, to notify prescriber if pregnancy is planned or suspected</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3415">
								<item>
									<label>•</label>
									<para>Not to operate machinery until effect is known, dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3420">
								<item>
									<label>•</label>
									<para>That regular follow-up and lab tests will be needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ru="yes">
			<mono_name>enzalutamide</mono_name>
			<info>
				<pronunciation>(en-zal-u′ta-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34320">Xtandi</tradename>
				</tradenames>
				<class type="func"> Antineoplastic hormone</class>
				<class type="chem"> Nonsteroidal antiandrogen</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="uses" id="sidelem4x3442">
				<sec_title>Uses:</sec_title>
				<para>Metastatic castration-resistant prostate cancer in those who have received DOCEtaxel</para>
			</section>
			<section type="contra" id="sidelem4x3447">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), women, hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x3452">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3460">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3460">
							<item>
								<label>•</label>
								<para> 160 mg (4 × 40-mg caps) daily</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x3464">
						<item>
							<label>•</label>
							<para>If a patient experiences a grade 3 or higher toxicity or an intolerable adverse effect, withhold dosing for 1 wk or until symptoms improve to grade 2 or less, then resume at the same or a reduced dosage (120 or 80 mg), if warranted</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x3469">
						<item>
							<label>•</label>
							<para>The concomitant use of strong cytochrome P450 (CYP-450) 2C8 inhibitors should be avoided if possible; if a strong CYP2C8 inhibitor must be coadministered, reduce the enzalutamide dosage to 80 mg once daily</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x3474">
					<section type="none" id="sidelem4x3475">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 40 mg</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>epinastine (ophthalmic)</mono_name>
			<info>
				<pronunciation>(ep-ih-nas′teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x34850">Elestat</tradename>
				</tradenames>
				<class type="func"> Antihistamine (ophthalmic)</class>
				<class type="chem"> Histamine 1 receptor antagonist/mast cell stabilizer</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3495">
				<sec_title>Action:</sec_title>
				<para>A topically active, direct H<emphasis style="inf">1</emphasis>-receptor antagonist and mast cell stabilizer; by reducing these inflammatory mediators, it relieves the ocular pruritus associated with allergic conjunctivitis</para>
			</section>
			<section type="uses" id="sidelem4x3504">
				<sec_title>Uses:</sec_title>
				<para>Prevention of ocular pruritus associated with signs and symptoms of allergic conjunctivitis</para>
			</section>
			<section type="contra" id="sidelem4x3509">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x3514">
					<section type="none" id="sidelem4x3515">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, contact lenses</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3520">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3528">
					<label>•</label>
					<sec_title>Adult/child ≥3 yr<route> OPHTH</route></sec_title>
					<para>
						<list id="lidelem4x3528">
							<item>
								<label>•</label>
								<para> Instill 1 drop in each eye bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3532">
					<section type="none" id="sidelem4x3533">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic sol 0.5%</para>
						<section type="none" id="sidelem4x3538">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x3542">
									<item>
										<label>•</label>
										<para>For topical ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>The preservative benzalkonium chloride may be absorbed by soft contact lenses; wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not share ophthalmic drops with others</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep bottle tightly closed when not in use</para>
									</item>
									<item>
										<label>•</label>
										<para>Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3568">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3571">
					<section type="none" id="sidelem4x3572">
						<sec_title>EENT:</sec_title>
						<para> Ocular irritation, folliculosis, hyperemia, ocular pruritus</para>
					</section>
					<section type="none" id="sidelem4x3577">
						<sec_title>MISC:</sec_title>
						<para> Infection (including cold symptoms and upper respiratory infections), headache, rhinitis, sinusitis, increased cough, pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3582">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 3-5 min, peak 2 hr, duration 8 hr</para>
			</section>
			<section type="considerations" id="sidelem4x3587">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3590">
					<section type="none" id="sidelem4x3591">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3595">
								<item>
									<label>•</label>
									<para>Eyes: for itching, redness, use of soft or hard contact lenses</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3601">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3605">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of redness, itching in the eyes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3611">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3614">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x3618">
									<item>
										<label>•</label>
										<para>Product is for topical ophthalmic use only</para>
									</item>
									<item>
										<label>•</label>
										<para>Wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger; squeeze the prescribed number of drops into the conjunctival sac and gently close eyes for 1-2 min; do not blink</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>Wait ≥10 min after instilling the ophthalmic solution before inserting contact lenses; contact lenses should not be worn if eye is red</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep bottle tightly closed when not in use</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not share ophthalmic drops with others</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove contact lenses before use because the preservative benzalkonium chloride may be absorbed by soft contact lenses; product should not be used to treat contact lens–related irritation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active" ha="yes">
			<mono_name>EPINEPHrine (Rx)</mono_name>
			<info>
				<pronunciation>(ep-i-nef′rin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36613">Adrenaclick</tradename>
					<tradename id="tnidelem4x36612">Primatene Mist</tradename>
					<tradename id="tnidelem4x36611">Twinject</tradename>
					<tradename id="tnidelem4x36610">Walgreens Bronchial Mist</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="21" status="active">
			<mono_name>EPINEPHrine HCL</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x36662">Adrenalin</tradename>
					<tradename id="tnidelem4x36661">EpiPen</tradename>
					<tradename id="tnidelem4x36660">EpiPen Jr.</tradename>
				</tradenames>
				<class type="func"> Bronchodilator nonselective adrenergic agonist, vasopressor</class>
				<class type="chem"> Catecholamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3676">
				<para>
					<confusion>
						<tradename id="tnidelem4x36760">EPINEPHrine</tradename>
						<drug type="generic" refid="idelem4x36760">ePHEDrine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3680">
				<sec_title>Action:</sec_title>
				<para>β<emphasis style="inf">1</emphasis>- and β<emphasis style="inf">2</emphasis>-agonist causing increased levels of cAMP, thereby producing bronchodilation, cardiac, and CNS stimulation; high doses cause vasoconstriction via α-receptors; low doses can cause vasodilation via β<emphasis style="inf">2</emphasis>-vascular receptors</para>
			</section>
			<section type="uses" id="sidelem4x3694">
				<sec_title>Uses:</sec_title>
				<para>Acute asthmatic attacks, hemostasis, bronchospasm, anaphylaxis, allergic reactions, cardiac arrest, adjunct in anesthesia, shock</para>
				<section type="none" id="sidelem4x3701">
					<section type="none" id="sidelem4x3702">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bradycardia, chloroquine overdose</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3707">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, sulfites, closed-angle glaucoma, nonanaphylactic shock during general anesthesia</para>
				<section type="none" id="sidelem4x3712">
					<section type="none" id="sidelem4x3713">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac disorders, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, hypertension, organic brain syndrome, local anesthesia of certain areas, labor, cardiac dilation, coronary insufficiency, cerebral arteriosclerosis, organic heart disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3718">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3721">
					<section type="none" id="sidelem4x3722">
						<sec_title>Anaphylaxis/severe asthma exacerbation</sec_title>
						<section type="none" id="sidelem4x3730">
							<label>•</label>
							<sec_title>Adult<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3730">
									<item>
										<label>•</label>
										<para> 0.3-0.5 mg, may repeat q10-15min (anaphylaxis) or q20min-4 hr (asthma)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3734">
						<sec_title>Severe allergic reactions type I</sec_title>
						<section type="none" id="sidelem4x3742">
							<label>•</label>
							<sec_title>Adult/child ≥30 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3742">
									<item>
										<label>•</label>
										<para> 0.3 mg (EpiPen/EpiPen 2-Pak, 1:1000)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3749">
							<label>•</label>
							<sec_title>Child &lt;30 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3749">
									<item>
										<label>•</label>
										<para> 0.15 mg (EpiPen Jr/EpiPen Jr 2-Pak 1:2000)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3756">
							<label>•</label>
							<sec_title>Adult/child ≥66 lb<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3756">
									<item>
										<label>•</label>
										<para> 0.3 mg (0.3 ml) initially (Twinject 1.1 ml 1:1000, 1 mg/ml, containing 2 doses of 0.3 mg)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3763">
							<label>•</label>
							<sec_title>Adult/child 33-66 lb<route> IM/SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3763">
									<item>
										<label>•</label>
										<para> 0.15 mg (0.15 ml) initially, may give another 0.15 mg after 10 min (Twinject 1.1 ml 1:1000 [1 mg/ml] containing 2 doses of 0.15 mg)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3767">
						<sec_title>Status asthmaticus</sec_title>
						<section type="none" id="sidelem4x3775">
							<label>•</label>
							<sec_title>Adult/adolescent<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3775">
									<item>
										<label>•</label>
										<para> 0.3-0.5 mg (0.3-0.5 ml of the 1:1000 injection) q20min × 3 doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3782">
							<label>•</label>
							<sec_title>Infant/child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3782">
									<item>
										<label>•</label>
										<para> 0.01 mg/kg-0.5 mg q20min × 3 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3786">
						<sec_title>Available forms:</sec_title>
						<para> Nasal spray (sol) 1 mg/ml; sol for inj 1 mg/ml, 1:10,000, 1:1000; inh vapor (sol) 0.22 mg/actuation; pressurized inh (sol) 0.22 mg/actuation; sol for inj 0.15 mg/0.15 ml autoinjector, 0.3 mg/0.3 ml autoinjector, 0.15 mg/0.3 ml</para>
					</section>
					<section type="none" id="sidelem4x3791">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3796">
								<item>
									<label>•</label>
									<para>Increased dose of insulin for diabetic patients if glucose is elevated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3801">
								<item>
									<label>•</label>
									<para>Check for correct concentrations, route, dosage before administering</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3806">
								<item>
									<label>•</label>
									<para>Give subcut, IM, intraosseously, IV; suspensions are for subcut use only; do not give IV</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3811">
								<item>
									<label>•</label>
									<para>Visually inspect parenteral products for particulate matter and discoloration before use; do not use sols that are pinkish to brownish or that contain a precipitate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3819">
							<label>•</label>
							<sec_title>
								<route>Avoid extravasation during parenteral administration; if extravasation occurs, infiltrate the affected area with phentolamine diluted in NS</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3825">
							<label>•</label>
							<sec_title>
								<route>Death has occurred from drug errors, make sure the right concentration is used</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3828">
								<item>
									<label>•</label>
									<para>Store reconstituted sol refrigerated ≤24 hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3833">
							<sec_title>Inhalation route</sec_title>
							<para>
								<list id="lidelem4x3837">
									<item>
										<label>•</label>
										<para>Place in nebulizer (10 drops of a 1% base sol)</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute racepinephrine 2.25% sol</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3848">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x3852">
									<item>
										<label>•</label>
										<para>EPINEPHrine injection should preferably be into the deltoid or anterior thigh (vastus lateralis); do not administer into the gluteal muscle</para>
									</item>
									<item>
										<label>•</label>
										<para>Twinject is light sensitive and should be stored in the carrying case provided; do not refrigerate; protect from freezing; replace if solution is discolored or contains a precipitate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3863">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x3867">
									<item>
										<label>•</label>
										<para>Inject, taking care not to inject intradermally; massage injection site well after use to enhance absorption and to decrease local vasoconstriction; injection can cause tissue irritation</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3873">
							<sec_title>Intraosseous INFUSION route (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x3877">
									<item>
										<label>•</label>
										<para>During CPR, the same EPINEPHrine dosage may be given via the intraosseous route when IV access is not available</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3883">
							<sec_title>Intracardiac route</sec_title>
							<para>
								<list id="lidelem4x3887">
									<item>
										<label>•</label>
										<para>Intracardiac route should be reserved for extreme emergencies; intracardiac injection should only be performed by properly trained medical personnel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3893">
							<sec_title>Endotracheal route</sec_title>
							<para>
								<list id="lidelem4x3898">
									<item>
										<label>•</label>
										<para>Per the ACLS or PALS guidelines, the EPINEPHrine parenteral product is administered via endotracheal (ET) route; ET administration should only be used if access to IV or intraosseous routes is not possible</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3908">
								<label>•</label>
								<sec_title>Adult</sec_title>
								<para>
									<list id="lidelem4x3908">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Adult:</emphasis> Dilute dose in 5-10 ml of NS or sterile distilled water; administer via ET tube; endotracheal absorption of EPINEPHrine may be improved by diluting with water instead of NS</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3915">
								<label>•</label>
								<sec_title>Child</sec_title>
								<para>
									<list id="lidelem4x3915">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child:</emphasis> after dose administration, flush the ET tube with a minimum of 5 ml NS</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3919">
							<sec_title>Direct IV INJ route</sec_title>
							<para>
								<list id="lidelem4x3924">
									<item>
										<label>•</label>
										<para>Inject EPINEPHrine directly into a vein over 5-10 min for adults or 1-3 min for children; may be given IV push in cardiac arrest</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x3929">
									<item>
										<label>•</label>
										<para>In neonates, may administer via the umbilical vein</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x3937">
								<label>•</label>
								<sec_title>During adult cardiopulmonary resuscitation (CPR)</sec_title>
								<para>
									<list id="lidelem4x3937">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">During adult cardiopulmonary resuscitation (CPR):</emphasis> Resuscitation drugs may be given IV by bolus injection into a peripheral vein, followed by an injection of 20 ml IV fluid; elevate the extremity for 10-20 sec to facilitate drug delivery to the central circulation</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x3941">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x3945">
									<item>
										<label>•</label>
										<para>Dilute 1 mg EPINEPHrine in 250 or 500 ml of a compatible IV infusion sol to provide a concentration of 4 or 2 mcg/ml, respectively; give into a large vein, if possible; more-concentrated sols (16-32 mcg/ml) may be used in fluid-restricted patients when administered through a central line</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, amiodarone, amphotericin B liposome, anidulafungin, ascorbic acid, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, DOXOrubicin, doxycycline, enalaprilat, epirubicin, epoetin alfa, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, folic acid, furosemide, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, imipenem-cilastatin, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopa, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, morphine, multiple vitamins, nafcillin, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pancuronium, pantoprazole, PEMEtrexed, penicillin G potassium, pentamidine, pentazocine, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, ritodrine, rocuronium, sodium acetate, streptomycin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimethaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex with C, voriconazole, warfarin, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3955">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3958">
					<section type="none" id="sidelem4x3959">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, headache, <emphasis style="italic">dizziness,</emphasis> confusion, hallucinations, <emphasis style="bold">cerebral hemorrhage</emphasis>, weakness, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x3973">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia,</emphasis> hypertension, <emphasis style="bold">dysrhythmias, increased T wave</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3983">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Anorexia, nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3990">
						<sec_title>MISC:</sec_title>
						<para> Sweating, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x3995">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea,</emphasis><emphasis style="bold">paradoxical bronchospasm (inhalation)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4004">
						<sec_title>META: </sec_title>
						<para>Hypoglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4010">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Crosses placenta, metabolized in liver</para>
				<section type="none" id="sidelem4x4015">
					<section type="none" id="sidelem4x4016">
						<sec_title>IM:</sec_title>
						<para> Onset variable, duration 1-4 hr</para>
					</section>
					<section type="none" id="sidelem4x4021">
						<sec_title>SUBCUT:</sec_title>
						<para> Onset 5-15 min, duration 20 min-4 hr</para>
					</section>
					<section type="none" id="sidelem4x4026">
						<sec_title>INH:</sec_title>
						<para> Onset 1-5 min, duration 1-3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x4031">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4039">
					<label>•</label>
					<sec_title>
						<route>Do not use with MAOIs or tricyclics; hypertensive crisis may occur</route>
					</sec_title>
				</section>
				<section type="none" id="sidelem4x4045">
					<label>•</label>
					<sec_title>Toxicity<route> other sympathomimetics</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypertensive effects—β-adrenergic blockers, stop β-blocker 3 days before starting product</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—α-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac effects—antihistamines, thyroid replacement hormones</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> dysrhythmias—cardiac glycosides</para>
				<section type="none" id="sidelem4x4064">
					<section type="none" id="sidelem4x4065">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x4069">
								<item>
									<label>•</label>
									<para>Increased stimulation: coffee, tea, guarana, yerba maté</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4075">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4078">
					<section type="none" id="sidelem4x4079">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4087">
							<label>•</label>
							<sec_title>Asthma</sec_title>
							<para>
								<list id="lidelem4x4087">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Asthma:</emphasis> auscultate lungs, pulse, B/P, respirations, sputum (color, character); monitor pulmonary function studies before and during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4094">
							<label>•</label>
							<sec_title>Vasopressor<route> ECG during administration continuously; if B/P increases, decrease dose; B/P, pulse q5min after parenteral route; CVP, ISVR, PCWP during infusion if possible; inadvertent high arterial B/P can result in angina, aortic rupture, cerebral hemorrhage</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x4097">
								<item>
									<label>•</label>
									<para>Inj site: tissue sloughing; administer phentolamine with NS</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4105">
							<label>•</label>
							<sec_title>
								<route>Sulfite sensitivity; may be life-threatening</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4108">
								<item>
									<label>•</label>
									<para>Cardiac status, I&amp;O; blood glucose in diabetes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4116">
							<label>•</label>
							<sec_title>Allergic reactions, bronchospasms (swelling of face/lips/eyelids, rash, difficulty breathing)<route> withhold dose, notify prescriber</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4119">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4123">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased B/P with stabilization or ease of breathing</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4129">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4133">
								<item>
									<label>•</label>
									<para>About the reason for product administration; how to administer</para>
								</item>
								<item>
									<label>•</label>
									<para>To rinse mouth after use to prevent dryness after inhalation</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to take OTC preparations</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>EPINEPHrine nasal agent</mono_name>
			<section type="none" id="sidelem4x4157">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="23" status="active" ha="yes">
			<mono_name>epirubicin (Rx)</mono_name>
			<info>
				<pronunciation>(ep-ih-roo′bi-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41681">Ellence</tradename>
					<tradename id="tnidelem4x41680">
						<country code="CAN">Pharmorubicin </country>
					</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, antibiotic</class>
				<class type="chem"> Anthracycline</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4180">
				<para>
					<confusion>
						<tradename id="tnidelem4x41800">DOXOrubicin</tradename>
						<drug type="generic" refid="idelem4x41800"/>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4187">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA synthesis primarily; replication is decreased by binding to DNA, which causes strand splitting; maximum cytotoxic effects at S and for G<emphasis style="inf">2</emphasis> phases; a vesicant</para>
			</section>
			<section type="uses" id="sidelem4x4195">
				<sec_title>Uses:</sec_title>
				<para>Adjuvant therapy for breast cancer with axillary node involvement after resection</para>
				<section type="none" id="sidelem4x4200">
					<section type="none" id="sidelem4x4201">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Used in combination for treatment of advanced forms of cancer: bladder, gastric, head and neck, hepatocellular, lung, ovarian, multiple myeloma, soft-tissue sarcoma</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4206">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding; hypersensitivity to product, anthracyclines, anthracenediones; baseline neutrophil count &lt;1500 cell/mm<emphasis style="sup">3</emphasis>, severe myocardial insufficiency, recent MI, heart failure, cardiomyopathy</para>
				<para>
					<bbw>Severe hepatic disease, IM/SUBCUT use</bbw>
				</para>
				<section type="none" id="sidelem4x4225">
					<section type="none" id="sidelem4x4226">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, cardiac/renal/hepatic disease, accidental exposure, angina, dental disease, herpes, hyperkalemia, hyperphosphatemia, hypertension, hyperuricemia, hypocalcemia, infection, infertility, tumor lysis syndrome, ventricular dysfunction, previous anthracycline use</para>
						<para>
							<bbw>Bone marrow depression (severe), heart failure, extravasation, secondary malignancy, requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4241">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4244">
					<section type="none" id="sidelem4x4245">
						<sec_title>Breast cancer with axillary node involvement following resection of the primary tumor in combination with cyclophosphamide and fluorouracil</sec_title>
						<section type="none" id="sidelem4x4253">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4253">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis> on day 1 with fluorouracil and cyclophosphamide (FEC regimen) every 21 days × 6 cycles or 60 mg/m<emphasis style="sup">2</emphasis> on days 1 and 8 with oral cyclophosphamide and fluorouracil every 28 days × 6 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4263">
						<sec_title>Breast cancer in combination with cyclophosphamide</sec_title>
						<section type="none" id="sidelem4x4271">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4271">
									<item>
										<label>•</label>
										<para> 60 mg/m<emphasis style="sup">2</emphasis> day 1 with cyclophosphamide (500 mg/m<emphasis style="sup">2</emphasis> IV day 1), repeated every 21 days × 8 cycles or a higher-dose regimen of epirubicin 100 mg/m<emphasis style="sup">2</emphasis> IV day 1 with cyclophosphamide (830 mg/m<emphasis style="sup">2</emphasis> IV day 1), every 21 days × 8 cycles</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4287">
						<sec_title>
							<emphasis style="bold">Dosage adjustments based upon hematologic and non-hematologic toxicities</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x4296">
							<label>•</label>
							<sec_title>Nadir platelet counts &lt;50,000/mm3, absolute neutrophil counts (ANC) &lt;250/mm3, neutropenic fever, or grades 3/4 non-hematologic toxicities<route> day 1 dose in subsequent cycles should be reduced by 25% of the previous dose</route></sec_title>
						</section>
						<section type="none" id="sidelem4x4308">
							<label>•</label>
							<sec_title>For patients receiving divided-dose epirubicin (i.e., days 1 and 8)<route> Day 8 dose should be reduced by 25% of the day 1 dose if the platelet counts are 75,000-100,000/mm3 and the ANC is 1000-1499/mm3; if day 8 platelet counts are &lt;75,000/mm3, ANC &lt;1000/mm3, or Grade 3/4 non-hematologic toxicity has occurred, omit the day 8 dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4323">
						<sec_title>
							<emphasis style="bold">Hepatic dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x4332">
							<label>•</label>
							<sec_title>Adult<route> IV Bilirubin 1.2-3 mg/dl or AST 2-4× normal upper limit, 50% of starting dose; bilirubin &gt;3-5 mg/dl or AST &gt;4 × normal upper limit, 25% of starting dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4335">
						<sec_title>Available forms:</sec_title>
						<para> Inj (2 mg/ml) 10 mg/5 ml, 50 mg/25 ml, 150 mg/75 ml, 200 mg/100 ml</para>
					</section>
					<section type="none" id="sidelem4x4340">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4345">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product to prevent vomiting
<bbw>To be used by a clinician experienced in giving cytotoxic products</bbw>

<bbw>Do not use IM/SUBCUT because of severe tissue necrosis, give IV, only, subcut; a vesicant; if extravasation occurs stop and complete via another vein, preferably in another limb; avoid infusion into veins over joints or in extremities with compromised venous or lymphatic drainage</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4368">
								<item>
									<label>•</label>
									<para>Rapid injection can cause facial flushing or erythema along the vein; avoid administration time of &lt;3 min</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4376">
							<label>•</label>
							<sec_title>
								<route>Product should be given to those with neutrophils ≥1500/mm3, platelet count ≥100,000/mm3, and nonhematologic toxicities recovered to ≤grade 1</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4385">
								<item>
									<label>•</label>
									<para>When refrigerated, the preservative-free, ready-to-use solution can form a gelled product and will return to solution after 2-4 hr at room temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4390">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter and discoloration before use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4395">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x4399">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures; pregnant women must not handle product</para>
									</item>
									<item>
										<label>•</label>
										<para>Reconstitute 50 mg and 200 mg powder for injection vials with 25 ml and 100 ml, respectively, of sterile water for injection (2 mg/ml), shake vigorously for up to 4 min; reconstituted sols are stable for 24 hr when stored refrigerated and protected from light or at room temperature in normal light</para>
									</item>
									<item>
										<label>•</label>
										<para>Solution can be further diluted with sterile water for injection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4416">
							<sec_title>IV INJ route</sec_title>
							<para>
								<list id="lidelem4x4420">
									<item>
										<label>•</label>
										<para>Give doses of 100-120 mg/m<emphasis style="sup">2</emphasis> into tubing of a freely flowing 0.9% sodium chloride (NS) or D<emphasis style="inf">5</emphasis>W IV infusion over 15-20 min; the infusion time may be decreased, proportionally, in those who require lower doses; infusion times &lt;3 min are not recommended</para>
									</item>
									<item>
										<label>•</label>
										<para>Direct injection into the vein is not recommended because of the risk of extravasation; avoid use with any solution of alkaline pH because hydrolysis will occur</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4437">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4441">
									<item>
										<label>•</label>
										<para>Dilute dose in 0.9% sodium chloride (NS) or D<emphasis style="inf">5</emphasis>W, infuse over 30-60 min, avoid use with any solution of alkaline pH because hydrolysis will occur</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amifostine, amikacin, aminocaproic acid, anidulafungin, argatroban, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefotaxime, ceftizoxime, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, DAPTOmycin, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, ertapenem, erythromycin, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, gatifloxacin, gemcitabine, gentamicin, granisetron, haloperidol, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), isoproterenol, labetalol, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, mannitol, meperidine, mesna, methotrexate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mivacurium, morphine, moxifloxacin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, pentamidine, pentazocine, phenylephrine, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiotepa, tigecycline, tirofiban, tobramycin, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4454">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4457">
					<section type="none" id="sidelem4x4458">
						<sec_title>CV:</sec_title>
						<para> Increased B/P, <emphasis style="bold">sinus tachycardia, PVCs,</emphasis> chest pain, <emphasis style="bold">bradycardia, extrasystoles,</emphasis> cardiomyopathy</para>
					</section>
					<section type="none" id="sidelem4x4469">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, mucositis, diarrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4476">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Amenorrhea, hot flashes, hyperuricemia, red urine</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4483">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, anemia, neutropenia, secondary AML</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4490">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">necrosis,</emphasis><emphasis style="italic">pain at inj site, reversible alopecia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4501">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Infection, febrile neutropenia, lethargy, fever, conjunctivitis,</emphasis><emphasis style="bold">tumor lysis syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4510">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Triphasic pattern of elimination; half-life 3 min, 1 hr, 30 hr; metabolized by liver; crosses placenta; excreted in urine, bile, breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x4515">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4523">
					<label>•</label>
					<sec_title>
						<route>Give epirubicin before PACLitaxel if both are given</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—other antineoplastics or radiation, cimetidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> ventricular dysfunction, CHF—trastuzumab</para>
				<para>
					<emphasis alert="lifethreat">Increased: heart failure—calcium channel blockers</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Decrease: antibody response—live virus vaccine</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x4540">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4543">
					<section type="none" id="sidelem4x4544">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression (severe):</emphasis> CBC, differential, platelet count weekly; withhold product if baseline neutrophil ≤1500/mm3; leukocyte nadir occurs 10-14 days after administration, recovery by day 21; notify prescriber of results</bbw>
						</para>
						<section type="none" id="sidelem4x4566">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x4566">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> treat before receiving this product if regimens &gt;120 mg/m<emphasis style="sup">2</emphasis>, prophylactic antibiotics should be given (trimethaprin-sulfamethoxazole or a quinolone)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4573">
								<item>
									<label>•</label>
									<para>Blood, urine uric acid levels; swelling, joint pain primarily in extremities; patient should be well hydrated to prevent urate deposits</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4578">
								<item>
									<label>•</label>
									<para>Renal disease: BUN, serum uric acid, urine CCr, electrolytes before, during therapy; I&amp;O ratio; report fall in urine output to &lt;30 ml/hr; dosage adjustment needed if serum creatinine &gt;5 mg/dl</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4583">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2-3 L/day to prevent urate, calculi formation</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Hepatic studies before, during therapy: bilirubin, AST, ALT, alk phos as needed or monthly</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Heart failure:</emphasis> B/P, pulse, character, rhythm, rate, ABGs, ECG, LVEF, MUGA scan, or ECHO; watch for ST-T wave changes, low QRS and T, possible dysrhythmias (sinus tachycardia, heart block, PVCs); identify cumulative amount of anthracycline received (lifetime)</bbw>
						</para>
						<para>
							<list id="lidelem4x4610">
								<item>
									<label>•</label>
									<para>Bleeding: hematuria, guaiac, bruising, or petechiae, mucosa or orifices q8hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Extravasation (vesicant):</emphasis> local irritation, pain, burning, necrosis at inj site, discontinue and start at another site</bbw>
						</para>
						<para>
							<list id="lidelem4x4633">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4639">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4643">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4649">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4654">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that wig or hairpiece may make patient feel better; that new hair may be different in color, texture; new hair growth occurs in ≤3 mo after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4659">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with infections when granulocyte count is low</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4667">
							<label>•</label>
							<sec_title>
								<route>That contraceptive measures recommended during therapy and for 4 mo thereafter for men and women; pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4670">
								<item>
									<label>•</label>
									<para>To avoid vaccinations because reactions may occur; to avoid cimetidine during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4675">
								<item>
									<label>•</label>
									<para>That urine may appear red for 2 days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4680">
								<item>
									<label>•</label>
									<para>To avoid OTC medications, supplements unless approved by prescriber
<bbw>That irreversible myocardial damage, leukopenia, menopause may occur</bbw>
</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4697">
							<label>•</label>
							<sec_title>
								<route>To report rapid heartbeat, trouble breathing, fever, nausea, vomiting, oral sores</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x4700">
								<item>
									<label>•</label>
									<para>To report pain at site immediately</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>eplerenone (Rx)</mono_name>
			<info>
				<pronunciation>(ep-ler-ee′known)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x47100">Inspra</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Selective aldosterone receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4720">
				<para>
					<confusion>
						<tradename id="tnidelem4x47200">Inspra</tradename>
						<drug type="generic" refid="idelem4x47201"/>
						<drug type="generic" refid="idelem4x47200">Spiriva</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4724">
				<sec_title>Action:</sec_title>
				<para>Binds to mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone system (RAAS)</para>
			</section>
			<section type="uses" id="sidelem4x4731">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics, CHF, post-MI</para>
			</section>
			<section type="contra" id="sidelem4x4736">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; increased serum creatinine &gt;2 mg/dl (male), &gt;1.8 mg/dl (female); potassium &gt;5.5 mEq/L, type 2 diabetes with microalbuminuria, hepatic disease, CCr &lt;30 ml/min; CCr &lt;50 ml/min in hypertension</para>
				<section type="none" id="sidelem4x4741">
					<section type="none" id="sidelem4x4742">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, impaired renal/hepatic function, hyperkalemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4747">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4750">
					<section type="none" id="sidelem4x4751">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x4759">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4759">
									<item>
										<label>•</label>
										<para> 50 mg/day initially, may increase to 50 mg bid after 4 wk; start dose at 25 mg/day if patient is taking CYP3A4 inhibitors</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4763">
						<sec_title>CHF or post-MI</sec_title>
						<section type="none" id="sidelem4x4771">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4771">
									<item>
										<label>•</label>
										<para> 25 mg/day initially, may increase to 50 mg/day max after 4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4775">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50 mg</para>
					</section>
					<section type="none" id="sidelem4x4780">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4784">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use salt substitutes containing potassium</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight container at ≤86° F (30° C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4800">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4803">
					<section type="none" id="sidelem4x4804">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="italic">dizziness, fatigue</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4811">
						<sec_title>CV:</sec_title>
						<para> Angina, <emphasis style="bold">MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4818">
						<sec_title>GI:</sec_title>
						<para> Increased GGT <emphasis style="italic">diarrhea,</emphasis> abdominal pain, increased ALT</para>
					</section>
					<section type="none" id="sidelem4x4826">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, mastodynia (males), abnormal vaginal bleeding</para>
					</section>
					<section type="none" id="sidelem4x4831">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hyperkalemia,</emphasis> hyponatremia, hypercholesteremia, hypertriglyceridemia, increased uric acid</para>
					</section>
					<section type="none" id="sidelem4x4839">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4846">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; serum protein binding 50%; half-life 4-6 hr; metabolized in liver by CYP3A4; excreted in urine, feces</para>
			</section>
			<section type="interactions" id="sidelem4x4857">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—ACE inhibitors, angiotensin II antagonists, NSAIDs, potassium supplements, potassium-sparing diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serum levels of lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> eplerenone levels—erythromycin, fluconazole, verapamil; reduce dose of eplerenone</para>
				<para>
					<emphasis alert="lifethreat">Increase: levels of eplerenone—CYP3A4 inhibitors (ketoconazole, itraconazole, saquinavir, clarithromycin, imatinib, nelfinavir, nefazodone, ritonavir, troleandomycin; do not use concurrently); reduce dose of eplerenone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<section type="none" id="sidelem4x4879">
					<section type="none" id="sidelem4x4880">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x4887">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x4891">
								<item>
									<label>•</label>
									<para>Grapefruit, grapefruit juice increase product level by 25%</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use salt substitutes containing potassium</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4902">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine, potassium, cholesterol, lipids, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> sodium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4913">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4916">
					<section type="none" id="sidelem4x4917">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4925">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x4925">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P at peak/trough level of product, orthostatic hypotension, syncope when used with diuretic; monitor lithium level in those also taking lithium</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4932">
							<label>•</label>
							<sec_title>Renal studies</sec_title>
							<para>
								<list id="lidelem4x4932">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal studies:</emphasis> protein, BUN, creatinine; increased LFTs, uric acid may be increased</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4936">
								<item>
									<label>•</label>
									<para>Potassium levels, hyperkalemia may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4941">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4945">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4951">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4955">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, allergy) unless directed by prescriber; not to use salt substitutes containing potassium without consulting prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, light-headedness; may occur during first few days of therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>How to take B/P; and about normal readings for age group</para>
								</item>
								<item>
									<label>•</label>
									<para>Avoid activities that require coordination</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active" ha="yes">
			<mono_name>epoetin alfa (Rx)</mono_name>
			<info>
				<pronunciation>(ee-poe′e-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x49942">Epogen</tradename>
					<tradename id="tnidelem4x49941">
						<country code="CAN">Eprex </country>
					</tradename>
					<tradename id="tnidelem4x49940">Procrit</tradename>
				</tradenames>
				<class type="func"> Antianemic, biologic modifier, hormone</class>
				<class type="chem"> Amino acid polypeptide</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5007">
				<sec_title>Action:</sec_title>
				<para>Erythropoietin is a factor controlling the rate of red cell production; product is developed by recombinant DNA technology</para>
			</section>
			<section type="uses" id="sidelem4x5012">
				<sec_title>Uses:</sec_title>
				<para>Anemia caused by reduced endogenous erythropoietin production, primarily end-stage renal disease; to correct hemostatic defect in uremia; anemia due to AZT treatment in patients with HIV or those receiving chemotherapy; reduction of allogenic blood transfusion in surgery patients</para>
				<section type="none" id="sidelem4x5017">
					<section type="none" id="sidelem4x5018">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Anemia in premature preterm infants, anemia due to ribavirin and interferon-alfa therapy in hepatitic C</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5023">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to mammalian-cell–derived products, human albumin; uncontrolled hypertension</para>
				<section type="none" id="sidelem4x5028">
					<section type="none" id="sidelem4x5029">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;1 mo, seizure disorder; multidose preserved formulation contains benzyl alcohol and should not be used in premature infants; porphyria, CV disease, hemodialysis, latex allergy, hypertension, history of CABG</para>
						<para>
							<bbw>Hgb &gt;11 g/dl, surgery, neoplastic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5044">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5047">
					<section type="none" id="sidelem4x5048">
						<sec_title>Anemia (chronic kidney disease including dialysis-dependent and dialysis-independent patients to decrease the need for red blood cell transfusion)</sec_title>
						<section type="none" id="sidelem4x5056">
							<label>•</label>
							<sec_title>Adult/adolescent ≥17 yr<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x5056">
									<item>
										<label>•</label>
										<para> Initially, 50–100 units/kg 3×/wk; for patients on dialysis, administer IV; for patients on dialysis, initiate treatment when hemoglobin (Hgb) is &lt;10 g/dl; if Hgb approaches or exceeds 11 g/dl, reduce or interrupt the dose; for patients not on dialysis, consider initiating treatment only when Hgb is &lt;10 g/dl and the rate of Hgb decline indicates the likelihood of requiring RBC transfusion and reducing the risk of alloimmunization and/or other RBC transfusion–related risks is a goal; if Hgb is &gt;10 g/dl, reduce or interrupt the dose, and use the lowest dose sufficient to reduce the need for RBC transfusions; if the Hgb rises &gt;1 g/dl in any 2-wk period, reduce dose by 25% or more as needed to reduce rapid responses; in contrast, if Hgb has not increased &gt;1 g/dl after 4 wk of therapy, increase the dose by 25%; for patients who do not respond adequately over a 12-wk escalation period, increasing the dose further is unlikely to improve response and can increase risks; use the lowest dose that will maintain a Hgb concentration sufficient to reduce the need for RBC transfusions; evaluate other causes of anemia, and discontinue if responsiveness does not improve</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5063">
							<label>•</label>
							<sec_title>Infant/child/adolescent ≤16 yr<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x5063">
									<item>
										<label>•</label>
										<para> 50 units/kg 3×/wk initially; for dosage adjustments, see adult dosage</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5067">
						<sec_title>Zidovudine-induced anemia in HIV-infected patients with circulating endogenous erythropoietin concentrations ≤500 mUnits/ml who are receiving a dose of zidovudine ≤4200 mg/wk</sec_title>
						<section type="none" id="sidelem4x5075">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT/IV</route></sec_title>
							<para>
								<list id="lidelem4x5075">
									<item>
										<label>•</label>
										<para> Initially, 100 units/kg 3×/wk; if Hgb does not increase after 8 wk, increase by 50-100 units/kg at 4- 8-wk intervals until Hgb is at a concentration to avoid RBC transfusions or a dose of 300 units/kg is reached; if the Hgb is &gt;12 g/dl, withhold, once Hgb is &lt;11 g/dl resume at a dose 25% below the previous dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5081">
						<sec_title>Anemia (non-myeloid malignancies when anemia is due to the effect of concomitantly administered chemotherapy and at least 2 additional mo of chemotherapy is planned)</sec_title>
						<section type="none" id="sidelem4x5089">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5089">
									<item>
										<label>•</label>
										<para> 150 units/kg 3×/wk or 40,000 units 1×/wk only when the hemoglobin is &lt;10 g/dl and only until the chemotherapy course is completed; adjust the dosage to maintain the lowest Hgb concentration rise of &lt;1-2 g/dl sufficient to avoid RBC transfusions; if no rise in Hgb ≥1 g/dl after 4 wk of therapy and Hgb is &lt;10 g/dl, the dosage may be increased to 300 units/kg subcut 3×/wk or 60,000 units 1×/wk; discontinue if after 8 wk of therapy there is no response as measured by Hgb concentrations or if transfusions are still required; reduce the dosage by approximately 25% if Hgb increases by &gt;1 g/dl in any 2-wk period or if Hgb reaches a concentration needed to avoid RBC infusion; if Hgb is increasing and exceeds a concentration necessary to avoid blood transfusions, hold therapy and reinstitute at a dose that is 25% lower when the Hgb reaches a concentration where transfusions may be needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5096">
							<label>•</label>
							<sec_title>Adolescent/child ≥5 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5096">
									<item>
										<label>•</label>
										<para> 600 units/kg/wk only when the hemoglobin is &lt;10 g/dl and only until the chemotherapy course is completed; adjust the dosage to maintain the lowest Hgb concentrations sufficient to avoid RBC transfusions; if no rise in Hgb ≥1 g/dl after 4 wk of therapy and Hgb is &lt;10 g/dl, the dosage may be increased to 900 units/kg (up to 60,000 units)/wk IV; discontinue if after 8 wk there is no response as measured by Hgb concentrations or if transfusions are still required; reduce the dosage by approximately 25% if Hgb increases by more than 1 g/dl in any 2-wk period or if Hgb reaches a concentration needed to avoid RBC infusion; if the Hgb is increasing and exceeds a concentration necessary to avoid blood transfusions, hold therapy and reinstitute at a dose that is 25% lower when the Hgb reaches a concentration where transfusions may be needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5100">
						<sec_title>To reduce the need for allogenic blood transfusions in anemic patients (hemoglobin &gt;10 and ≤13 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery</sec_title>
						<section type="none" id="sidelem4x5108">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x5108">
									<item>
										<label>•</label>
										<para> 300 units/kg/day × 10 days before surgery, on the day of surgery, and for 4 days after surgery (15 days total) or 600 units/kg 1×/wk, 21, 14, and 7 days before surgery plus 1 dose on the day of surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5112">
						<sec_title>Available forms:</sec_title>
						<para> Inj 2000, 3000, 4000, 10,000, 20,000, 40,000 units/ml</para>
					</section>
					<section type="none" id="sidelem4x5117">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5121">
								<item>
									<label>•</label>
									<para>Do not shake vial</para>
								</item>
								<item>
									<label>•</label>
									<para>Use 1 single-use vial/dose, once syringe has entered single-dose vial, sterility cannot be guaranteed, do not administer with other product, multidose vials can be stored in refrigerator up to 21 days once opened, do not use if discolored or particulates are present</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5132">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x5136">
									<item>
										<label>•</label>
										<para>Before injecting preservative-free, single-dose formulation may be admixed using 0.9% NaCl with benzyl alcohol 0.9% at a 1:1 ratio to reduce inj-site discomfort, store solution in refrigerator, protect from light</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5142">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x5146">
									<item>
										<label>•</label>
										<para>Additional heparin to lower chance of clots</para>
									</item>
									<item>
										<label>•</label>
										<para>By direct inj or bolus into IV tubing or venous line at end of dialysis</para>
									</item>
									<item>
										<label>•</label>
										<para>Decrease dose by 25% if Hgb increases by 1 g/dl in 2 wk; increase dose if Hgb does not increase by 5-6 pts after 8 wk of therapy; suggested target Hgb range 30%-36%</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> Do not dilute or administer with other sol</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5166">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5169">
					<section type="none" id="sidelem4x5170">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> coldness, sweating, headache, fatigue, dizziness</para>
					</section>
					<section type="none" id="sidelem4x5178">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension,</emphasis><emphasis style="bold">hypertensive encephalopathy, CHF,</emphasis> edema, <emphasis style="bold">DVT</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5191">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash, inj site reaction</para>
					</section>
					<section type="none" id="sidelem4x5196">
						<sec_title>MISC:</sec_title>
						<para> Iron deficiency</para>
					</section>
					<section type="none" id="sidelem4x5201">
						<sec_title>MS:</sec_title>
						<para> Bone pain, arthralgia, myalgia</para>
					</section>
					<section type="none" id="sidelem4x5206">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5211">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5214">
					<section type="none" id="sidelem4x5215">
						<sec_title>IV:</sec_title>
						<para> Metabolized in body, extent of metabolism unknown, onset of increased reticulocyte count 2-6 wk, peak immediate; <emphasis style="bold">Subcut:</emphasis> Peak 5-24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5223">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x5227">
						<item>
							<label>•</label>
							<para>Need for increased heparin during hemodialysis</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x5233">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5236">
					<section type="none" id="sidelem4x5237">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5242">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood, BUN, creatinine; I&amp;O, report drop in output &lt;50 ml/hr
<bbw>Blood studies: ferritin, transferrin, serum iron monthly; transferrin sat ≥20%, ferritin ≥100 ng/ml; Hct 2×/wk until stabilized in target range (30%-36%) then at regular intervals; those with endogenous erythropoietin levels of &lt;500 units/L respond to product; monitor Hct 2×/wk with chronic renal failure; patients treated with zidovudine or patients with cancer should be monitored weekly, then periodically after stabilization; death may occur with Hgb &gt;12 g/dl</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5257">
								<item>
									<label>•</label>
									<para>B/P; check for rising B/P as Hct rises, antihypertensives may be needed; hypertension may occur rapidly, leading to hypertensive encephalopathy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5262">
								<item>
									<label>•</label>
									<para>CNS symptoms: coldness, sweating, pain in long bones; for seizures if Hct is increased within 2 wk by 4 pts</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5267">
								<item>
									<label>•</label>
									<para>Hypersensitivity reactions: skin rashes, urticaria (rare), antibody development does not occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5273">
								<item>
									<para>
										<emphasis alert="nurse">Pure cell aplasia (PRCA) in absence of other causes; evaluate by testing sera for recombinant erythropoetin antibodies; any loss of response to epoetin should be evaluated</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5278">
								<item>
									<label>•</label>
									<para>Dialysis patients: thrill, bruit of shunts; monitor for circulation impairment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5286">
							<label>•</label>
							<sec_title>Seizures<route> place patient on seizure precautions if increase of ≥4 points HCT in 2 wk, increased B/P; more common in chronic renal failure during the first 90 days of treatment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5289">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5293">
								<item>
									<label>•</label>
									<para>Therapeutic response: increase in reticulocyte count in 2-6 wk, Hgb/Hct; increased appetite, enhanced sense of well-being</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5299">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5303">
								<item>
									<label>•</label>
									<para>To avoid driving or hazardous activities during beginning of treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To monitor B/P</para>
								</item>
								<item>
									<label>•</label>
									<para>To take iron supplements, vit B<emphasis style="inf">12</emphasis>, folic acid as directed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active">
			<mono_name>eprosartan (Rx)</mono_name>
			<info>
				<pronunciation>(ep-roh-sar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x53270">Teveten</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II–receptor antagonist (Subtype AT)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x5340">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x5348">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or with other antihypertensives</para>
			</section>
			<section type="contra" id="sidelem4x5353">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x5368">
					<section type="none" id="sidelem4x5369">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, hypersensitivity to ACE inhibitors; renal/hepatic disease, angioedema, hyperkalemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5374">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5382">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5382">
							<item>
								<label>•</label>
								<para> 600 mg/day; dose may be divided, given bid, with total daily doses from 400-800 mg, max 900 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5387">
					<section type="none" id="sidelem4x5388">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x5397">
							<label>•</label>
							<sec_title>Adult<route> PO CCr ≤30 ml/min, max 600 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5400">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 600 mg</para>
					</section>
					<section type="none" id="sidelem4x5405">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5409">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5415">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5418">
					<section type="none" id="sidelem4x5419">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> depression, <emphasis style="italic">fatigue,</emphasis> headache</para>
					</section>
					<section type="none" id="sidelem4x5430">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypotension, palpitations</para>
					</section>
					<section type="none" id="sidelem4x5435">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis</para>
					</section>
					<section type="none" id="sidelem4x5440">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dyspepsia, abdominal pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5447">
						<sec_title>GU:</sec_title>
						<para> UTI</para>
					</section>
					<section type="none" id="sidelem4x5452">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5459">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5466">
						<sec_title>META:</sec_title>
						<para> Hypertriglyceridemia</para>
					</section>
					<section type="none" id="sidelem4x5471">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Myalgia,</emphasis> arthralgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5481">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, upper respiratory infection,</emphasis> rhinitis, pharyngitis, viral infection</para>
					</section>
					<section type="none" id="sidelem4x5489">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5496">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, food delays absorption; protein binding 98%; moderate renal impairment increases product levels by 30%, hepatic impairment increases levels by 40%; excreted in urine and feces; half-life 5-9 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5501">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—other antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, potassium supplements</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lithium toxicity—lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x5524">
					<section type="none" id="sidelem4x5525">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
					</section>
					<section type="none" id="sidelem4x5536">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, alk phos, potassium</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5547">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5550">
					<section type="none" id="sidelem4x5551">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5556">
								<item>
									<label>•</label>
									<para>B/P with position changes, pulse q4hr; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5562">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity reactions, including anaphylaxis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5568">
								<item>
									<para>
										<emphasis alert="nurse">Myalgia, arthralgia; may cause rhabdomyolysis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5573">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5578">
								<item>
									<label>•</label>
									<para>Edema in feet, legs daily, weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5583">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5588">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5592">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5598">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5602">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of fever; chest pain; swelling of hands, feet, face, lip, or tongue</para>
								</item>
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, diarrhea may lead to fall in B/P; consult prescriber if these occur, maintain adequate hydration</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness; to avoid hazardous activities until effect is known; to rise slowly from sitting
<bbw>Not to take this product if pregnant or breastfeeding, or if have had an allergic reaction to product</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To take missed dose as soon as possible unless within 1 hr before next dose</para>
								</item>
								<item>
									<label>•</label>
									<para>That therapeutic effect may take 2-3 wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="27" status="active" ha="yes">
			<mono_name>eptifibatide (Rx)</mono_name>
			<info>
				<pronunciation>(ep-tih-fib′ah-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x56490">Integrilin</tradename>
				</tradenames>
				<class type="func"> Antiplatelet agent</class>
				<class type="chem"> Glycoprotein IIb/IIIa inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5659">
				<sec_title>Action:</sec_title>
				<para>Platelet glycoprotein antagonist; this agent reversibly prevents fibrinogen, von Willebrand’s factor from binding to the glycoprotein IIb/IIIa receptor, thus inhibiting platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x5666">
				<sec_title>Uses:</sec_title>
				<para>Acute coronary syndrome including those undergoing percutaneous coronary intervention (PCI)</para>
			</section>
			<section type="contra" id="sidelem4x5671">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, active internal bleeding; recent history of bleeding, stroke within 30 days or any hemorrhagic stroke; major surgery with severe trauma, severe hypertension, current or planned use of another parenteral GP IIb/IIIa inhibitor, dependence on renal dialysis, coagulopathy, AV malformation, aneurysm</para>
				<section type="none" id="sidelem4x5676">
					<section type="none" id="sidelem4x5677">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, bleeding, impaired renal function</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5682">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5685">
					<section type="none" id="sidelem4x5686">
						<sec_title>Acute coronary syndrome</sec_title>
						<section type="none" id="sidelem4x5694">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x5694">
									<item>
										<label>•</label>
										<para> 180 mcg/kg as soon as diagnosed, max 22.6 mg, then  2 mcg/kg/min or CABG discontinue ≥2-4 hr before procedure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5701">
						<sec_title>PCI in patients without acute coronary syndrome</sec_title>
						<section type="none" id="sidelem4x5709">
							<label>•</label>
							<sec_title>Adult<route> IV BOL</route></sec_title>
							<para>
								<list id="lidelem4x5709">
									<item>
										<label>•</label>
										<para> 180 mcg/kg given immediately before PCI, then 2 mcg/kg/min × 18 hr CONT IV INFUSION and a second 180-mcg/kg bolus by 10 min after 1st bolus; continue infusion for up to 18-24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5713">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x5722">
							<label>•</label>
							<sec_title>Adult<route> IV maintenance CCr &lt;50 ml/min, 1 mcg/kg/min, max rate 7.5 mg/hr; CCr &lt;10 ml/min, contraindicated</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5725">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 2 mg/ml (10 ml), 0.75 mg/ml (100 ml)</para>
					</section>
					<section type="none" id="sidelem4x5730">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5735">
								<item>
									<label>•</label>
									<para>Aspirin may be given with this product; check for bleeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5740">
								<item>
									<label>•</label>
									<para>D/C heparin before removing femoral artery sheath, after PCI</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5745">
								<item>
									<label>•</label>
									<para>Do not give discolored solutions, those with particulates; discard unused amount, protect from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5753">
							<label>•</label>
							<sec_title>
								<route>Discontinue product before CABG</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x5756">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x5760">
									<item>
										<label>•</label>
										<para>After withdrawing bolus dose from 10-ml vial, give IV push over 1-2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5766">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5770">
									<item>
										<label>•</label>
										<para>Follow bolus dose with continuous infusion using pump; give product undiluted directly from 100-ml vial, spike 100-ml vial with vented infusion set, use caution when centering spike on circle of stopper top, refrigerate vials, or may store vials ≤2 mo at room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, alteplase, amikacin, aminophylline, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, atropine, azithromycin, aztreonam, bivalirudin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, clindamycin, cycloSPORINE, DAPTOmycin, dexamethasone, D<emphasis style="inf">5</emphasis>/NaCl 0.9%, diazepam, diltiazem, diphenhydrAMINE, DOBUTamine, dolasetron, DOPamine, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, ertapenem, erythromycin, esmolol, famotidine, fentaNYL, fluconazole, fosphenytoin, ganciclovir, gatifloxacin, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, imipenem-cilastatin, inamrinone, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, meperidine, meropenem, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, minocycline, mivacurium, morphine, nalbuphine, naloxone, niCARdipine, nitroglycerin, nitroprusside, NS, octreotide, ofloxacin, ondansetron, oxytocin, palonosetron, pancuronium, PEMEtrexed, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, ranitidine, remifentanil, rocuronium, sodium bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, teniposide, theophylline, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, trimethobenzamide, vancomycin, vecuronium, verapamil, zidovudine, zoledronic acid</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> 0.9% NaCl, D<emphasis style="inf">5</emphasis>/0.9% NaCl</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5792">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5795">
					<section type="none" id="sidelem4x5796">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Stroke,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x5804">
						<sec_title>GU:</sec_title>
						<para> Hematuria</para>
					</section>
					<section type="none" id="sidelem4x5809">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, platelet dysfunction</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5816">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Major/minor bleeding from any site, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5823">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset within 1 hr, protein binding 25%, half-life 1.5-2 hr, steady state 4-6 hr, metabolism limited, excretion via kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x5828">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5836">
					<label>•</label>
					<sec_title>
						<route>Do not give with glycoprotein inhibitors IIb, IIIa</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—aspirin, heparin, NSAIDs, anticoagulants, ticlopidine, clopidogrel, dipyridamole, thrombolytics, valproate, abciximab, SSRIs, SNRIs</para>
				<section type="none" id="sidelem4x5843">
					<section type="none" id="sidelem4x5844">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> Bleeding risk—feverfew, garlic, ginger, ginkgo, ginseng</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5851">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5854">
					<section type="none" id="sidelem4x5855">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis alert="nurse">Thrombocytopenia: platelets, Hgb, Hct, creatinine, APTT baseline within 6 hr of loading dose, daily therafter, patients undergoing PCI should have ACT monitored; maintain APTT 50-70 sec unless PCI to be performed; during PCI, ACT should be 200-300 sec; if platelets drop &lt;100,000/mm<emphasis style="sup">3</emphasis>, obtain additional platelet counts; if thrombocytopenia is confirmed, discontinue product; draw Hct, Hgb, serum creatinine</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Bleeding: gums, bruising, ecchymosis, petechiae; from GI, GU tract, cardiac cath sites, IM inj sites</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x5871">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5876">
								<item>
									<label>•</label>
									<para>About reason for medication and expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5884">
							<label>•</label>
							<sec_title>
								<route>To report bruising, bleeding, chest pain immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="28" status="active" ha="yes">
			<mono_name>eribulin</mono_name>
			<info>
				<pronunciation>(er′i-bu′lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x58940">Halaven</tradename>
				</tradenames>
				<class type="func"> Antineoplastics—non-taxane</class>
			</info>
			<section type="confusion" id="sidelem4x5900">
				<para>
					<confusion>
						<tradename id="tnidelem4x59000">eribulin</tradename>
						<drug type="generic" refid="idelem4x59000">epirubicin/erlotinib</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x5904">
				<sec_title>Action:</sec_title>
				<para>Potent antimitotic agent, different from taxanes, vinca alkaloids, epothilones; blocks cell progression during G2-M phase; inhibits the growth phase of microtubules and sequesters tubules, leading to the disruption of mitotic spindles and apoptotic cell death</para>
			</section>
			<section type="uses" id="sidelem4x5909">
				<sec_title>Uses:</sec_title>
				<para>Metastatic breast cancer in patients who have received at least 2 chemotherapy regimens</para>
			</section>
			<section type="contra" id="sidelem4x5914">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, pregnancy (D)</para>
				<section type="none" id="sidelem4x5919">
					<section type="none" id="sidelem4x5920">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, neonates, infants, children, bradycardia, electrolyte imbalances, heart failure, hypokalemia, hypomagnesemia, infertility, neutropenia, peripheral neuropathy, QT prolongation, hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5925">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5933">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5933">
							<item>
								<label>•</label>
								<para> 1.4 mg/m<emphasis style="sup">2</emphasis> over 2-5 min on days 1 and 8, repeat q21days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5944">
					<label>•</label>
					<sec_title>Recommendations for dose delay<route> for ANC &lt;1000/mm3, platelets &lt;75,000/mm3, or grade 3 or 4 nonhematologic toxicities</route></sec_title>
				</section>
				<section type="none" id="sidelem4x5956">
					<label>•</label>
					<sec_title>Dose adjustments for hematologic toxicity<route> ANC &lt;500/mm3 for &gt;7 days or ANC &lt;1000/mm3 with fever or infection</route></sec_title>
				</section>
				<section type="none" id="sidelem4x5992">
					<label>•</label>
					<sec_title>Dose adjustments of eribulin for nonhematologic toxicity during treatment<route> any Grade 3 or 4 nonhematologic toxicity</route></sec_title>
				</section>
				<section type="none" id="sidelem4x6010">
					<section type="none" id="sidelem4x6011">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 1 mg/2 ml</para>
					</section>
					<section type="none" id="sidelem4x6016">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6019">
							<sec_title>IV direct, intermittent route</sec_title>
							<para>
								<list id="lidelem4x6023">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter, discoloration as solution and container permit; withdraw required amount (0.5 mg/ml) from single-use vial, give undiluted over 2-5 min or diluted in 100 ml 0.9% NaCl and give as intermittent infusion; do not give through line with dextrose or any other product</para>
									</item>
									<item>
										<label>•</label>
										<para>Store at room temperature for 4 hr or 24 hr refrigerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6034">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6037">
					<section type="none" id="sidelem4x6038">
						<sec_title>CNS:</sec_title>
						<para> Depression, dizziness, <emphasis style="italic">fatigue,</emphasis> fever, headache, insomnia, <emphasis style="italic">peripheral neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6048">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT prolongation,</emphasis> peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x6056">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, vomiting, weight loss</para>
					</section>
					<section type="none" id="sidelem4x6061">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, neutropenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6068">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis> rash, stomatitis, infusion-related reactions</para>
					</section>
					<section type="none" id="sidelem4x6076">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x6081">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, bone/back pain</para>
					</section>
					<section type="none" id="sidelem4x6086">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x6091">
						<sec_title>SYST:</sec_title>
						<para> Infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6096">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 49%-65%; inhibits CYP3A4; excreted in feces 82%; urine 9%; elimination half-life 40 hr; increased levels in hepatic/renal disease</para>
			</section>
			<section type="interactions" id="sidelem4x6102">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—arsenic trioxide, bepridil, chloroquine, certain phenothiazines (chlorproMAZINE, mesoridazine, thioridazine), clarithromycin, class IA antiarrhythmics (disopyramide, procainamide, quiNIDine), class III antiarrhythmics (amiodarone, bretylium, dofetilide, ibutilide, sotalol), dextromethorphan; quiNIDine, dronedarone, droperidol, erythromycin, halofantrine, haloperidol, levomethadyl, methadone, pentamidine, pimozide, posaconazole, probucol, propafenone, saquinavir, sparfloxacin, troleandomycin, and ziprasidone; also to a lesser degree abarelix, alfuzosin, amoxapine, apomorphine, artemether; lumefantrine, asenapine, β-agonists, ofloxacin, cloZAPine, cyclobenzaprine, dasatinib, dolasetron, flecainide, gatifloxacin, gemifloxacin, halogenated anesthetics, iloperidone, lapatinib, levofloxacin, local anesthetics, lopinavir; ritonavir, magnesium sulfate; potassium sulfate; sodium sulfate, maprotiline, mefloquine, moxifloxacin, nilotinib, norfloxacin, octreotide, ciprofloxacin, OLANZapine, ondansetron, paliperidone, palonosetron, some phenothiazines (fluPHENAZine, perphenazine, prochlorperazine, trifluoperazine), QUEtiapine, ranolazine, risperiDONE, sertindole, SUNItinib, tacrolimus, telavancin, telithromycin, tetrabenazine, tricyclic antidepressants, venlafaxine, vardenafil, vorinostat</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x6108">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6111">
					<section type="none" id="sidelem4x6112">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6117">
								<item>
									<label>•</label>
									<para>Peripheral neuropathy: pain, numbness in extremities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6122">
								<item>
									<label>•</label>
									<para>Infection: increased temperature, sore throat, flulike symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6130">
							<label>•</label>
							<sec_title>QT prolongation<route> assess for drug interactions that may occur; monitor ECG, heart rate</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6136">
							<label>•</label>
							<sec_title>Bone marrow depression<route> CBC, differential, serum creatinine, BUN, electrolytes, LFTs at baseline, periodically; increased AST/ALT &gt;3 × ULN or total bilirubin &gt;1.5 × ULN involve greater chance of Grade 4 or febrile neutropenia</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6139">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6147">
							<label>•</label>
							<sec_title>Infection<route> to notify prescriber of increased temperature, sore throat, fatigue, flulike symptoms</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6153">
							<label>•</label>
							<sec_title>QT prolongation<route> to report extra heartbeats</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6159">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x6159">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> to report tingling, pain in extremities</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6163">
								<item>
									<label>•</label>
									<para>About reason for product and expected results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6168">
								<item>
									<label>•</label>
									<para>To avoid other medications, supplements unless approved by provider; serious drug interactions may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6173">
								<item>
									<label>•</label>
									<para>About hair loss, use of wig or hairpiece</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6181">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected (pregnancy [D]), to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="29" status="active" ha="yes">
			<mono_name>erlotinib (Rx)</mono_name>
			<info>
				<pronunciation>(er-loe′tye-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61910">Tarceva</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Epidermal growth factor receptor inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x6201">
				<sec_title>Action:</sec_title>
				<para>Not fully understood; inhibits intracellular phosphorylation of cell-surface receptors associated with epidermal growth factor receptors</para>
			</section>
			<section type="uses" id="sidelem4x6206">
				<sec_title>Uses:</sec_title>
				<para>Non–small-cell lung cancer (NSCLC) including EGFR ex on 19 deletions or ex on 21 substitution mutations, pancreatic cancer</para>
			</section>
			<section type="contra" id="sidelem4x6211">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding</para>
				<section type="none" id="sidelem4x6216">
					<section type="none" id="sidelem4x6217">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, ocular/pulmonary/renal/hepatic disorders, diverticulitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6222">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6225">
					<section type="none" id="sidelem4x6226">
						<sec_title>Non–small-cell lung cancer (NSCLC)</sec_title>
						<section type="none" id="sidelem4x6234">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6234">
									<item>
										<label>•</label>
										<para> 150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6238">
						<sec_title>Pancreatic cancer</sec_title>
						<section type="none" id="sidelem4x6246">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6246">
									<item>
										<label>•</label>
										<para> 100 mg/day in combination with gemcitabine 1000 mg/m<emphasis style="sup">2</emphasis> cycle 1, days 1, 8, 15, 22, 29, 36, 43 of 8-wk cycle; cycle 2 and subsequent cycle, days 1, 8, 15 of 4-wk cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6253">
						<sec_title>CYP3A4 inducers concurrently (rifampin, phenytoin)</sec_title>
						<para>
							<list id="lidelem4x6257">
								<item>
									<label>•</label>
									<para>Dosage increase is advised</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6263">
						<sec_title>CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, telithromycin, ritonavir, saquinavir, troleandomycin, nelfinavir)</sec_title>
						<para>
							<list id="lidelem4x6267">
								<item>
									<label>•</label>
									<para>Dosage reduction may be needed</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6274">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x6282">
							<label>•</label>
							<sec_title>Adult<route> PO interrupt if total bilirubin &gt;3 times ULN and/or transaminases &gt;5 times ULN</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6285">
						<sec_title>Head or neck cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6293">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6293">
									<item>
										<label>•</label>
										<para> 150 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6297">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 100, 150 mg</para>
					</section>
					<section type="none" id="sidelem4x6302">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6306">
								<item>
									<label>•</label>
									<para>1 hr before or 2 hr after food; at same time of day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6312">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6315">
					<section type="none" id="sidelem4x6316">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">CVA,</emphasis> anxiety, depression, headache, rigors, insomnia</para>
					</section>
					<section type="none" id="sidelem4x6324">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI/ischemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6331">
						<sec_title>EENT:</sec_title>
						<para> Ocular changes, <emphasis style="italic">conjunctivitis, eye pain,</emphasis> hypertrichosis</para>
					</section>
					<section type="none" id="sidelem4x6339">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting, anorexia, mouth ulceration,</emphasis><emphasis style="bold">hepatic failure, GI perforation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6348">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal impairment/failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6355">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Deep vein thrombosis, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6362">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis><emphasis style="bold">Stevens-Johnson–like skin reaction, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6371">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Fatigue, infection</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6378">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Interstitial lung disease,</emphasis><emphasis style="italic">cough, dyspnea,</emphasis><emphasis style="bold">ARDS, pulmonary fibrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6389">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Hepatorenal syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6396">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Slowly absorbed (60%); peak 3-7 hr; excreted in feces (86%), urine (&lt;4%); metabolized by CYP3A4; elimination half-life 36 hr; protein binding 93%</para>
			</section>
			<section type="interactions" id="sidelem4x6401">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: GI bleeding, may be fatal—warfarin, NSAIDs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> erlotinib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin, telithromycin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of warfarin, metoprolol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myopathy—HMG-CoA reductase inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> erlotinib levels—CYP3A4 inducers (phenytoin, rifampin, carBAMazepine, PHENobarbital), proton-pump inhibitors</para>
				<section type="none" id="sidelem4x6423">
					<section type="none" id="sidelem4x6424">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> erlotinib levels—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x6431">
						<sec_title>Drug/Smoking</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> erlotinib level; dose may need to be increased</para>
					</section>
					<section type="none" id="sidelem4x6438">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect of erlotinib—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x6445">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> INR, PT, AST, ALT, bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6452">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6455">
					<section type="none" id="sidelem4x6456">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6464">
							<label>•</label>
							<sec_title>Serious skin toxicities<route> toxic epidermal necrolysis, Stevens-Johnson syndrome, check for rash, blistering, discontinue treatment, may need corticosteroids</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6468">
								<item>
									<para>
										<emphasis alert="nurse">MI/ischemia, CVA in patients with pancreatic cancer</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6474">
								<item>
									<para>
										<emphasis alert="nurse">Pulmonary changes: lung sounds, cough, dyspnea; interstitial lung disease may occur, may be fatal; discontinue therapy if confirmed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6482">
							<label>•</label>
							<sec_title>Ocular changes</sec_title>
							<para>
								<list id="lidelem4x6482">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ocular changes:</emphasis> eye irritation, corneal erosion/ulcer, aberrant eyelash growth</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6486">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools; if diarrhea is poorly tolerated, therapy may be discontinued for ≤14 days, monitor for dehydration, fluid status during period of vomiting and diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6491">
								<item>
									<label>•</label>
									<para>Blood studies: INR, LFTs, PT</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6499">
							<label>•</label>
							<sec_title>Hepatic failure<route> interrupt dosing if severe changes to liver function occur (total bilirubin &gt;3× ULN and/or transaminases &gt;5× ULN when normal pretreatment LFTs)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x6505">
							<label>•</label>
							<sec_title>GI perforation/bleeding<route> some cases have been fatal, usually occurs in those using NSAIDs, taxanes; or those with diverticulitis or peptic ulcer disease, discontinue if these occur</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6508">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6512">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in NSCLC cells, pancreatic cancer cells</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6518">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6524">
								<item>
									<para>
										<emphasis alert="nurse">To report adverse reactions immediately: SOB, severe abdominal pain, persistent diarrhea or vomiting, ocular changes, skin eruptions (face, upper chest/back pain)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6529">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6538">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception during treatment (pregnancy D); to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6541">
								<item>
									<label>•</label>
									<para>To avoid use with other products, herbs, supplements unless approved by provider</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6546">
								<item>
									<label>•</label>
									<para>To avoid smoking, decreases effect of this product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>ertapenem (Rx)</mono_name>
			<info>
				<pronunciation>(er-tah-pen′em)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x65560">INVanz</tradename>
				</tradenames>
				<class type="func"> Antiinfective—miscellaneous</class>
				<class type="chem"> Carbapenem</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6566">
				<para>
					<confusion>
						<tradename id="tnidelem4x65660">INVanz</tradename>
						<drug type="generic" refid="idelem4x65660">AVINza</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6570">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-wall replication of susceptible organisms; bactericidal</para>
			</section>
			<section type="uses" id="sidelem4x6575">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="italic">Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Citrobacter koseri, Clostridium clostridioforme, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Eubacterium lentum, Fusobacterium</emphasis> sp., <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase negative), <emphasis style="italic">Haemophilus influenzae</emphasis> (beta-lactamase positive), <emphasis style="italic">Haemophilus parainfluenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxella catarrhalis, Morganella morganii, Peptostreptococcus</emphasis> sp., <emphasis style="italic">Porphyromonas asaccharolytica, Prevotella bivia, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Serratia marcescens, Staphylococcus aureus</emphasis> (MSSA), <emphasis style="italic">Staphylococcus epidermidis, Streptococcus agalactiae</emphasis> (group B streptococci), <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes</emphasis> (group A beta-hemolytic streptococci); bacteremia, community-acquired pneumonia, diabetic foot ulcer, endometritis, gyn/intraabdominal skin/skin structure/urinary tract infections, surgical infection prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x6600">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, its components, amide-type local anesthetics (IM only); anaphylactic reactions to β-lactams, other carbapenems</para>
				<section type="none" id="sidelem4x6605">
					<section type="none" id="sidelem4x6606">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, GI/renal/hepatic disease, seizures</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6611">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6614">
					<section type="none" id="sidelem4x6615">
						<sec_title>Complicated intraabdominal infections</sec_title>
						<section type="none" id="sidelem4x6623">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6623">
									<item>
										<label>•</label>
										<para> 1 g/day × 5-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6630">
							<label>•</label>
							<sec_title>Infant ≥3 mo/child<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6630">
									<item>
										<label>•</label>
										<para> 15 mg/kg bid (max 1 g/day) × 5-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6634">
						<sec_title>Complicated skin/skin-structure infections</sec_title>
						<section type="none" id="sidelem4x6642">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6642">
									<item>
										<label>•</label>
										<para> 1 g/day × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6649">
							<label>•</label>
							<sec_title>Child 3 mo-12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6649">
									<item>
										<label>•</label>
										<para> 15 mg/kg bid × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6653">
						<sec_title>Community-acquired pneumonia</sec_title>
						<section type="none" id="sidelem4x6661">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6661">
									<item>
										<label>•</label>
										<para> 1 g/day × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6668">
							<label>•</label>
							<sec_title>Child 3 mo-12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6668">
									<item>
										<label>•</label>
										<para> 15 mg/kg bid × 10-14 days, max 1 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6672">
						<sec_title>Complicated UTI</sec_title>
						<section type="none" id="sidelem4x6680">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6680">
									<item>
										<label>•</label>
										<para> 1 g/day × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6687">
							<label>•</label>
							<sec_title>Child 3 mo-12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6687">
									<item>
										<label>•</label>
										<para> 15 mg/kg bid × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6691">
						<sec_title>Acute pelvic infections</sec_title>
						<section type="none" id="sidelem4x6699">
							<label>•</label>
							<sec_title>Adult/adolescent<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6699">
									<item>
										<label>•</label>
										<para> 1 g/day × 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6706">
							<label>•</label>
							<sec_title>Child 3 mo-12 yr<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x6706">
									<item>
										<label>•</label>
										<para> 15 mg/kg bid 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6710">
						<sec_title>Surgical infection prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x6718">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6718">
									<item>
										<label>•</label>
										<para> 1 g as a single dose 1 hr before surgical incision</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6722">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x6731">
							<label>•</label>
							<sec_title>Adult<route> IM/IV CCr ≤30 ml/min 500 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6734">
						<sec_title>Available form:</sec_title>
						<para> Powder, lyophilized, 1 g</para>
					</section>
					<section type="none" id="sidelem4x6739">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x6742">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x6747">
									<item>
										<label>•</label>
										<para>Reconstitute the 1-g vial of ertapenem with 3.2 ml of 1% lidocaine HCl injection (without EPINEPHrine) (280 mg/ml), agitate well to form a solution; the IM reconstituted formulation is not for IV use</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x6754">
									<item>
										<label>•</label>
										<para>IM administration may be used as an alternative to IV administration in the treatment of infections where IM therapy is appropriate; only give via IM injection × 7 days</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6762">
								<label>•</label>
								<sec_title>For a 1-g dose</sec_title>
								<para>
									<list id="lidelem4x6762">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">For a 1-g dose:</emphasis> immediately withdraw the contents of the vial and inject deeply into a large muscle, aspirate before injection to avoid injection into a blood vessel</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6769">
								<label>•</label>
								<sec_title>
									<route>For a dose</route>
								</sec_title>
								<para>
									<list id="lidelem4x6769">
										<item>
											<label>•</label>
											<para>&lt;1 g (i.e., for pediatric patients 3 mo-12 yr): immediately withdraw a volume equal to 15 mg/kg (max 1 g/day) and inject deeply into a large muscle, aspirate before injection to avoid injecting into a blood vessel; use the reconstituted IM sol within 1 hr after preparation</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x6773">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6778">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use, may be colorless to pale yellow; do not mix with other products; dextrose sols are not compatible</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x6786">
								<label>•</label>
								<sec_title>1-g vial</sec_title>
								<para>
									<list id="lidelem4x6786">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">1-g vial:</emphasis> For each gram reconstitute with 10 ml of either NS injection, sterile water for injection, or bacteriostatic water for injection to 100 mg/ml, shake</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x6793">
								<label>•</label>
								<sec_title>
									<route>1 g dose</route>
								</sec_title>
								<para>
									<list id="lidelem4x6793">
										<item>
											<label>•</label>
											<para>: immediately transfer contents of the reconstituted vial to 50 ml of NS injection; for a dose &lt;1 g (pediatric patients 3 mo-12 yr): from the reconstituted vial, immediately withdraw a volume equal to 15 mg/kg of body weight (max 1 g/day) and dilute in NS injection to a concentrations of 20 mg/ml or less</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x6797">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6801">
									<item>
										<label>•</label>
										<para>Complete the infusion within 6 hr of reconstitution, infuse over 30 min; do not co-infuse with other medications</para>
									</item>
									<item>
										<label>•</label>
										<para>The reconstituted IV sol may be stored at room temperature if used within 6 hr, or store under refrigeration for 24 hr and use within 4 hours after removal from refrigeration; do not freeze</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, amphotericin B liposome, argatroban, arsenic trioxide, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, chloramphenicol, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, dolasetron, DOPamine, doxacurium, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, ifosfamide, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lepirudin, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, metaraminol, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, milrinone, mitoMYcin, mivacurium, morphine, moxifloxacin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxaliplatin, oxytocin, PACLitaxel, pamidronate, pancuronium, pantoprazole, PEMEtrexed, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, polymyxin B, potassium acetate/chloride/phosphates, procainamide, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, tigecycline, tirofiban, tobramycin, trimethobenzamide, vancomycin, vasopressin, vecuronium, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6817">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6820">
					<section type="none" id="sidelem4x6821">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, <emphasis style="bold">seizures,</emphasis> dizziness, <emphasis style="italic">headache,</emphasis> agitation, confusion, somnolence, disorientation, edema, hypotension</para>
					</section>
					<section type="none" id="sidelem4x6832">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Tachycardia, seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6839">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, vomiting,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis> cholelithiasis, jaundice, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x6849">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Vaginitis,</emphasis> dysuria</para>
					</section>
					<section type="none" id="sidelem4x6857">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, <emphasis style="italic">pruritus,</emphasis> pain at inj site, <emphasis style="italic">infused vein complication, phlebitis/thrombophlebitis,</emphasis> erythema at inj site, dermatitis</para>
					</section>
					<section type="none" id="sidelem4x6871">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough, pharyngitis, crackles, respiratory distress</para>
					</section>
					<section type="none" id="sidelem4x6876">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6883">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6886">
					<section type="none" id="sidelem4x6887">
						<sec_title>IV:</sec_title>
						<para> Onset immediate; peak dose dependent; half-life 4 hr; metabolized by liver; excreted in urine, feces, breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6892">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> INR—warfarin</para>
				<para>
					<emphasis alert="lifethreat">Increase: ertapenem levels—probenecid; do not coadminister</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of valproic acid</para>
				<section type="none" id="sidelem4x6906">
					<section type="none" id="sidelem4x6907">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hepatic enzymes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6914">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6917">
					<section type="none" id="sidelem4x6918">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6923">
								<item>
									<label>•</label>
									<para>Renal disease: lower dose may be required</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6931">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6934">
								<item>
									<label>•</label>
									<para>For infection: temperature, sputum, characteristics of wound before, during, after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6940">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis; rash, urticaria, pruritus; may occur a few days after therapy begins; sensitivity to carbapenem antibiotics, other β-lactam antibiotics, penicillins</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6948">
							<label>•</label>
							<sec_title>Overgrowth of infection<route> perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough or sputum</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6951">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6955">
								<item>
									<label>•</label>
									<para>Therapeutic response: negative C&amp;S; absence of signs, symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6961">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x6969">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea (may indicate pseudomembranous colitis), CNS side effects</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x6975">
							<label>•</label>
							<sec_title>To report overgrowth of infection<route> black, furry tongue; vaginal itching; foul-smelling stools</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x6978">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding; product is excreted in breast milk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>erythromycin (ophthalmic)</mono_name>
			<info>
				<pronunciation>(e-rith′roe-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x69931">Ilotycin</tradename>
					<tradename id="tnidelem4x69930">Romycin</tradename>
				</tradenames>
				<class type="func"> Ophthalmic antiinfective</class>
				<class type="chem"> Macrolide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x7003">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis, thereby decreasing bacterial replication</para>
			</section>
			<section type="uses" id="sidelem4x7008">
				<sec_title>Uses:</sec_title>
				<para>Conjunctivitis, eye infections, prevention of ophthalmic neonatorum</para>
			</section>
			<section type="contra" id="sidelem4x7013">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or macrolides</para>
				<section type="none" id="sidelem4x7018">
					<section type="none" id="sidelem4x7019">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7024">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7027">
					<section type="none" id="sidelem4x7028">
						<sec_title>Bacterial conjunctivitis</sec_title>
						<section type="none" id="sidelem4x7036">
							<label>•</label>
							<sec_title>Adult/adolescent/child</sec_title>
							<para>
								<list id="lidelem4x7036">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child:</emphasis> apply 1 cm of ointment directly to the eye up to 6 times a day ×7-10 days depending on severity of infection</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7040">
						<sec_title>Prevention of ophthalmic neonatorum</sec_title>
						<para>
							<emphasis style="bold">Neonate:</emphasis> Ointment apply 1-cm ribbon to lower conjunctival sac of each eye once after birth</para>
					</section>
					<section type="none" id="sidelem4x7047">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7050">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x7054">
									<item>
										<label>•</label>
										<para>Apply ribbon of ointment directly to the eye; for ophthalmic use only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7060">
						<sec_title>Available forms:</sec_title>
						<para> ointment/ophthalmic 0.5%</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7066">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7069">
					<section type="none" id="sidelem4x7070">
						<sec_title>EENT:</sec_title>
						<para> Hypersensitivity, irritation, redness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7075">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Unknown</para>
			</section>
			<section type="considerations" id="sidelem4x7080">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7083">
					<section type="none" id="sidelem4x7084">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7092">
							<label>•</label>
							<sec_title>Allergic reaction<route> assess for hypersensitivity, discontinue product</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7095">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7099">
								<item>
									<label>•</label>
									<para>Decreased ophthalmic infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7105">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7108">
							<sec_title>Ophthalmic route:</sec_title>
							<para>
								<list id="lidelem4x7112">
									<item>
										<label>•</label>
										<para>Apply ribbon of ointment directly to the eye; for ophthalmic use only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>erythromycin base (Rx)</mono_name>
			<info>
				<pronunciation>(eh-rith-roh-my′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71233">
						<country code="CAN">Apo-Erythro </country>
					</tradename>
					<tradename id="tnidelem4x71232">Ery-Tab</tradename>
					<tradename id="tnidelem4x71231">
						<country code="CAN">Novo-Rythro Encap </country>
					</tradename>
					<tradename id="tnidelem4x71230">PCE</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="33" status="active">
			<mono_name>erythromycin ethylsuccinate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x71344">
						<country code="CAN">Apo-Erythro-Es </country>
					</tradename>
					<tradename id="tnidelem4x71343">E.E.S.</tradename>
					<tradename id="tnidelem4x71342">
						<country code="CAN">Erythro-Es</country>
					</tradename>
					<tradename id="tnidelem4x71341">Ery Ped</tradename>
					<tradename id="tnidelem4x71340">
						<country code="CAN">Novo-Rythro </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="34" status="active">
			<mono_name>erythromycin lactobionate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x71470">Erythrocin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="35" status="active">
			<mono_name>erythromycin stearate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x71523">
						<country code="CAN">Apo-Erythro-S </country>
					</tradename>
					<tradename id="tnidelem4x71522">Erythrocin</tradename>
					<tradename id="tnidelem4x71521">My-E</tradename>
					<tradename id="tnidelem4x71520">
						<country code="CAN">Novo-Rythro </country>
					</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Macrolide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7167">
				<para>
					<confusion>
						<tradename id="tnidelem4x71670">erythromycin</tradename>
						<drug type="generic" refid="idelem4x71670">azithromycin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7171">
				<sec_title>Action:</sec_title>
				<para>Binds to 50S ribosomal subunits of susceptible bacteria and suppresses protein synthesis</para>
			</section>
			<section type="uses" id="sidelem4x7176">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate respiratory tract, skin, soft-tissue infections caused by <emphasis style="italic">Bordetella pertussis, Borrelia burgdorferi, Chlamydia trachomatis; Corynebacterium diphtheriae, Haemophilus influenzae</emphasis> (when used with sulfonamides); <emphasis style="italic">Legionella pneumophila,</emphasis> Legionnaire’s disease, <emphasis style="italic">Listeria monocytogenes; Mycoplasma pneumoniae, Streptococcus pneumoniae,</emphasis> syphilis: <emphasis style="italic">Treponema pallidum; Staphylococcus</emphasis> sp.</para>
				<section type="none" id="sidelem4x7193">
					<section type="none" id="sidelem4x7194">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bartonellosis, burn wound infection, chancroid, cholera, diabetic gastroparesis, endocarditis prophylaxis, gastroenteritis, granuloma inguinale, Lyme disease, tetanus</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7199">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, preexisting hepatic disease (estolate)</para>
				<section type="none" id="sidelem4x7204">
					<section type="none" id="sidelem4x7205">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, hepatic disease, GI disease, QT prolongation, seizure disorder, myasthenia gravis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7210">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7213">
					<section type="none" id="sidelem4x7214">
						<sec_title>Acne vulgaris</sec_title>
						<section type="none" id="sidelem4x7222">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7222">
									<item>
										<label>•</label>
										<para> 250 mg qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7226">
						<sec_title>Mild to moderately severe upper respiratory tract infections (otitis media, sinusitis) or lower respiratory tract infections (pneumonia, bronchitis) caused by susceptible organisms</sec_title>
						<section type="none" id="sidelem4x7234">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7234">
									<item>
										<label>•</label>
										<para> 250-500 mg (of base, estolate, or stearate) every 6 hr or 400-800 mg (ethylsuccinate) every 6 hr;  15-20 mg/kg/day in divided doses every 4-6 hr, max 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7244">
							<label>•</label>
							<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7244">
									<item>
										<label>•</label>
										<para> 20-50 mg/kg/day divided every 6 hr, max adult doses;  15-20 mg/kg/day in divided doses every 4-6 hr, or as a continuous infusion, max dose 4 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7254">
							<label>•</label>
							<sec_title>Neonate &gt;7 days, ≥1200 g<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7254">
									<item>
										<label>•</label>
										<para> 30 mg/kg/day in divided doses every 8 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7261">
							<label>•</label>
							<sec_title>Neonates &gt;7 days, &lt;1200 g<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7261">
									<item>
										<label>•</label>
										<para> 20 mg/kg/day in divided doses every 12 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7268">
							<label>•</label>
							<sec_title>Neonates ≤7 days<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7268">
									<item>
										<label>•</label>
										<para> 20 mg/kg/day in divided doses every 12 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7272">
						<sec_title>Pneumonia caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7283">
							<label>•</label>
							<sec_title>Infant/neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7283">
									<item>
										<label>•</label>
										<para> CDC recommends 50 mg/kg/day in 4 divided doses × 14 days (erythromycin base or ethylsuccinate)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7289">
						<sec_title>Mycoplasma infection such as <emphasis style="bold">
								<emphasis style="italic">Mycoplasma pneumoniae</emphasis>
							</emphasis> pneumonia</sec_title>
						<section type="none" id="sidelem4x7301">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7301">
									<item>
										<label>•</label>
										<para> 250-500 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7308">
							<label>•</label>
							<sec_title>Adult/adolescent/child/infant<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7308">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg/day, given in divided doses every 4-6 hr, or as a continuous infusion, max dose 4 g/day; replace by oral dosage as soon as possible</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7312">
						<sec_title>Legionnaire’s disease (caused by <emphasis style="bold">
								<emphasis style="italic">Legionella pneumophila</emphasis>
							</emphasis>)</sec_title>
						<section type="none" id="sidelem4x7324">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x7324">
									<item>
										<label>•</label>
										<para> 0.5-1 g every 6 hr × 21 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7328">
						<sec_title>Treatment of group A β-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis)</sec_title>
						<section type="none" id="sidelem4x7336">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7336">
									<item>
										<label>•</label>
										<para> 250-500 mg (base, estolate, or stearate) every 6 hr or 400-800 mg (ethylsuccinate) every 6 hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7343">
							<label>•</label>
							<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7343">
									<item>
										<label>•</label>
										<para> 20-50 mg/kg/day, divided every 6 hr × 10 days, max adult dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7347">
						<sec_title>Secondary prevention of rheumatic fever (prevention of recurrent attacks of rheumatic fever)</sec_title>
						<section type="none" id="sidelem4x7355">
							<label>•</label>
							<sec_title>Adult/adolescent/child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7355">
									<item>
										<label>•</label>
										<para> 250 mg bid in patients allergic to penicillin and sulfADIAZINE for 10 yr or age 40, whichever is longer, secondary prophylaxis (American Heart Association)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7359">
						<sec_title>Listeriosis</sec_title>
						<section type="none" id="sidelem4x7367">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7367">
									<item>
										<label>•</label>
										<para> 250-500 mg (base, estolate or stearate) every 6 hr or 400-800 mg (ethylsuccinate) every 6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7374">
							<label>•</label>
							<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7374">
									<item>
										<label>•</label>
										<para> 20-50 mg/kg/day, divided every 6 hr, max adult doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7378">
						<sec_title>Cervicitis caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7389">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7389">
									<item>
										<label>•</label>
										<para> CDC recommends erythromycin base 500 mg qid or erythromycin ethylsuccinate 800 mg qid × 7 days as alternatives to first-line agents doxycycline or azithromycin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7396">
							<label>•</label>
							<sec_title>Pregnant females<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7396">
									<item>
										<label>•</label>
										<para> As alternatives to first-line agents azithromycin or amoxicillin, CDC recommends base 500 mg q12hr, 333 mg q8hr, or 250 mg qid × 14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7403">
							<label>•</label>
							<sec_title>Child ≤45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7403">
									<item>
										<label>•</label>
										<para> CDC recommends base or ethylsuccinate 50 mg/kg/day in 4 doses × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7407">
						<sec_title>Chlamydial conjunctivitis caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis> including trachoma and inclusion conjunctivitis</sec_title>
						<section type="none" id="sidelem4x7419">
							<label>•</label>
							<sec_title>Pregnant/lactating woman/child &lt;8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7419">
									<item>
										<label>•</label>
										<para> 250-500 mg qid × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7423">
						<sec_title>Infant pneumonia caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7434">
							<label>•</label>
							<sec_title>Infant/neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7434">
									<item>
										<label>•</label>
										<para> (base or ethylsuccinate) CDC recommends 50 mg/kg/day 4 divided doses × 14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7441">
							<label>•</label>
							<sec_title>Pregnant female<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7441">
									<item>
										<label>•</label>
										<para> CDC recommends base 400 mg qid × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7445">
						<sec_title>Non-gonococcal urethritis (NGU) caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis> or <emphasis style="bold">
								<emphasis style="italic">Ureaplasma urealyticum</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7460">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7460">
									<item>
										<label>•</label>
										<para> CDC recommends 500 mg (base) qid or 800 mg (ethylsuccinate) qid × 7 days as alternatives to first-line agents doxycycline or azithromycin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7467">
							<label>•</label>
							<sec_title>Child &lt;45 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7467">
									<item>
										<label>•</label>
										<para> CDC recommends base 50 mg/kg/day in 4 divided doses × 14 days, second course of therapy may be required</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7471">
						<sec_title>Ophthalmia neonatorum caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7482">
							<label>•</label>
							<sec_title>Neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7482">
									<item>
										<label>•</label>
										<para> (erythromycin base or ethylsuccinate) CDC recommends 50 mg/kg/day qid × 14 days, may repeat if condition returns</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7486">
						<sec_title>Lymphogranuloma venereum caused by <emphasis style="bold">
								<emphasis style="italic">Chlamydia trachomatis</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x7497">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7497">
									<item>
										<label>•</label>
										<para> (base) CDC recommends 500 mg qid × 21 days as an alternative to doxycycline</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7501">
						<sec_title>Adjunctive treatment of diphtheria to prevent establishment of carrier state and to eradicate <emphasis style="bold">
								<emphasis style="italic">Corynebacterium diphtheriae</emphasis>
							</emphasis> in carriers</sec_title>
						<section type="none" id="sidelem4x7513">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7513">
									<item>
										<label>•</label>
										<para> 500 mg every 6 hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7517">
						<sec_title>Intestinal amebiasis (unable to take metroNIDAZOLE)</sec_title>
						<section type="none" id="sidelem4x7525">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7525">
									<item>
										<label>•</label>
										<para> 250 mg every 6 hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7532">
							<label>•</label>
							<sec_title>Adolescent/child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7532">
									<item>
										<label>•</label>
										<para> 30-50 mg/kg/day, divided every 6 hr × 10-14 days, max adult dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7537">
						<sec_title>Pertussis (whooping cough) caused by <emphasis style="bold">
								<emphasis style="italic">Bordetella pertussis</emphasis>
							</emphasis> or for postexposure pertussis prophylaxis</sec_title>
						<section type="none" id="sidelem4x7549">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7549">
									<item>
										<label>•</label>
										<para> 500 mg qid (2 g total) × 14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7556">
							<label>•</label>
							<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7556">
									<item>
										<label>•</label>
										<para> 40-50 mg/kg/day (max 2 g/day) in 4 divided doses × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7560">
						<sec_title>Primary or secondary syphilis (caused by <emphasis style="bold">
								<emphasis style="italic">Treponema pallidum</emphasis>
							</emphasis>) in penicillin-allergic nonpregnant patients</sec_title>
						<section type="none" id="sidelem4x7572">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7572">
									<item>
										<label>•</label>
										<para> 48-64 g (ethylsuccinate) or 30-40 g (base or stearate) in divided doses × 10-15 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7576">
						<sec_title>Surgical infection prophylaxis as a bowel preparation in combination with neomycin</sec_title>
						<section type="none" id="sidelem4x7584">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x7584">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> It is generally recommended that if surgery is scheduled for 8 <emphasis style="smallcaps">am</emphasis>, 1 g of erythromycin PO with neomycin sulfate PO should be given at 1 <emphasis style="smallcaps">pm</emphasis>, 2 <emphasis style="smallcaps">pm</emphasis>, and 11 <emphasis style="smallcaps">pm</emphasis> on the day before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7600">
						<sec_title>Impetigo, burn wound infection (unlabeled)</sec_title>
						<section type="none" id="sidelem4x7608">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7608">
									<item>
										<label>•</label>
										<para> 250-500 mg q6hr (base, estolate, stearate) or 400-800 mg (ethylsuccinate) q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7615">
							<label>•</label>
							<sec_title>Infant/child/adolescent</sec_title>
							<para>
								<list id="lidelem4x7615">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infant/child/adolescent:</emphasis> 20-50 mg/kg/day divided q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7619">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Base:</emphasis> enteric-coated tabs 250, 333, 500 mg; film-coated tabs 250, 500 mg; enteric-coated caps 250, 333 mg; <emphasis style="italic">stearate:</emphasis> film-coated tabs 250 mg; <emphasis style="italic">ethylsuccinate:</emphasis> granules for oral susp 200, 400 mg/5 ml; powder for inj 500 mg, 1 g (lactobionate), 1 g (as gluceptate)</para>
					</section>
					<section type="none" id="sidelem4x7633">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7637">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew time rel cap or tab; chew only chewable tabs; enteric-coated tablets may be given with food</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not give by IM or IV push</para>
								</item>
								<item>
									<label>•</label>
									<para>Oral product with full glass of water; do not give with fruit juice</para>
								</item>
								<item>
									<label>•</label>
									<para>Give 1 hr before or 2 hr after meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature; store susp in refrigerator</para>
								</item>
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L) during diarrhea episodes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7668">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x7676">
								<label>•</label>
								<sec_title>
									<route>reconstituting</route>
								</sec_title>
								<para>
									<list id="lidelem4x7676">
										<item>
											<label>•</label>
											<para>After  500 mg or less/10 ml sterile water without preservatives; dilute further in 100-250 ml of 0.9% NaCl, LR, Normosol-R; may be  to 1 mg/ml and  as cont infusion; run 1 g or less/100 ml over <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr; cont infusion over 6 hr, may require buffers to neutralize pH if dilution is &lt;250 ml, use infusion pump</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x7693">
						<sec_title>Lactobionate</sec_title>
						<para>
							<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, atenolol, atosiban, atracurium, atropine, azaTHIOprine, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, cefotaxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, CISplatin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, doxapram, DOXOrubicin, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, foscarnet, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, insulin (regular), irinotecan, isoproterenol, labetalol, levofloxacin, lidocaine, LORazepam, LR, mannitol, mechlorethamine, meperidine, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, miconazole, midazolam, milrinone, mitoXANtrone, morphine, multiple vitamins injection, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, nitroglycerin, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, pentamidine, pentazocine, perphenazine, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, ranitidine, Ringer’s, ritodrine, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, temocillin, teniposide, theophylline, thiamine, thiotepa, tigecycline, tirofiban, TNA, tobramycin, tolazoline, TPN, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zidovudine, zoledronic acid</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7702">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7705">
					<section type="none" id="sidelem4x7706">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7713">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias, QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7720">
						<sec_title>EENT:</sec_title>
						<para> Hearing loss, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x7725">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> abdominal pain, stomatitis, heartburn, anorexia, <emphasis style="bold">pseudomembranous colitis, esophagitis, hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7737">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Vaginitis, moniliasis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7744">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, pruritus, thrombophlebitis, inj-site reactions (IV site)</para>
					</section>
					<section type="none" id="sidelem4x7749">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7756">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-4 hr (base); <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr (ethylsuccinate); half-life 1-2 hr; metabolized in liver; excreted in bile, feces; protein binding 75%-90%; inhibitor of CYP3A4 and P-glycoprotein</para>
			</section>
			<section type="interactions" id="sidelem4x7773">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Serious dysrhythmias—diltiazem, itraconazole, ketoconazole, nefazodone, pimozide, protease inhibitors, verapamil</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—products that increase QT prolongation</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action, toxicity of alfentanil, ALPRAZolam, bromocriptine, busPIRone, carBAMazepine, cilostazol, clindamycin, cloZAPine, cycloSPORINE, diazepam, digoxin, disopyramide, ergots, felodipine, HMG-CoA reductase inhibitors, ibrutinib methylPREDNISolone, midazolam, quiNIDine, rifabutin, sildenafil, tacrolimus, tadalafil, theophylline, triazolam, vardenafil, vinBLAStine, warfarin</para>
				<section type="none" id="sidelem4x7788">
					<section type="none" id="sidelem4x7789">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> folate assay</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> 17-OHCS/17-KS</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7804">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7807">
					<section type="none" id="sidelem4x7808">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7816">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x7816">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> temperature, characteristics of wounds, urine, stools, sputum, WBCs at baseline and periodically</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7820">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria in renal disease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7825">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT if patient is receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7830">
								<item>
									<label>•</label>
									<para>Hearing at baseline and after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7835">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7840">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be given as soon as culture is taken; C&amp;S may be repeated after treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7848">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea with blood, mucus; abdominal pain, fever; product should be discontinued immediately, notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7854">
							<label>•</label>
							<sec_title>Anaphylaxis<route> generalized hives, itching, flushing, swelling of lips, tongue, throat, wheezing; have emergency equipment nearby</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7860">
							<label>•</label>
							<sec_title>QT prolongation<route> may occur (IV &gt;15 mg/min); those with electrolyte imbalances, congenital QT prolongation, elderly at greater risk; correct electrolyte imbalances before treatment, ECG</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7863">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7867">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7873">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x7881">
							<label>•</label>
							<sec_title>
								<route>To report sore throat, fever, fatigue (could indicate superinfection), rhythm changes in the heart, hearing loss</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x7887">
							<label>•</label>
							<sec_title>
								<route>To notify nurse of diarrhea stools, dark urine, pale stools, jaundice of eyes or skin, severe abdominal pain</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7890">
								<item>
									<label>•</label>
									<para>To take at evenly spaced intervals; to complete dosage regimen; to take without food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7895">
								<item>
									<label>•</label>
									<para>To avoid use with other products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>erythromycin (topical)</mono_name>
			<info>
				<pronunciation>(e-rith-roe-mye′sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79141">Akne-mycin</tradename>
					<tradename id="tnidelem4x79140">
						<country code="CAN">Ery-sol </country>
					</tradename>
				</tradenames>
				<class type="func"> Topical antiinfective, anti-acne</class>
				<class type="chem"> Macrolide</class>
			</info>
			<section type="actions" id="sidelem4x7926">
				<sec_title>Action:</sec_title>
				<para>Antibacterial activity results from inhibition of protein synthesis; bacteriostatic</para>
			</section>
			<section type="uses" id="sidelem4x7931">
				<sec_title>Uses:</sec_title>
				<para>Treatment of acne vulgaris</para>
			</section>
			<section type="contra" id="sidelem4x7936">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, children</para>
			</section>
			<section type="doses" id="sidelem4x7941">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7944">
					<section type="none" id="sidelem4x7945">
						<sec_title>Acne vulgaris</sec_title>
						<section type="none" id="sidelem4x7953">
							<label>•</label>
							<sec_title>Adult/adolescent<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x7953">
									<item>
										<label>•</label>
										<para> Apply to affected areas bid, <emphasis style="smallcaps">am</emphasis>, <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7962">
						<sec_title>Available forms:</sec_title>
						<para> Topical gel, ointment, pledget, solution 2%</para>
					</section>
					<section type="none" id="sidelem4x7967">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7970">
							<sec_title>Topical route</sec_title>
							<para>
								<list id="lidelem4x7975">
									<item>
										<label>•</label>
										<para>For external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x7980">
									<item>
										<label>•</label>
										<para>Wash hands before and after use. Wash affected area and gently pat dry before using</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x7988">
								<label>•</label>
								<sec_title>Gel/ointment/pledget/solution</sec_title>
								<para>
									<list id="lidelem4x7988">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel/ointment/pledget/solution:</emphasis> Apply to the cleansed affected area. Massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x7992">
									<item>
										<label>•</label>
										<para>Each pledget should be used once and discarded</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7997">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8000">
					<section type="none" id="sidelem4x8001">
						<sec_title>INTEG:</sec_title>
						<para> Burning, rash, pruritus, peeling, irritation</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8006">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8009">
					<section type="none" id="sidelem4x8010">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8018">
							<label>•</label>
							<sec_title>Allergic reaction<route> assess for hypersensitivity, product might need to be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8024">
							<label>•</label>
							<sec_title>
								<route>Infection</route>
							</sec_title>
							<para>
								<list id="lidelem4x8024">
									<item>
										<label>•</label>
										<para>: assess for number of lesions, severity in acne</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8028">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8032">
								<item>
									<label>•</label>
									<para>Decreased lesions in acne</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8038">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8041">
							<sec_title>Topical Route:</sec_title>
							<para>
								<list id="lidelem4x8046">
									<item>
										<label>•</label>
										<para>That product is for external use only; do not use skin products near the eyes, nose, or mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8051">
									<item>
										<label>•</label>
										<para>To wash hands before and after use, wash affected area and gently pat dry before using</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8059">
								<label>•</label>
								<sec_title>Gel/pledget/solution/ointment/lotion</sec_title>
								<para>
									<list id="lidelem4x8059">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Gel/pledget/solution/ointment/lotion:</emphasis> To apply to the cleansed affected area; massage gently into affected areas</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x8063">
									<item>
										<label>•</label>
										<para>That each pledget should be used once and discarded</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>escitalopram (Rx)</mono_name>
			<info>
				<pronunciation>(es-sit-tal′oh-pram)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80731">
						<country code="CAN">Cipralex</country>
					</tradename>
					<tradename id="tnidelem4x80730">Lexapro</tradename>
				</tradenames>
				<class type="func"> Antidepressant, SSRI (selective serotonin reuptake inhibitor)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8082">
				<sec_title>Action:</sec_title>
				<para>Inhibits CNS neuron uptake of serotonin but not of norepinephrine</para>
			</section>
			<section type="uses" id="sidelem4x8087">
				<sec_title>Uses:</sec_title>
				<para>General anxiety disorder; major depressive disorder in adults/adolescents</para>
				<section type="none" id="sidelem4x8092">
					<section type="none" id="sidelem4x8093">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Panic disorder, social phobia, autism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8098">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, citalopram, MAOIs</para>
				<section type="none" id="sidelem4x8103">
					<section type="none" id="sidelem4x8104">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, renal/hepatic disease, history of seizures, abrupt discontinuation, bleeding, anticoagulants</para>
						<para>
							<bbw>Children/adolescents ≤12 yr, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8119">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8127">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8127">
							<item>
								<label>•</label>
								<para> 10 mg/day in <emphasis style="smallcaps">am</emphasis> or <emphasis style="smallcaps">pm</emphasis>; after 1 wk, if no clinical improvement is noted, dose may be increased to 20 mg/day <emphasis style="smallcaps">pm</emphasis>; maintenance 10-20 mg/day; reassess to determine need for treatment</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8142">
					<section type="none" id="sidelem4x8143">
						<sec_title>Hepatic dose/geriatric</sec_title>
						<section type="none" id="sidelem4x8151">
							<label>•</label>
							<sec_title>Adult<route> PO 10 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8154">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20 mg; oral sol 5 mg (as base)/5 ml (contains sorbitol)</para>
					</section>
					<section type="none" id="sidelem4x8159">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8164">
								<item>
									<label>•</label>
									<para>With food or milk for GI symptoms, give with full glass of water</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8169">
								<item>
									<label>•</label>
									<para>Crushed if patient is unable to swallow medication whole, scored tabs can be cut</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8174">
								<item>
									<label>•</label>
									<para>Dosage at bedtime if oversedation occurs during the day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8179">
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8187">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x8187">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> measure with calibrated device</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8191">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8196">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8199">
					<section type="none" id="sidelem4x8200">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, nervousness, insomnia,</emphasis><emphasis style="bold">suicidal ideation,</emphasis><emphasis style="italic">drowsiness, anxiety, tremor, dizziness, fatigue, sedation, poor concentrations, abnormal dreams, agitation,</emphasis><emphasis style="bold">seizures,</emphasis> apathy, euphoria, hallucinations, delusions, psychosis, <emphasis style="bold">neuroleptic malignant-like syndrome,</emphasis> ataxia, worsening depression</para>
					</section>
					<section type="none" id="sidelem4x8217">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hot flashes, palpitations,</emphasis> angina pectoris, <emphasis style="bold">hemorrhage,</emphasis> hypertension, <emphasis style="bold">tachycardia,</emphasis> 1st-degree AV block, <emphasis style="bold">bradycardia, MI, thrombophlebitis,</emphasis> postural hypotension</para>
					</section>
					<section type="none" id="sidelem4x8234">
						<sec_title>EENT:</sec_title>
						<para> Visual changes, ear/eye pain, photophobia, tinnitus, pupil dilation, dental pain</para>
					</section>
					<section type="none" id="sidelem4x8239">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, dry mouth, anorexia, dyspepsia, constipation, cramps, vomiting, taste changes, flatulence, decreased appetite,</emphasis><emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8248">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Dysmenorrhea, decreased libido, urinary frequency, UTI,</emphasis> amenorrhea, cystitis, impotence, urine retention, ejaculation disorder</para>
					</section>
					<section type="none" id="sidelem4x8256">
						<sec_title>HEMA: </sec_title>
						<para>Impaired platelet aggregation</para>
					</section>
					<section type="none" id="sidelem4x8261">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Sweating, rash, pruritus,</emphasis> acne, alopecia, urticaria, photosensitivity, bruising</para>
					</section>
					<section type="none" id="sidelem4x8269">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Pain,</emphasis> arthritis, twitching, osteopenia</para>
					</section>
					<section type="none" id="sidelem4x8277">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Infection, pharyngitis, nasal congestion, sinus headache, sinusitis, cough, dyspnea, bronchitis,</emphasis> asthma, hyperventilation, pneumonia</para>
					</section>
					<section type="none" id="sidelem4x8285">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Asthenia, viral infection, fever, allergy, chills,</emphasis><emphasis style="bold">serotonin syndrome, neonatal abstinence syndrome, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8294">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x8297">
					<section type="none" id="sidelem4x8298">
						<sec_title>PO:</sec_title>
						<para> Metabolized in liver; excreted in urine; 56% protein binding; metabolized by CYP2C19, 3A4, half-life 27-32 hr; half-life increased by 50% in geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8303">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x8307">
						<item>
							<label>•</label>
							<para>Paradoxical worsening of OCD: busPIRone</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome—tryptophan, amphetamines, busPIRone, lithium, amantadine, bromocriptine, SSRI, SNRIs, serotonin-receptor agonists, traMADol</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Do not use pimozide, MAOIs, with or 14 days before escitalopram</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antidepressants, opioids, sedatives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects of escitalopram—highly protein-bound products</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels or toxicity of carBAMazepine, lithium, warfarin, phenytoin, antipsychotics, antidysrhythmics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of tricyclics, phenothiazines, haloperidol, diazepam</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, salicylates, anticoagulants, SSRIs, platelet inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> escitalopram effect—cyproheptadine</para>
				<section type="none" id="sidelem4x8345">
					<section type="none" id="sidelem4x8346">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x8350">
								<item>
									<label>•</label>
									<para>St. John’s wort: do not use together, serotonin syndrome may occur</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS effect—kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x8360">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x8364">
								<item>
									<label>•</label>
									<para>Grapefruit juice—increased escitalopram effect</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8370">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum bilirubin, blood glucose, alk phos</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, 5-HIAA</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8386">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8389">
					<section type="none" id="sidelem4x8390">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, sensorium, affect, <emphasis alert="lifethreat">suicidal tendencies,</emphasis> increase in psychiatric symptoms, depression, panic, not approved for use in children</bbw>
						</para>
						<para>
							<list id="lidelem4x8407">
								<item>
									<label>•</label>
									<para>Appetite with bulimia nervosa, weight daily; increase nutritious foods in diet, watch for binging and vomiting</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8415">
							<label>•</label>
							<sec_title>Allergic reactions<route> itching, rash, urticaria; product should be discontinued, may need to give antihistamine</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8418">
								<item>
									<label>•</label>
									<para>B/P (lying/standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8423">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, leukocytes, differential, cardiac enzymes if patient receiving long-term therapy; check platelets; bleeding can occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8431">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> nausea, vomiting, sedation, dizziness, sweating, facial flushing, mental changes, shivering, increased B/P; discontinue product, notify prescriber</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8434">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine; thyroid function studies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8439">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may decrease with product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8447">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening of T wave, bundle branch, AV block, dysrhythmias in cardiac patients</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8450">
								<item>
									<label>•</label>
									<para>Alcohol consumption; if alcohol is consumed, hold dose until <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8460">
							<label>•</label>
							<sec_title>Sexual dysfunction</sec_title>
							<para>
								<list id="lidelem4x8460">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Sexual dysfunction:</emphasis> ejaculation dysfunction, erectile dysfunction, decreased libido, orgasm dysfunction, priapism</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8464">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during therapy, since drowsiness, dizziness occur; safety measures primarily for geriatric patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8469">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8473">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8479">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8484">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take 1-4 wk, may have increased anxiety for first 5-7 days, do not abruptly discontinue</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8492">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> To report immediately nausea, vomiting, sedation, dizziness, sweating, facial flushing, mental changes, shivering</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8495">
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because drowsiness, dizziness, blurred vision may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8500">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants; to avoid all OTC products unless approved by prescriber, to take without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8505">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant or planning to become pregnant or breastfeeding, discuss sexual dysfunction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8510">
								<item>
									<label>•</label>
									<para>To change positions slowly, orthostatic hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8515">
								<item>
									<label>•</label>
									<para>To report signs of urinary retention immediately
<bbw>That clinical worsening and suicide risk may occur especially in adolescents and young adults</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8529">
								<item>
									<label>•</label>
									<para>To use MedGuide provided</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="38" status="active" ha="yes">
			<mono_name>eslicarbazepine</mono_name>
			<info>
				<pronunciation>(es′lye-kar-bay′ze-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x85460">Aptiom</tradename>
				</tradenames>
			</info>
			<section type="actions" id="sidelem4x8556">
				<sec_title>Action:</sec_title>
				<para>Exact mechanism unknown; a voltage-gated sodium-channel blocker inhibits repetitive neuronal firing</para>
			</section>
			<section type="uses" id="sidelem4x8561">
				<sec_title>Uses:</sec_title>
				<para>Partial seizures, adjunctive treatment</para>
			</section>
			<section type="contra" id="sidelem4x8566">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or OXcarbazepine</para>
				<section type="none" id="sidelem4x8573">
					<section type="none" id="sidelem4x8574">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, abrupt discontinuation, depression, driving/operating machinery, ethanol intoxication, hepatic disease, renal disease, hyponatremia, suicidal ideation, pregnancy (C)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8579">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8587">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8587">
							<item>
								<label>•</label>
								<para> 400 mg daily; after 1 wk, increase to 800 mg daily, max 1600 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8591">
					<section type="none" id="sidelem4x8592">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x8600">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;50 ml/min 200 mg daily; after 2 wk, increase to 400 mg daily, max 600 mg daily</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8603">
						<sec_title>Available forms:</sec_title>
						<para> Tab 200, 400, 600, 800 mg</para>
					</section>
					<section type="none" id="sidelem4x8608">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8612">
								<item>
									<label>•</label>
									<para>May be taken without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>May be crushed or whole</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8623">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8626">
					<section type="none" id="sidelem4x8627">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, dizziness, amnesia, depression, insomnia, lethargy, memory impairment, confusion, fatigue, headache, speech disturbance, suicidal thoughts/behaviors, tremors</para>
					</section>
					<section type="none" id="sidelem4x8632">
						<sec_title>CV:</sec_title>
						<para> Hypertension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x8637">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, nystagmus, diplopia</para>
					</section>
					<section type="none" id="sidelem4x8642">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, diarrhea, hypercholesterolemia/hypertriglyceridemia, vomiting, hepatotoxicity</para>
					</section>
					<section type="none" id="sidelem4x8647">
						<sec_title>GU:</sec_title>
						<para> Cystitis</para>
					</section>
					<section type="none" id="sidelem4x8652">
						<sec_title>INTEG:</sec_title>
						<para> Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, angioedema</para>
					</section>
					<section type="none" id="sidelem4x8657">
						<sec_title>META:</sec_title>
						<para> Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x8662">
						<sec_title>RESP:</sec_title>
						<para> Cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8667">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-4 hr; metabolized by liver; moderate CYP2C19 inhibitor; weak/moderate CYP3A4 inducer; steady state 4-5 days; excreted in urine, feces; half-life 13-20 hr; protein binding &lt;40%</para>
			</section>
			<section type="interactions" id="sidelem4x8672">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of bedaquiline, boceprevir, bosutinib, cabozantinib, cobicistat, elvitegravir, emtricitabine, crizotinib, cycloSPORINE, dronedarone, erlotinib, fosamprenavir, galantamine, gefitinib, HYDROcodone, maraviroc, oxyCODONE, paliperidone, perm panel, pimozide, praziquantel, QUEtiapine, ranolazine, rilpivirine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> eslicarbazepine effect CYP1A2, CYP2C19 substrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of CYP3A inducers</para>
			</section>
			<section type="considerations" id="sidelem4x8687">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8690">
					<section type="none" id="sidelem4x8691">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8699">
							<label>•</label>
							<sec_title>Hyponatremia</sec_title>
							<para>
								<list id="lidelem4x8699">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyponatremia:</emphasis> assess for nausea, vomiting, increased seizures, headache, weakness, confusion, irritability</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8703">
								<item>
									<label>•</label>
									<para>Seizures: character, location, duration, intensity, frequency, presence of aura</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8708">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin; sodium
<bbw>Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8722">
								<item>
									<label>•</label>
									<para>Eye problems: need for ophthalmic examinations before, during, after treatment (slit lamp, fundoscopy, tonometry)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8727">
								<item>
									<label>•</label>
									<para>Allergic reaction: purpura, red, raised rash; if these occur, product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8735">
							<label>•</label>
							<sec_title>Pregnancy (C)</sec_title>
							<para>
								<list id="lidelem4x8735">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pregnancy (C):</emphasis> patient should enroll in North American Antiepileptic Drug Pregnancy Registry (1-888-233-2334)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8739">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8743">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; document on patient’s chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8749">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8754">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name, and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8759">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness usually for the first 3 days of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8764">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8772">
							<label>•</label>
							<sec_title>
								<route>To notify if pregnancy is planned or suspected, pregnancy (C), to use additional contraceptives, if using hormonal contraceptives; to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x8775">
								<item>
									<label>•</label>
									<para>Not to abruptly discontinue drug</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8780">
								<item>
									<label>•</label>
									<para>To report signs of decreased renal function, dizziness, increased cholesterol, ocular toxicity, suicide risk, skin rashes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8786">
								<item>
									<label>•</label>
									<para>To take with or without food; that tablet can be crushed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8791">
								<item>
									<label>•</label>
									<para>To report increased seizures, headache, nausea, vomiting, weakness, confusion, irritability (hyponatremia)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="39" status="active" ha="yes">
			<mono_name>esmolol (Rx)</mono_name>
			<info>
				<pronunciation>(ez′moe-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x88030">Brevibloc</tradename>
				</tradenames>
				<class type="func"> β-Adrenergic blocker (antidysrhythmic II)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8809">
				<para>
					<confusion>
						<tradename id="tnidelem4x88090">esmolol</tradename>
						<drug type="generic" refid="idelem4x88090">Osmitrol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8816">
				<sec_title>Action:</sec_title>
				<para>Competitively blocks stimulation of β<emphasis style="inf">1</emphasis>-adrenergic receptors in the myocardium; produces negative chronotropic, inotropic activity (decreases rate of SA node discharge, increases recovery time), slows conduction of AV node, decreases heart rate, decreases O<emphasis style="inf">2</emphasis> consumption in myocardium; also decreases renin-aldosterone-angiotensin system at high doses; inhibits β<emphasis style="inf">2</emphasis>-receptors in bronchial system at higher doses</para>
			</section>
			<section type="uses" id="sidelem4x8830">
				<sec_title>Uses:</sec_title>
				<para>Supraventricular tachycardia, noncompensatory sinus tachycardia, intraoperative and postoperative tachycardia and hypertension, atrial fibrillation/flutter</para>
				<section type="none" id="sidelem4x8835">
					<section type="none" id="sidelem4x8836">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Acute MI, ECT, thyroid storm, pheochromocytoma, hypertensive crisis/urgency, unstable angina, hypertensive crisis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8841">
				<sec_title>Contraindications:</sec_title>
				<para>2nd- or 3rd-degree heart block; cardiogenic shock, CHF, cardiac failure, hypersensitivity, severe bradycardia</para>
				<section type="none" id="sidelem4x8846">
					<section type="none" id="sidelem4x8847">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, hypotension, peripheral vascular disease, diabetes, hypoglycemia, thyrotoxicosis, renal disease, atrial fibrillation, bronchospasms, hyperthyroidism, myasthenia gravis, asthma, COPD, CV disease, pheochromocytoma, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8852">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8855">
					<section type="none" id="sidelem4x8856">
						<sec_title>Atrial fibrillation/flutter</sec_title>
						<section type="none" id="sidelem4x8864">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8864">
									<item>
										<label>•</label>
										<para> loading dose 500 mcg/kg/min over 1 min; maintenance 50 mcg/kg/min for 4 min; if no response after 5 min, give 2nd loading dose, then increase infusion to 100 mcg/kg/min for 4 min; if no response, repeat loading dose, then increase maintenance infusion by 50 mcg/kg/min (max of 200 mcg/kg/min); titrate to patient response</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8871">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8871">
									<item>
										<label>•</label>
										<para> total loading dose of 600 mcg/kg over 2 min, maintenance  200 mcg/kg/min, titrate upward by 50-100 mcg/kg/min q5-10min until B/P, heart rate reduced by &gt;10%</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8878">
						<sec_title>Perioperative hypertension/tachycardia</sec_title>
						<section type="none" id="sidelem4x8886">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8886">
									<item>
										<label>•</label>
										<para> Immediate control 80 mg (bolus) over 30 seconds, then 150 mcg/kg/min, adjust to response, max 300 mcg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8890">
						<sec_title>Hypertensive emergency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8898">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8898">
									<item>
										<label>•</label>
										<para> 250-500 mcg/kg over 1 min, then  50-100 mcg/kg/min × 4 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8905">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg, 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x8910">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8914">
								<item>
									<label>•</label>
									<para>Do not discontinue product suddenly</para>
								</item>
								<item>
									<label>•</label>
									<para>Store protected from light, moisture; in cool environment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8925">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x8933">
								<label>•</label>
								<sec_title>
									<route>Check that correct concentrations being given</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x8936">
									<item>
										<label>•</label>
										<para>10 mg/ml inj sol needs no dilution, may be used as an IV loading dose using a handheld syringe</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8941">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8945">
									<item>
										<label>•</label>
										<para>Ready-to-use bags of premixed isotonic sol of 10 mg/ml and 20 mg/ml available in 100-, 250-ml bags; use controlled infusion device, central line preferred; rate is based on patient’s weight</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amikacin, aminophylline, amiodarone, atracurium, butorphanol, calcium chloride, ceFAZolin, cefTAZidime, ceftizoxime, chloramphenicol, cimetidine, cisatracurium, clindamycin, diltiazem, DOPamine, enalaprilat, erythromycin, famotidine, fentaNYL, gentamicin, insulin (regular), labetalol, magnesium sulfate, methyldopate, metroNIDAZOLE, midazolam, morphine, nitroglycerin, nitroprusside, norepinephrine, pancuronium, penicillin G potassium, piperacillin, polymyxin B, potassium chloride, potassium phosphate, propofol, ranitidine, remifentanil, streptomycin, tacrolimus, tobramycin, trimethoprim-sulfamethoxazole, vancomycin, vecuronium, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8957">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8960">
					<section type="none" id="sidelem4x8961">
						<sec_title>CNS:</sec_title>
						<para> Confusion, light-headedness, paresthesia, somnolence, fever, dizziness, fatigue, headache, depression, anxiety, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8968">
						<sec_title>CV:</sec_title>
						<para> Hypotension, bradycardia, chest pain, peripheral ischemia, SOB, <emphasis style="bold">CHF,</emphasis> conduction disturbances; 1st-, 2nd-, 3rd-degree heart block</para>
					</section>
					<section type="none" id="sidelem4x8976">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, gastric pain, flatulence, constipation, heartburn, bloating</para>
					</section>
					<section type="none" id="sidelem4x8984">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, impotence, dysuria</para>
					</section>
					<section type="none" id="sidelem4x8989">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Induration, inflammation at site,</emphasis> discoloration, edema, erythema, burning pallor, flushing, rash, pruritus, dry skin, alopecia</para>
					</section>
					<section type="none" id="sidelem4x8997">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, cough, wheeziness, nasal stuffiness, <emphasis style="bold">pulmonary edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9007">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset very rapid, duration short, half-life 9 min, metabolized by hydrolysis of ester linkage, excreted via kidneys</para>
			</section>
			<section type="interactions" id="sidelem4x9012">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x9020">
					<label>•</label>
					<sec_title>
						<route>Avoid use with MAOIs, Sotalol</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of antidiabetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> possible fatal B/P increase—clonidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> potentiate suppressive effects of diltiazem, verapamil</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—general anesthetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin levels—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> α-adrenergic stimulation—ePHEDrine, EPINEPHrine, amphetamine, norepinephrine, phenylephrine, pseudoePHEDrine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of thyroid hormones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of esmolol—thyroid hormone, salicylates</para>
				<section type="none" id="sidelem4x9055">
					<section type="none" id="sidelem4x9056">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> β-blocking effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x9067">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose/insulin tolerance test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9074">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9077">
					<section type="none" id="sidelem4x9078">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9086">
							<label>•</label>
							<sec_title>CHF<route> I&amp;O ratio, weight daily, jugular venous distention, weight gain, crackles, edema</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9092">
							<label>•</label>
							<sec_title>Dysrhythmias<route> B/P, pulse q4hr; note rate, rhythm, quality; rapid changes can cause shock; if systolic &lt;100 or diastolic &lt;60, notify prescriber before giving product; ECG continuously during infusion, hypotension common, if severe, slow or stop infusion</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9095">
								<item>
									<label>•</label>
									<para>Baselines in renal/hepatic studies, blood glucose before therapy begins</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9103">
							<label>•</label>
							<sec_title>Bronchospasm<route> breath sounds, respiratory pattern</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9106">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9110">
								<item>
									<label>•</label>
									<para>Therapeutic response: lower B/P immediately, lower heart rate</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9116">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9121">
								<item>
									<label>•</label>
									<para>About reason for use, expected results</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9129">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if chest pain, SOB, wheezing, hypotension, bradycardia, pain, swelling at IV site occurs</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>esomeprazole (Rx)</mono_name>
			<info>
				<pronunciation>(es′oh-mep′rah-zohl)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x91420">NexIUM</tradename>
				</tradenames>
				<class type="func"> Antiulcer</class>
				<class type="chem"> Proton-pump inhibitor, benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9153">
				<para>
					<confusion>
						<tradename id="tnidelem4x91530">NexIUM</tradename>
						<drug type="generic" refid="idelem4x91530">NexAVAR</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9157">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretions by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cell; characterized as gastric acid pump inhibitor because it blocks the final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x9162">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), adult/child/infant; severe erosive esophagitis, adult/child; treatment of active duodenal ulcers in combination with antiinfectives for <emphasis style="italic">Helicobacter pylori</emphasis> infection; long-term use for hypersecretory conditions</para>
			</section>
			<section type="contra" id="sidelem4x9170">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to proton-pump inhibitors (PPIs)</para>
				<section type="none" id="sidelem4x9175">
					<section type="none" id="sidelem4x9176">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hypomagnesemia, osteoporosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9181">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9184">
					<section type="none" id="sidelem4x9185">
						<sec_title>Active duodenal ulcers associated with <emphasis style="italic">H. pylori</emphasis></sec_title>
						<section type="none" id="sidelem4x9195">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9195">
									<item>
										<label>•</label>
										<para> 40 mg/day × 10-14 days in combination with clarithromycin 500 mg bid × 10 days and amoxicillin 1000 mg bid × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9199">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x9207">
							<label>•</label>
							<sec_title>Adult<route> PO/IV max 20 mg/day (severe hepatic disease)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9210">
						<sec_title>GERD/erosive esophagitis</sec_title>
						<section type="none" id="sidelem4x9218">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9218">
									<item>
										<label>•</label>
										<para> 20 or 40 mg/day × 4-8 wk; no adjustment needed in renal/liver failure, geriatric patients;  20 or 40 mg/day up to 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9228">
							<label>•</label>
							<sec_title>Adolescent and child 12-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9228">
									<item>
										<label>•</label>
										<para> 20 or 40 mg/day 1 hr before meals for ≤8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9235">
							<label>•</label>
							<sec_title>Child 1-11 yr and ≥20 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9235">
									<item>
										<label>•</label>
										<para> 10 mg/day 1 hr before meals for ≤8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9242">
							<label>•</label>
							<sec_title>Infant ≥1 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9242">
									<item>
										<label>•</label>
										<para> 0.5 mg/kg over 10-30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9249">
							<label>•</label>
							<sec_title>Infant 1-11 mo (&gt;7.5-12 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9249">
									<item>
										<label>•</label>
										<para> 10 mg daily × up to 6 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9256">
							<label>•</label>
							<sec_title>Infant 1-11 mo (&gt;5-7.5 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9256">
									<item>
										<label>•</label>
										<para> 5 mg daily × up to 6 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9263">
							<label>•</label>
							<sec_title>Infant 1-11 mo (3-5 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9263">
									<item>
										<label>•</label>
										<para> 2.5 mg daily × up to 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9267">
						<sec_title>Available forms:</sec_title>
						<para> Del rel caps 20, 40 mg; powder for IV inj 20, 40 mg/vial; del rel powder for oral susp 2.5, 5, 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x9272">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9275">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9280">
									<item>
										<label>•</label>
										<para>Swallow caps whole; do not crush or chew; cap may be opened and sprinkled over Tbsp of applesauce</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9285">
									<item>
										<label>•</label>
										<para>Same time daily, 1 hr before meal</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x9293">
								<label>•</label>
								<sec_title>Oral susp (del rel)</sec_title>
								<para>
									<list id="lidelem4x9293">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral susp (del rel):</emphasis> empty contents of packet into container with 1 Tbsp of water, let stand 2-3 min to thicken, restir, give within 30 min of mixing; any residual product should be flushed with more water, taken immediately</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x9300">
								<label>•</label>
								<sec_title>NG tube (del rel oral susp)</sec_title>
								<para>
									<list id="lidelem4x9300">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">NG tube (del rel oral susp):</emphasis> add 15 ml water to contents of packet in syringe, shake, leave 2-3 min to thicken, shake, inject through NG tube within 30 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x9304">
							<sec_title>IV, direct route</sec_title>
							<para>
								<list id="lidelem4x9308">
									<item>
										<label>•</label>
										<para>Reconstitute each vial with 5 ml 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, LR; give over 3 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9317">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9321">
									<item>
										<label>•</label>
										<para>Dilute reconstituted sol to 50 ml, give over 30 min, do not admix, flush line with D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, LR after infusion</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, LR, 0.9% NaCl</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9337">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9340">
					<section type="none" id="sidelem4x9341">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9348">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, flatulence,</emphasis> abdominal pain, constipation, dry mouth, <emphasis style="bold">hepatic failure, hepatitis,</emphasis> microscopic colitis</para>
					</section>
					<section type="none" id="sidelem4x9359">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dry skin</para>
					</section>
					<section type="none" id="sidelem4x9367">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9374">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough,</emphasis><emphasis style="bold">pneumonia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9383">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9390">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed 90%; protein binding 97%; extensively metabolized in liver (CYP2C19); terminal half-life 1-1.5 hr; eliminated in urine as metabolites and in feces; in geriatric patients, elimination rate decreased, bioavailability increased</para>
			</section>
			<section type="interactions" id="sidelem4x9396">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: effect, toxicity of diazepam, digoxin, penicillins, saquinavir, cilostazol, clozapine, those drugs metabolized by CYP2C19</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of methotrexate, tacrolimus, warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect—atazanavir, nelfinavir, dapsone, iron, itraconazole, ketoconazole, indinavir, calcium carbonate, vit B<emphasis style="inf">12</emphasis>, clopidogrel, iron salts, mycophenolate</para>
				<section type="none" id="sidelem4x9413">
					<section type="none" id="sidelem4x9414">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> sodium, Hgb, WBC, platelets, magnesium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9421">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9424">
					<section type="none" id="sidelem4x9425">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9433">
							<label>•</label>
							<sec_title>GI system<route> bowel sounds, abdomen for pain, swelling, anorexia, bloody stools; pseudomembranous colitis may occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9439">
							<label>•</label>
							<sec_title>Hepatic failure, hepatitis<route> AST, ALT, alk phos at baseline and periodically during treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9445">
							<label>•</label>
							<sec_title>Serious skin disorders<route> Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9448">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9452">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9458">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9466">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea; abdominal pain; black, tarry stools, rash; product may have to be discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9469">
								<item>
									<label>•</label>
									<para>That hypoglycemia may occur if diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9474">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9479">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, NSAIDs; may cause GI irritation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9484">
								<item>
									<label>•</label>
									<para>To take ≥1 hr before meal; not to crush, chew del rel product, if missed, take as soon as remembered if not almost time for next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9489">
								<item>
									<label>•</label>
									<para>If cap is unable to be swallowed, whole contents may be mixed with a Tbsp of applesauce</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>estradiol (Rx)</mono_name>
			<info>
				<pronunciation>(es-tra-dye′ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x94990">Estrace</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="42" status="active">
			<mono_name>estradiol cypionate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95040">Depo-Estradiol</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="43" status="active">
			<mono_name>estradiol gel (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95092">Divigel</tradename>
					<tradename id="tnidelem4x95091">Elestrin</tradename>
					<tradename id="tnidelem4x95090">Estrogel</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="44" status="active">
			<mono_name>estradiol spray (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95140">Evamist</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="45" status="active">
			<mono_name>estradiol topical emulsion (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95190">Estrasorb</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="46" status="active">
			<mono_name>estradiol valerate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95240">Delestrogen</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="47" status="active">
			<mono_name>estradiol transdermal system (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95293">Alora</tradename>
					<tradename id="tnidelem4x95292">Climara</tradename>
					<tradename id="tnidelem4x95291">Minivelle</tradename>
					<tradename id="tnidelem4x95290">Vivelle-Dot</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="48" status="active">
			<mono_name>estradiol vaginal tablet (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95340">Vagifem</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="49" status="active">
			<mono_name>estradiol vaginal ring (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x95391">Estring</tradename>
					<tradename id="tnidelem4x95390">Femring</tradename>
				</tradenames>
				<class type="func"> Estrogen, progestins</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x9545">
				<sec_title>Action:</sec_title>
				<para>Needed for adequate functioning of female reproductive system; affects release of pituitary gonadotropins; inhibits ovulation, adequate calcium use in bone</para>
			</section>
			<section type="uses" id="sidelem4x9550">
				<sec_title>Uses:</sec_title>
				<para>Vasomotor symptoms (menopause), inoperable breast cancer (selected cases), prostatic cancer, atrophic vaginitis, kraurosis vulvae, hypogonadism, primary ovarian failure, prevention of osteoporosis, castration</para>
			</section>
			<section type="contra" id="sidelem4x9555">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, reproductive cancer, genital bleeding (abnormal, undiagnosed), protein S or C deficiency, antithrombin deficiency, angioedema, MI, stroke</para>
				<para>
					<bbw>Breast/endometrial cancer, thromboembolic disorders, MI, stroke</bbw>
				</para>
				<section type="none" id="sidelem4x9572">
					<section type="none" id="sidelem4x9573">
						<sec_title>Precautions:</sec_title>
						<para> Hypertension, asthma, blood dyscrasias, gallbladder/bone/renal/hepatic disease, CHF, diabetes mellitus, depression, migraine headache, seizure disorders, family history of cancer of breast or reproductive tract, smoking, uterine fibroids, vaginal irritation/infection, history of angioedema</para>
						<para>
							<bbw>Cardiac disease, dementia, accidental exposure pets/children (topical)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9588">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9591">
					<section type="none" id="sidelem4x9592">
						<sec_title>Hormone replacement/menopause symptoms</sec_title>
						<section type="none" id="sidelem4x9600">
							<label>•</label>
							<sec_title>Adult<route> TRANSDERMAL</route></sec_title>
							<para>
								<list id="lidelem4x9600">
									<item>
										<label>•</label>
										<para> 1 patch delivering 0.025, 0.0375, 0.05, 0.075, or 0.1 mg/day 2×/wk (Alora, Estraderm, Vivelle-Dot); 1 patch delivering 0.025, 0.0375, 0.05, 0.06, 0.075, or 0.1 mg/day replace q7days (Climara); 1 patch delivering 0.025 mg/day, replace q7days, may increase to 2 patches after 4-6 wk;  apply entire unit-dose packet to 5 × 7-inch area of upper thigh/day, alternate thighs;  (Evamist) 1 spray to inner surface of forearm/day in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9612">
						<sec_title>Menopause/hypogonadism/castration/ovarian failure</sec_title>
						<section type="none" id="sidelem4x9620">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9620">
									<item>
										<label>•</label>
										<para> 0.5-2 mg/day, 3 wk on, 1 wk off or continuously;  (cypionate) 1-5 mg q3-4wk; (valerate) 10-20 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9630">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x9630">
									<item>
										<label>•</label>
										<para> (Estraderm) 0.05 mg/24 hr applied 2×/wk; (Climara) 0.05 mg/hr applied 1×/wk in cyclic regimen; women with hysterectomy may use continuously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9634">
						<sec_title>Prostatic cancer (inoperable)</sec_title>
						<section type="none" id="sidelem4x9642">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x9642">
									<item>
										<label>•</label>
										<para> (valerate) 30 mg q1-2wk;  (oral estradiol) 1-2 mg bid-tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9649">
						<sec_title>Breast cancer (palliative treatment)</sec_title>
						<section type="none" id="sidelem4x9657">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9657">
									<item>
										<label>•</label>
										<para> 10 mg tid × 3 mo or longer</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9661">
						<sec_title>Atropic vaginitis/kraurosis vulvae</sec_title>
						<section type="none" id="sidelem4x9669">
							<label>•</label>
							<sec_title>Adult<route> VAG CREAM</route></sec_title>
							<para>
								<list id="lidelem4x9669">
									<item>
										<label>•</label>
										<para> 2-4 g/day × 1-2 wk, then 1 g 1-3×/wk cycled; vag tab 1/day × 2 wk, maintenance 1 tab 2×/wk;  inserted, left in place continuously for 3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9676">
						<sec_title>Vasomotor symptoms</sec_title>
						<section type="none" id="sidelem4x9684">
							<label>•</label>
							<sec_title>Adult<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x9684">
									<item>
										<label>•</label>
										<para> after cleaning and drying skin on left thigh, calf, rub in contents of pouch using both hands until completely absorbed; wash hands</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9688">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">
								<emphasis style="italic">Estradiol:</emphasis>
							</emphasis> tabs 0.5, 1, 2 mg; <emphasis style="bold">
								<emphasis style="italic">valerate:</emphasis>
							</emphasis> inj 10, 20, 40 mg/ml; <emphasis style="bold">
								<emphasis style="italic">transdermal:</emphasis>
							</emphasis> 0.014, 0.025, 0.0375, 0.05, 0.075, 0.1 mg/24 hr release rate; <emphasis style="bold">
								<emphasis style="italic">vag cream:</emphasis>
							</emphasis> 100 mcg/g; <emphasis style="bold">
								<emphasis style="italic">vag tab:</emphasis>
							</emphasis> 10 mcg; <emphasis style="bold">
								<emphasis style="italic">vag ring:</emphasis>
							</emphasis> 2 mg/90 days; <emphasis style="bold">
								<emphasis style="italic">topical emulsion:</emphasis>
							</emphasis> 2.5 mg; <emphasis style="bold">
								<emphasis style="italic">gel</emphasis>
							</emphasis> (Divigel) 0.06%, 0.1%; <emphasis style="bold">
								<emphasis style="italic">spray</emphasis>
							</emphasis> (Evamist) 1.53 mg/acuation</para>
					</section>
					<section type="none" id="sidelem4x9729">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9733">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
								<item>
									<label>•</label>
									<para>IM inj deeply in large muscle mass</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9744">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x9748">
									<item>
										<label>•</label>
										<para>With food or milk to decrease GI symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9754">
							<sec_title>Transdermal route</sec_title>
							<para>
								<list id="lidelem4x9758">
									<item>
										<label>•</label>
										<para>May contain aluminum or other metals in backing of patch, can overheat in MRI scan and burn patients</para>
									</item>
									<item>
										<label>•</label>
										<para>Apply to trunk of body 2×/wk; press firmly, hold in place for 10 sec to ensure good contact; do not apply to breasts</para>
									</item>
									<item>
										<label>•</label>
										<para>On intermittent cycle schedule: 3 wk on, then 1 wk off; if patch falls off, reapply</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9774">
							<sec_title>Topical route</sec_title>
							<section type="none" id="sidelem4x9782">
								<label>•</label>
								<sec_title>
									<route>avoid secondary exposure to children, pets, caregivers</route>
								</sec_title>
								<para>
									<list id="lidelem4x9782">
										<item>
											<label>•</label>
											<para>Use Evamist daily; spray to inner upper arm; may increase to 2-3×/day based on response; allow to dry for 2 min, </para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x9786">
							<sec_title>Vaginal route</sec_title>
							<para>
								<list id="lidelem4x9790">
									<item>
										<label>•</label>
										<para>Use a new applicator daily, provided</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9796">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9799">
					<section type="none" id="sidelem4x9800">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, migraines, depression, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9807">
						<sec_title>CV:</sec_title>
						<para> Hypertension, thrombophlebitis, edema, <emphasis style="bold">thromboembolism, stroke, pulmonary embolism, MI,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x9816">
						<sec_title>EENT:</sec_title>
						<para> Contact lens intolerance, increased myopia, astigmatism, throat swelling, eyelid edema</para>
					</section>
					<section type="none" id="sidelem4x9821">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, anorexia, pancreatitis, cramps, constipation, increased appetite, increased weight, <emphasis style="bold">cholestatic jaundice, hepatic adenoma</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9831">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, cervical erosion, breakthrough bleeding, dysmenorrhea, vaginal candidiasis, breast changes, <emphasis style="italic">gynecomastia, testicular atrophy, impotence,</emphasis><emphasis style="bold">increased risk of breast cancer, endometrial cancer,</emphasis> changes in libido; <emphasis style="bold">toxic shock, vaginal wall ulceration/erosion (vag ring)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9843">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, acne, hirsutism, alopecia, oily skin, seborrhea, purpura, erythema, pruritus, melasma; site irritation (transdermal)</para>
					</section>
					<section type="none" id="sidelem4x9848">
						<sec_title>META:</sec_title>
						<para> Folic acid deficiency, hypercalcemia, hyperglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9853">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9856">
					<section type="none" id="sidelem4x9857">
						<sec_title>PO/INJ/TRANSDERMAL:</sec_title>
						<para> Degraded in liver, excreted in urine, crosses placenta, excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9862">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of corticosteroids, tricyclics</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—cycloSPORINE, dantrolene</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of anticoagulants, oral hypoglycemics, tamoxifen</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> estradiol action—anticonvulsants, barbiturates, phenylbutazone, rifampin, calcium</para>
				<section type="none" id="sidelem4x9880">
					<section type="none" id="sidelem4x9881">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x9885">
								<item>
									<label>•</label>
									<para>Altered estrogen effect: black cohosh, DHEA</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> estrogen effect—saw palmetto, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x9895">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> estrogen level—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x9902">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BSP retention test, PBI, T<emphasis style="inf">4</emphasis>, serum sodium, platelet aggregation, thyroxine-binding globulin (TBG), prothrombin; factors VII, VIII, IX, X; triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum folate, serum triglyceride, T<emphasis style="inf">3</emphasis> resin uptake test, glucose tolerance test, antithrombin III, pregnanediol, metyrapone test</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> LE prep, ANA</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9923">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9926">
					<section type="none" id="sidelem4x9927">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>For previous breast/endometrial cancer, thrombo-embolic disorders, MI, stroke, dementia, use adequate screening for these conditions, estrogen increases the risk</bbw>
						</para>
						<para>
							<list id="lidelem4x9940">
								<item>
									<label>•</label>
									<para>Blood glucose of diabetic patient; hyperglycemia may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly weight gain &gt;5 lb; if increase, diuretic may be ordered</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P q4hr; watch for increase caused by water and sodium retention</para>
								</item>
								<item>
									<label>•</label>
									<para>I&amp;O ratio; decreasing urinary output, increasing edema, report changes</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies, including AST, ALT, bilirubin, alk phos at baseline, periodically; periodic folic acid level</para>
								</item>
								<item>
									<label>•</label>
									<para>Hypertension, cardiac symptoms, jaundice, hypercalcemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
								<item>
									<label>•</label>
									<para>Female patient for intact uterus; if so, progesterone should be added to estrogen therapy to decrease risk of endometrial cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9981">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9985">
								<item>
									<label>•</label>
									<para>Therapeutic response: reversal of menopause symptoms; decrease in tumor size in prostatic, breast cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9991">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9996">
								<item>
									<label>•</label>
									<para>To weigh weekly; to report gain &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10002">
								<item>
									<para>
										<emphasis alert="nurse">To report breast lumps, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, headache, blurred vision, abdominal pain, numbness or stiffness in legs, chest pain; tenderness, redness, and swelling in extremities; males to report impotence, gynecomastia; to report dermal rash with transdermal patch</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10007">
								<item>
									<label>•</label>
									<para>To avoid grapefruit or grapefruit juice (PO)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10012">
								<item>
									<label>•</label>
									<para>That smoking increases CV conditions, encourage to stop</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10021">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, and not to become pregnant when using estrogen</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10024">
								<item>
									<label>•</label>
									<para>To report changes in blood glucose, if diabetic</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>estrogens, conjugated (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x100321">Cenestin</tradename>
					<tradename id="tnidelem4x100320">Premarin</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="51" status="active">
			<mono_name>estrogens, conjugated synthetic B (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x100370">Enjuvia</tradename>
				</tradenames>
				<class type="func"> Estrogen, hormone</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10043">
				<para>
					<confusion>
						<tradename id="tnidelem4x100430">Premarin</tradename>
						<drug type="generic" refid="idelem4x100430">Provera</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10047">
				<sec_title>Action:</sec_title>
				<para>Needed for adequate functioning of female reproductive system; affects release of pituitary gonadotropins, inhibits ovulation, adequate calcium use in bone</para>
			</section>
			<section type="uses" id="sidelem4x10052">
				<sec_title>Uses:</sec_title>
				<para>Vasomotor symptoms (menopause), inoperable breast cancer, prostatic cancer, abnormal uterine bleeding, hypogonadism, primary ovarian failure, prevention of osteoporosis, castration, atrophic vaginitis</para>
				<section type="none" id="sidelem4x10057">
					<section type="none" id="sidelem4x10058">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hyperparathyroidism, infertility</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10063">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, thromboembolic disorders, reproductive cancer, genital bleeding (abnormal, undiagnosed), hypersensitivity, MI, stroke, thrombophlebitis</para>
				<para>
					<bbw>Endometrial, breast cancer, thromboembolic diseases</bbw>
				</para>
				<section type="none" id="sidelem4x10078">
					<section type="none" id="sidelem4x10079">
						<sec_title>Precautions:</sec_title>
						<para> Hypertension, asthma, blood dyscrasias, CHF, diabetes mellitus, depression, migraine headache, seizure disorders, gallbladder/bone/hepatic/renal disease, family history of cancer of breast or reproductive tract, smoking, dementia, hypothyroidism, obesity, SLE</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10084">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10087">
					<sec_title>
						<emphasis style="italic">Estrogens conjugated</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x10091">
						<sec_title>Vasomotor symptoms (menopause)</sec_title>
						<section type="none" id="sidelem4x10099">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10099">
									<item>
										<label>•</label>
										<para> 0.3-1.25 mg/day 3 wk on, 1 wk off</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10103">
						<sec_title>Prevention of osteoporosis</sec_title>
						<section type="none" id="sidelem4x10111">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10111">
									<item>
										<label>•</label>
										<para> 0.3 mg/day or in cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10115">
						<sec_title>Atrophic vaginitis</sec_title>
						<section type="none" id="sidelem4x10123">
							<label>•</label>
							<sec_title>Adult<route> VAG CREAM</route></sec_title>
							<para>
								<list id="lidelem4x10123">
									<item>
										<label>•</label>
										<para> 0.5 g/day × 21 days, off 7 days, repeat</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10127">
						<sec_title>Prostatic cancer</sec_title>
						<section type="none" id="sidelem4x10135">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10135">
									<item>
										<label>•</label>
										<para> 1.25-2.5 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10139">
						<sec_title>Advanced inoperable breast cancer</sec_title>
						<section type="none" id="sidelem4x10147">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10147">
									<item>
										<label>•</label>
										<para> 10 mg tid × ≥3 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10151">
						<sec_title>Abnormal uterine bleeding</sec_title>
						<section type="none" id="sidelem4x10159">
							<label>•</label>
							<sec_title>Adult<route> IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x10159">
									<item>
										<label>•</label>
										<para> 25 mg q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10163">
						<sec_title>Castration/primary ovarian failure</sec_title>
						<section type="none" id="sidelem4x10171">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10171">
									<item>
										<label>•</label>
										<para> 1.25 mg/day 3 wk on, 1 wk off</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10175">
						<sec_title>Hypogonadism</sec_title>
						<section type="none" id="sidelem4x10183">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10183">
									<item>
										<label>•</label>
										<para> 0.3 or 0.625 mg daily (3 wk on, 1 wk off), adjust to response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x10187">
					<sec_title>
						<emphasis style="bold">
							<emphasis style="italic">Estrogens conjugated synthetic B</emphasis>
						</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x10192">
						<sec_title>Vasomotor symptoms (menopause)</sec_title>
						<section type="none" id="sidelem4x10200">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10200">
									<item>
										<label>•</label>
										<para> 0.625 mg/day initially; may increase based on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10204">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.3, 0.45, 0.625, 0.9, 1.25, 2.5 mg; inj 25 mg/vial; vag cream 0.625 mg/g; <emphasis style="italic">synthetic B:</emphasis> tabs 0.625, 1.25 mg</para>
					</section>
					<section type="none" id="sidelem4x10212">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10216">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10222">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10226">
									<item>
										<label>•</label>
										<para>Give with or immediately after food to reduce nausea</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10232">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x10236">
									<item>
										<label>•</label>
										<para>IM reconstitute after withdrawing 5 ml of air from container, inject sterile diluent on vial side, rotate to dissolve; give inj deep in large muscle mass, aspirate before inj</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10242">
							<sec_title>Vaginal route</sec_title>
							<para>
								<list id="lidelem4x10246">
									<item>
										<label>•</label>
										<para>Use applicator provided, wash after use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10252">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x10256">
									<item>
										<label>•</label>
										<para>IV, after reconstituting as for IM, inject into distal port of running IV line of D<emphasis style="inf">5</emphasis>W, 0.9% NaCl at ≤5 mg/min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Heparin, hydrocortisone, potassium chloride, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10271">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10274">
					<section type="none" id="sidelem4x10275">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, migraine, depression, <emphasis style="bold">seizures,</emphasis> mood disturbances</para>
					</section>
					<section type="none" id="sidelem4x10283">
						<sec_title>CV:</sec_title>
						<para> Hypertension, thrombophlebitis, edema, <emphasis style="bold">thromboembolism, stroke, pulmonary embolism, MI,</emphasis> chest pain</para>
					</section>
					<section type="none" id="sidelem4x10291">
						<sec_title>EENT:</sec_title>
						<para> Contact lens intolerance, increased myopia, astigmatism</para>
					</section>
					<section type="none" id="sidelem4x10296">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, anorexia, pancreatitis, cramps, constipation, increased appetite, <emphasis style="bold">cholestatic jaundice, hepatic adenoma,</emphasis> weight gain/loss</para>
					</section>
					<section type="none" id="sidelem4x10307">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, cervical erosion, breakthrough bleeding, dysmenorrhea, vaginal candidiasis, breast changes, <emphasis style="italic">gynecomastia, testicular atrophy, impotence,</emphasis><emphasis style="bold">increased risk of breast cancer, endometrial cancer,</emphasis> libido changes</para>
					</section>
					<section type="none" id="sidelem4x10317">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, acne, hirsutism, alopecia, oily skin, seborrhea, purpura, melasma</para>
					</section>
					<section type="none" id="sidelem4x10322">
						<sec_title>META:</sec_title>
						<para> Folic acid deficiency, hypercalcemia, hyperglycemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10327">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10330">
					<section type="none" id="sidelem4x10331">
						<sec_title>PO/IM/IV:</sec_title>
						<para> Degraded in liver, excreted in urine, crosses placenta, excreted in breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10336">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—cycloSPORINE, dantrolene</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of corticosteroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of estrogens—anticonvulsants, barbiturates, phenylbutazone, rifampin, bosentan</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of anticoagulants, oral hypoglycemics, tamoxifen, thyroid, tricyclics</para>
				<section type="none" id="sidelem4x10354">
					<section type="none" id="sidelem4x10355">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> estrogen level—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x10362">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BSP retention test, PBI, T<emphasis style="inf">4</emphasis>, serum sodium, platelet aggregation, thyroxine-binding globulin (TBG), prothrombin; factors VII, VIII, IX, X; triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> serum folate, serum triglyceride, T<emphasis style="inf">3</emphasis> resin uptake test, glucose tolerance test, antithrombin III, pregnanediol, metyrapone test</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> LE prep, antinuclear antibodies</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10383">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10386">
					<section type="none" id="sidelem4x10387">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Breast, endometrial cancer:</emphasis> estrogens should not be used in known, suspected, or history of these disorders</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Stroke, thromboembolic disease of MI:</emphasis> Should not be used in these conditions or known protein C deficiency, protein S deficiency, or antithrombin deficiency</bbw>
						</para>
						<para>
							<list id="lidelem4x10414">
								<item>
									<label>•</label>
									<para>Blood glucose if diabetic patient; hyperglycemia may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly weight gain &gt;5 lb; if increase, diuretic may be ordered; check for edema; B/P baseline and periodically</para>
								</item>
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, alk phos</para>
								</item>
								<item>
									<label>•</label>
									<para>Hypertension, cardiac symptoms, jaundice, hypercalcemia</para>
								</item>
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
								<item>
									<label>•</label>
									<para>Female patient for intact uterus; if so, progesterone should be added to estrogen therapy to decrease risk of endometrial cancer; abnormal uterine bleeding, breast exam; Pap smear</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10445">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10449">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of breast engorgement, reversal of menopause symptoms, decrease in tumor size with prostatic cancer</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10455">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10459">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding, since product excreted in breast milk</para>
								</item>
								<item>
									<label>•</label>
									<para>To weigh weekly; to report gain &gt;5 lb
<bbw>To report breast lumps, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, headache, blurred vision, abdominal pain; leg pain and redness, numbness or stiffness; chest pain; males to report impotence or gynecomastia</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid sunlight or wear sunscreen; burns may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected</para>
								</item>
								<item>
									<label>•</label>
									<para>That vasomotor symptoms improve in 2 wk, max relief in 8 wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="52" status="active" ha="yes">
			<mono_name>eszopiclone (Rx)</mono_name>
			<info>
				<pronunciation>(es-zop′i-klone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x105010">Lunesta</tradename>
				</tradenames>
				<class type="func"> Sedative/hypnotic, nonbenzodiazepine</class>
				<class type="chem"> Cyclopyrrolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x10514">
				<sec_title>Action:</sec_title>
				<para>Interacts with GABA receptors</para>
			</section>
			<section type="uses" id="sidelem4x10519">
				<sec_title>Uses:</sec_title>
				<para>Insomnia</para>
			</section>
			<section type="contra" id="sidelem4x10524">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x10529">
					<section type="none" id="sidelem4x10530">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, severe hepatic disease, abrupt discontinuation, COPD, depression, labor, sleep apnea, substance abuse, suicidal ideation, ethanol intoxication</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10535">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10543">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10543">
							<item>
								<label>•</label>
								<para> 1 mg immediately before bed, may increase to 3 mg if needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10547">
					<section type="none" id="sidelem4x10548">
						<sec_title>
							<emphasis style="bold">Hepatic dose/CYP3A4 inhibitors</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x10557">
							<label>•</label>
							<sec_title>Adult<route> PO 1 mg immediately before bed with severe hepatic disease, max 2 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10560">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 3 mg</para>
					</section>
					<section type="none" id="sidelem4x10565">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10569">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew tab</para>
								</item>
								<item>
									<label>•</label>
									<para>Immediately before bedtime; avoid use with food; for short-term use only</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10580">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10583">
					<section type="none" id="sidelem4x10584">
						<sec_title>CNS:</sec_title>
						<para> Worsening depression, hallucinations, headache, daytime drowsiness, <emphasis style="bold">suicidal thoughts/actions,</emphasis> migraine, restlessness, anxiety, sleep driving, sleepwalking</para>
					</section>
					<section type="none" id="sidelem4x10592">
						<sec_title>CV:</sec_title>
						<para> Peripheral edema, chest pain</para>
					</section>
					<section type="none" id="sidelem4x10597">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, bitter taste (dysgeusia)</para>
					</section>
					<section type="none" id="sidelem4x10602">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, dysmenorrhea</para>
					</section>
					<section type="none" id="sidelem4x10607">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10614">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset rapid; peak 1 hr; duration 6 hr; extensively metabolized in the liver by CYP3A4, CYP2E1; excreted via kidneys; half-life 6 hr, geriatric patients 9 hr, protein binding 52%-59%</para>
			</section>
			<section type="interactions" id="sidelem4x10619">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity due to decreased eszopiclone elimination—CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, troleandomycin, SSRIs)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> eszopiclone effect—CYP3A4 inducers (dexamethasone, barbiturates, carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, ethotoin)</para>
				<section type="none" id="sidelem4x10634">
					<section type="none" id="sidelem4x10635">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> product action—food</para>
					</section>
					<section type="none" id="sidelem4x10642">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> eszopiclone effect—St. John’s Wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10649">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10652">
					<section type="none" id="sidelem4x10653">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10661">
							<label>•</label>
							<sec_title>Sleep pattern<route> ability to go to sleep, stay asleep, early morning awakenings, conservative methods used</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10664">
								<item>
									<label>•</label>
									<para>For abuse of this product, other products</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10672">
							<label>•</label>
							<sec_title>Anaphylaxis, angioedema<route> monitor during first dose</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x10675">
								<item>
									<label>•</label>
									<para>Alternative methods to improve sleep: reading, quiet environment, warm bath, milk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10680">
								<item>
									<label>•</label>
									<para>Assistance with ambulation, night light, call bell within reach</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10685">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10689">
								<item>
									<label>•</label>
									<para>Therapeutic response: ability to fall asleep and stay asleep throughout the night</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10695">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10699">
								<item>
									<label>•</label>
									<para>That daytime drowsiness may occur; not to engage in hazardous activities until effect is known; that memory problems may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That all other medications and supplements should be avoided unless approved by prescriber; to avoid alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is suspected or planned</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid use after a high-fat meal</para>
								</item>
								<item>
									<label>•</label>
									<para>To swallow tab whole</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to stop drug abruptly, tolerance may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active">
			<mono_name>etanercept (Rx)</mono_name>
			<info>
				<pronunciation>(eh-tan′er-sept)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107370">Enbrel</tradename>
				</tradenames>
				<class type="func"> Antirheumatic agent (disease modifying) (DMARDs)</class>
				<class type="chem"> Anti-TNF agent</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x10747">
				<sec_title>Action:</sec_title>
				<para>Binds tumor necrosis factor (TNF), which is involved in immune and inflammatory reactions</para>
			</section>
			<section type="uses" id="sidelem4x10752">
				<sec_title>Uses:</sec_title>
				<para>Acute, chronic rheumatoid arthritis that has not responded to other disease-modifying agents, polyarticular course of juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, plaque psoriasis, psoriatic arthritis</para>
				<section type="none" id="sidelem4x10757">
					<section type="none" id="sidelem4x10758">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Crohn’s disease; plaque psoriasis (child ≥4 yr)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10763">
				<sec_title>Contraindications:</sec_title>
				<para>Sepsis</para>
				<section type="none" id="sidelem4x10768">
					<section type="none" id="sidelem4x10769">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children &lt;4 yr, geriatric patients, malignancies, CHF, seizures, multiple sclerosis, latex hypersensitivity</para>
						<para>
							<bbw>Infection, lymphoma, neoplastic disease, TB</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10784">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10787">
					<section type="none" id="sidelem4x10788">
						<sec_title>Rheumatoid/psoriatic arthritis, ankylosing spondylitis</sec_title>
						<section type="none" id="sidelem4x10796">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10796">
									<item>
										<label>•</label>
										<para> 50 mg/wk or 25 mg 2×/wk, 3-4 days apart; may be used with methotrexate for psoriatic arthritis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10803">
							<label>•</label>
							<sec_title>Child 2-17 yr<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10803">
									<item>
										<label>•</label>
										<para> 0.8 mg/kg/wk, max 50 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10807">
						<sec_title>Plaque psoriasis</sec_title>
						<section type="none" id="sidelem4x10815">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10815">
									<item>
										<label>•</label>
										<para> 50 mg 2×/wk × 3 mo, then 50 mg q wk maintenance</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10822">
							<label>•</label>
							<sec_title>Adolescent/child 4-17 yr (unlabeled)<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10822">
									<item>
										<label>•</label>
										<para> 0.8 mg/kg/wk, max 50 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10826">
						<sec_title>Juvenile rheumatoid arthritis (JRA)</sec_title>
						<section type="none" id="sidelem4x10834">
							<label>•</label>
							<sec_title>Adolescent/child 2-17 yr<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x10834">
									<item>
										<label>•</label>
										<para> 0.8 mg/kg/wk, max 50 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10838">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 25 mg; inj 50 mg/ml; autoinjector, single use</para>
					</section>
					<section type="none" id="sidelem4x10843">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10847">
								<item>
									<label>•</label>
									<para>May be administered by the patient or a caregiver. Assess the patient’s or caregiver’s ability to inject subcut and observe the first injection</para>
								</item>
								<item>
									<label>•</label>
									<para>Administration of one 50-mg/ml prefilled syringe or autoinjector provides a dose equivalent to two 25-mg prefilled syringes or two 25-mg vials of lyophilized</para>
								</item>
								<item>
									<label>•</label>
									<para>The needle cap on the prefilled syringe and on the SureClick autoinjector contain dry natural rubber (latex) and should not be handled by persons sensitive to this product</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10863">
						<sec_title>Route-Specific Use</sec_title>
						<section type="none" id="sidelem4x10866">
							<sec_title>Injectable Use</sec_title>
							<para>
								<list id="lidelem4x10870">
									<item>
										<label>•</label>
										<para>Inspect for particulate matter and discoloration before use, solution should be clear and colorless, although small white particles may be noted in the autoinjector or prefilled syringe</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10876">
							<sec_title>Subcut Use</sec_title>
							<para>
								<list id="lidelem4x10880">
									<item>
										<label>•</label>
										<para>Injection sites include front of the thigh, abdomen except the 2 in around the navel, or outer area of the upper arm; rotate injection sites; do not administer where skin is tender, bruised, red, or hard; do not inject directly into any raised, thick, red, or scaly skin patches or lesions related to psoriasis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10886">
							<sec_title>Reconstitution and administration of the vial:</sec_title>
							<para>
								<list id="lidelem4x10891">
									<item>
										<label>•</label>
										<para>Do not mix or transfer the contents of one vial into another vial; do not filter reconstituted product during preparation or administration; do not add other medications to solutions containing etanercept; ONLY use the supplied diluent</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10897">
									<item>
										<label>•</label>
										<para>A vial adaptor is supplied for use when reconstituting the powder; however, the adaptor should not be used if multiple doses are going to be withdrawn from the vial; to reconstitute using the vial adaptor, slide the plunger into the flange end of the syringe; attach the plunger to the gray rubber stopper in the syringe by turning the plunger clockwise until a slight resistance is felt; remove the twist-off cap from the prefilled diluent syringe by turning counterclockwise; once the twist-off cap is removed, twist the vial adapter onto the syringe clockwise until a slight resistance is felt; place the vial adapter over the top of the vial, being careful not to bump or touch the plunger, the plastic spike inside the vial adapter should puncture the gray stopper; push the plunger down until all the liquid from the syringe is in the vial and gently swirl to dissolve the powder; after the diluent is added, some foaming may occur; do not shake; generally, dissolution takes less than 10 min; the solution should be clear and colorless. Each reconstituted vial contains 25 mg/ml of etanercept; turn the vial upside down and slowly pull the plunger down to the unit markings on the side of the syringe that correspond with the needed dose; gently tap the syringe to make any air bubbles rise to the top of the syringe, and slowly push the plunger up to remove them; remove the syringe from the vial adapter by turning the syringe counterclockwise and attach the 27-gauge needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10902">
									<item>
										<label>•</label>
										<para>If the vial will be used for multiple doses, use a 25-gauge needle for reconstituting and withdrawing the solution; insert the 25-gauge needle or the vial adapter straight into the center of the gray stopper; a “pop” will be felt; inject the diluent very slowly; after the diluent is added, some foaming may occur; do not shake; swirl contents gently during dissolution; generally, dissolution takes less than 10 minutes; the solution should be clear and colorless; write the mixing date on the supplied sticker and attach to the vial; each reconstituted vial contains 25 mg/ml of etanercept; withdraw the correct dose of the solution into the syringe; remove any air bubbles; remove the 25-gauge needle from the syringe; attach a 27-gauge needle</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10907">
									<item>
										<label>•</label>
										<para>Hold the barrel of the syringe with one hand and pull the needle cover straight off; hold the syringe in one hand like a pencil and use the other hand to gently pinch a fold of skin at the cleaned injection site; insert the needle at a 45-degree angle to the skin; let go of the skin and hold the syringe near its base to stabilize it; push the plunger to inject all of the solution at a slow, steady rate; withdraw the needle at the same angle as insertion; do NOT rub the site</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10912">
									<item>
										<label>•</label>
										<para>Use as soon as possible after reconstitution; place reconstituted vials for multiple doses in the refrigerator at 36°-46° F (2°-8° C) within 4 hr of reconstitution and may be stored up to 14 days; DO NOT FREEZE</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10920">
								<label>•</label>
								<sec_title>Use of the SureClick autoinjector</sec_title>
								<para>
									<list id="lidelem4x10920">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Use of the SureClick autoinjector:</emphasis> allow to reach room temperature, do not shake; immediately before use, remove the needle shield by pulling it straight off</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10924">
									<item>
										<label>•</label>
										<para>Stretch the skin under and around the prefilled autoinjector, place the open end against the injection site at a 90-degree angle; without pushing the purple button on top, push the autoinjector firmly against the skin to unlock; press the purple button on top once and release the button; listen for the first click; wait for the second click or wait 15 seconds, and remove the autoinjector from injection site; do NOT rub the site</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10929">
									<item>
										<label>•</label>
										<para>Look at the inspection window; if it is not purple, call 1-888-436-2735; do not try to reuse the autoinjector</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10934">
							<sec_title>Use of the prefilled syringe:</sec_title>
							<section type="none" id="sidelem4x10942">
								<label>•</label>
								<sec_title>Single-use</sec_title>
								<para>
									<list id="lidelem4x10942">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Single-use:</emphasis> allow to reach room temperature, do not shake; remove the needle shield; check to see if the amount of liquid in the prefilled syringe falls between the two purple fill level indicator lines on the syringe; if bubbles are seen, gently tap the syringe; turn the syringe so that the purple horizontal lines on the barrel are directly facing you; do not use if the syringe does not have the right amount of liquid</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10948">
									<item>
										<label>•</label>
										<para>Hold the barrel of the prefilled syringe with one hand and pull the needle cover straight off; holding the syringe with the needle pointing up, check the syringe for air bubbles; if there are bubbles, gently tap until the air bubbles rise to the top of the syringe; slowly push the plunger up to force the air bubbles out of the syringe</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10953">
									<item>
										<label>•</label>
										<para>Insert the needle at a 45-degree angle to the pinched skin; push the plunger to inject all of the solution at a slow, steady rate; withdraw the needle at the same angle as insertion; do NOT rub the site</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10958">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10961">
					<section type="none" id="sidelem4x10962">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> asthenia, dizziness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10972">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10979">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, dyspepsia, vomiting, <emphasis style="bold">hepatitis,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x10987">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Pancytopenia, anemia, thrombocytopenia, leukopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10994">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="italic">inj-site reaction,</emphasis> keratoderma blenorrhagicum</para>
					</section>
					<section type="none" id="sidelem4x11002">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Pharyngitis, cough, URI, non-URI,</emphasis> sinusitis, <emphasis style="italic">rhinitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11012">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serious infections, sepsis, death, malignancies, Stevens-Johnson syndrome, reactivation of hepatitis B virus, lupus-like syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11019">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Elimination half-life 102 hr, 60% absorbed (SUBCUT)</para>
			</section>
			<section type="interactions" id="sidelem4x11024">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x11032">
					<label>•</label>
					<sec_title>Increase</sec_title>
					<para>
						<list id="lidelem4x11032">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Increase:</emphasis> neutropenia—sulfaSALAzine</para>
							</item>
						</list>
					</para>
				</section>
				<para>
					<list id="lidelem4x11036">
						<item>
							<label>•</label>
							<para>Do not give concurrently with live virus vaccines; immunizations should be brought up to date before treatment</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x11041">
						<item>
							<label>•</label>
							<para>Avoid use with anakinra, cyclophosphamide, rilonacept</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x11046">
					<section type="none" id="sidelem4x11047">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11054">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11057">
					<section type="none" id="sidelem4x11058">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11066">
							<label>•</label>
							<sec_title>RA</sec_title>
							<para>
								<list id="lidelem4x11066">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">RA:</emphasis> pain, stiffness, ROM, swelling of joints before, during, after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11073">
							<para>
								<list id="lidelem4x11073">
									<item>
										<label>•</label>
										<para>For inj-site pain, swelling; usually occurs after 2 inj (4-5 days)
<bbw>
												<emphasis alert="lifethreat">Infection:</emphasis> patients using immunosuppressives, corticosteroids, methotrexate at greater risk; assess for fever, discontinue in those who develop a serious infection, do not use in active infection</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11089">
							<label>•</label>
							<sec_title>Hypersensitivity<route> to this product, latex needle cap, benzyl alcohol; usual reactions to product last 3-5 days</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11092">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11096">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11102">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11106">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving; dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to receive live vaccinations during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>About self-administration if appropriate: inj should be made in thigh, abdomen, upper arm; rotate sites at least 1 in from previous site, check for inj reactions that last 3-5 days</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of possible infection (upper respiratory, other)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="54" status="active">
			<mono_name>ethambutol (Rx)</mono_name>
			<info>
				<pronunciation>(e-tham′byoo-tole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x111371">
						<country code="CAN">Etibi </country>
					</tradename>
					<tradename id="tnidelem4x111370">Myambutol</tradename>
				</tradenames>
				<class type="func"> Antitubercular</class>
				<class type="chem"> Diisopropylethylene diamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11150">
				<para>
					<confusion>
						<tradename id="tnidelem4x111500">ethambutol</tradename>
						<drug type="generic" refid="idelem4x111500">Ethmozine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11154">
				<sec_title>Action:</sec_title>
				<para>Inhibits RNA synthesis, decreases tubercle bacilli replication</para>
			</section>
			<section type="uses" id="sidelem4x11159">
				<sec_title>Uses:</sec_title>
				<para>Pulmonary TB as an adjunct, other mycobacterial infections</para>
			</section>
			<section type="contra" id="sidelem4x11164">
				<sec_title>Contraindications:</sec_title>
				<para>Children &lt;13 yr, hypersensitivity, optic neuritis</para>
				<section type="none" id="sidelem4x11171">
					<section type="none" id="sidelem4x11172">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal disease, diabetic retinopathy, cataracts, ocular defects, hepatic and hematopoietic disorders</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11177">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11185">
					<label>•</label>
					<sec_title>Adult/child &gt;13 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11185">
							<item>
								<label>•</label>
								<para> 15-25 mg/kg/day as single dose (treatment naive) or 25 mg/kg daily (treatment experienced)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11189">
					<section type="none" id="sidelem4x11190">
						<sec_title>
							<emphasis style="bold">Renal disease</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x11199">
							<label>•</label>
							<sec_title>
								<route>CCr 10-50 ml/min, dose q24-36hr; CCr &lt;10 ml/min, dose q48hr</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11202">
						<sec_title>Retreatment</sec_title>
						<section type="none" id="sidelem4x11210">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11210">
									<item>
										<label>•</label>
										<para> 25 mg/kg/day as single dose × 2 mo with at least 1 other product, then decrease to 15 mg/kg/day as single dose, max 2.5 g/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11217">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11217">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11221">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x11226">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11230">
								<item>
									<label>•</label>
									<para>With meals to decrease GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Antiemetic if vomiting occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>After C&amp;S completed; monthly to detect resistance</para>
								</item>
								<item>
									<label>•</label>
									<para>4 hr between this product and antacids</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11251">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11254">
					<section type="none" id="sidelem4x11255">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, confusion,</emphasis> fever, malaise, dizziness, <emphasis style="italic">disorientation,</emphasis> hallucinations, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x11266">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, optic neuritis, photophobia, decreased visual acuity</para>
					</section>
					<section type="none" id="sidelem4x11271">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal distress, anorexia, nausea, vomiting</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11278">
						<sec_title>INTEG:</sec_title>
						<para> Dermatitis, pruritus, <emphasis style="bold">toxic epidermal necrolysis,</emphasis> erythema multiforme</para>
					</section>
					<section type="none" id="sidelem4x11286">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Elevated uric acid, acute gout,</emphasis> impaired hepatic function</para>
					</section>
					<section type="none" id="sidelem4x11294">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia,</emphasis> joint pain, <emphasis style="bold">anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11304">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-4 hr, half-life 3 hr, metabolized in liver, excreted in urine (unchanged product/inactive metabolites, unchanged product in feces)</para>
			</section>
			<section type="interactions" id="sidelem4x11309">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x11314">
						<item>
							<label>•</label>
							<para>Delayed absorption of ethambutol: aluminum salts, separate by 4 hr</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x11322">
					<label>•</label>
					<sec_title>Neurotoxicity<route> other neurotoxics</route></sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11325">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11328">
					<section type="none" id="sidelem4x11329">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11334">
								<item>
									<label>•</label>
									<para>Hepatic studies weekly × 2 wk, then q2mo: ALT, AST, bilirubin; decreased appetite, jaundice, dark urine, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11339">
								<item>
									<label>•</label>
									<para>Signs of anemia: Hct, Hgb, fatigue</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11344">
								<item>
									<label>•</label>
									<para>Mental status often: affect, mood, behavioral changes; psychosis may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11349">
								<item>
									<label>•</label>
									<para>C&amp;S, including sputum, before treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11354">
								<item>
									<label>•</label>
									<para>Visual status: decreased activity, altered color perception</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11362">
							<label>•</label>
							<sec_title>Serious skin reactions<route> toxic epidermal necrolysis</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11365">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11369">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of TB, decrease in acid-fast bacteria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11375">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11380">
								<item>
									<label>•</label>
									<para>To avoid alcohol products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11385">
								<item>
									<label>•</label>
									<para>That compliance with dosage schedule, duration is necessary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11390">
								<item>
									<label>•</label>
									<para>That scheduled appointments must be kept or relapse may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11398">
							<label>•</label>
							<sec_title>
								<route>To report to prescriber any visual changes; rash; hot, swollen, painful joints; numbness, tingling of extremities</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="55" status="active">
			<mono_name>etodolac</mono_name>
			<info>
				<pronunciation>(ee-toe′doe-lak)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x114060">
						<country code="CAN">Ultradol</country>
					</tradename>
				</tradenames>
				<class type="func"> Nonsteroidal antiinflammatory/nonopioid analgesic</class>
			</info>
			<section type="actions" id="sidelem4x11414">
				<sec_title>Action:</sec_title>
				<para>Inhibits COX1,2; analgesic, antiinflammatory</para>
			</section>
			<section type="uses" id="sidelem4x11419">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate pain, osteoarthritis, rheumatoid arthritis, arthralgia, myalgia, juvenile rheumatoid arthritis</para>
			</section>
			<section type="contra" id="sidelem4x11424">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity; patients in whom aspirin, iodides, or NSAIDs have produced asthma; urticaria</para>
				<para>
					<bbw>Coronary artery bypass graft surgery (CABG)</bbw>
				</para>
				<section type="none" id="sidelem4x11440">
					<section type="none" id="sidelem4x11441">
						<sec_title>Precautions:</sec_title>
						<para> Edema, renal/hepatic disease, children, GI ulcers, geriatric patients, bronchospasm, nasal polyps, alcoholism, bone marrow suppression, MI, hemophilia, neutropenia, ulcerative colitis</para>
						<para>
							<bbw>GI bleeding, perforation, MI, stroke</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11456">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11459">
					<section type="none" id="sidelem4x11460">
						<sec_title>Osteoarthritis</sec_title>
						<section type="none" id="sidelem4x11468">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11468">
									<item>
										<label>•</label>
										<para> 300 mg bid-tid, or 400-500 mg bid initially, then adjust dosage to 600-1200 mg/day in divided doses; max 1200 mg/day; ext rel 400-1000 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11472">
						<sec_title>Analgesia</sec_title>
						<section type="none" id="sidelem4x11480">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11480">
									<item>
										<label>•</label>
										<para> 200-400 mg every 6-8 hr up to 1000 mg daily; max 1200 mg/day; patients &lt;60 kg, max 20 mg/kg; ext rel 400-1000 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11484">
						<sec_title>Available forms:</sec_title>
						<para> Caps 200, 300 mg; tabs 400, 500 mg; ext rel 400, 500, 600 mg</para>
					</section>
					<section type="none" id="sidelem4x11489">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11493">
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11504">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11507">
					<section type="none" id="sidelem4x11508">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, drowsiness, fatigue, tremors, confusion, insomnia, anxiety, depression, light-headedness, vertigo</para>
					</section>
					<section type="none" id="sidelem4x11513">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, peripheral edema, fluid retention, palpitations, <emphasis style="bold">dysrhythmias, CHF</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11520">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, hearing loss, blurred vision, photophobia</para>
					</section>
					<section type="none" id="sidelem4x11525">
						<sec_title>GI:</sec_title>
						<para> Nausea, anorexia, vomiting, diarrhea, jaundice, <emphasis style="bold">cholestatic hepatitis,</emphasis> constipation, flatulence, cramps, dry mouth, peptic ulcer, dyspepsia, GI bleeding</para>
					</section>
					<section type="none" id="sidelem4x11533">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity: dysuria, hematuria, oliguria, azotemia, cystitis, urinary tract infection</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11540">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Blood dyscrasias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11547">
						<sec_title>INTEG:</sec_title>
						<para> Erythema, urticaria, purpura, rash, pruritus, sweating, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11554">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11561">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr, serum protein binding &gt;99%, half-life 7 hr; metabolized by liver (metabolites excreted in urine)</para>
			</section>
			<section type="interactions" id="sidelem4x11572">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—cycloSPORINE, digoxin, lithium, methotrexate, phenytoin, cidofovir, aminoglycosides</para>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> GI toxicity—aspirin, NSAIDs</bbw>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—etodolac: antacids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—beta blockers, diuretics</para>
				<section type="none" id="sidelem4x11600">
					<section type="none" id="sidelem4x11601">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11612">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11615">
					<section type="none" id="sidelem4x11616">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11624">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x11624">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, frequency, characteristics; relief after medication</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11628">
								<item>
									<label>•</label>
									<para>Blood, renal, liver tests: BUN, creatinine, AST, ALT, Hgb, platelets before treatment, periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11633">
								<item>
									<label>•</label>
									<para>For GI bleeding: black stools, hematemesis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11638">
								<item>
									<label>•</label>
									<para>Audiometric, ophthalmic examination before, during, after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11643">
								<item>
									<label>•</label>
									<para>For eye, ear problems: blurred vision, tinnitus; can indicate toxicity</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11651">
							<label>•</label>
							<sec_title>
								<route>For asthma, aspirin hypersensitivity, nasal polyps that may be hypersensitive to etodolac</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11654">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11658">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased pain, stiffness, swelling in joints, ability to move more easily</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11664">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11669">
								<item>
									<label>•</label>
									<para>To report blurred vision or ringing, roaring in the ears; might indicate toxicity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11674">
								<item>
									<label>•</label>
									<para>Not to break, crush, or chew ext rel tabs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11683">
							<label>•</label>
							<sec_title>
								<route>To report change in urine pattern, weight increase, edema, pain increase in joints, fever, blood in urine; indicates nephrotoxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11686">
								<item>
									<label>•</label>
									<para>That therapeutic effects can take up to 1 mo
<bbw>To avoid aspirin, NSAIDs, acetaminophen, alcoholic beverages while taking this medication</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="56" status="active" ha="yes">
			<mono_name>etoposide (Rx)</mono_name>
			<info>
				<pronunciation>(e-toe-poe′side)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117071">Toposar</tradename>
					<tradename id="tnidelem4x117070">
						<country code="CAN">VePesid</country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="57" status="active">
			<mono_name>etoposide phosphate (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x117140">Etopophos</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Semisynthetic podophyllotoxin</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x11724">
				<sec_title>Action:</sec_title>
				<para>Inhibits cells from entering mitosis, depresses DNA/RNA synthesis, cell-cycle–specific S and G<emphasis style="inf">2</emphasis>; binds to a complex of DNA and topoisomerase II leading to DNA strand breaks</para>
			</section>
			<section type="uses" id="sidelem4x11732">
				<sec_title>Uses:</sec_title>
				<para>Testicular cancer, small-cell lung cancer</para>
				<section type="none" id="sidelem4x11737">
					<section type="none" id="sidelem4x11738">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Leukemias (ALL, AML), desmoid tumor, gastric/ovarian cancer, bone marrow ablation, Hodgkin’s/non-Hodgkin’s lymphoma, malignant glioma, neuroblastoma, stem cell transplant preparation, trophoblastic disease</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11743">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x11748">
					<section type="none" id="sidelem4x11749">
						<sec_title>Precautions:</sec_title>
						<para> Children, renal/hepatic disease, gout, neutropenia, thrombocytopenia</para>
						<para>
							<bbw>Bone marrow depression, infection, bleeding, requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11764">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11767">
					<section type="none" id="sidelem4x11768">
						<sec_title>Testicular cancer</sec_title>
						<section type="none" id="sidelem4x11776">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11776">
									<item>
										<label>•</label>
										<para> 100 mg/m<emphasis style="sup">2</emphasis>/day on days 1, 2 in combination with bleomycin and Cisplatin (BEP) or 100 mg/m<emphasis style="sup">2</emphasis>/day on days 1, 3, 5 or 100 mg/m<emphasis style="sup">2</emphasis>/day on days 1, 3, 5, repeat q3-4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11789">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x11798">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 45-60 ml/min, reduce dose by 15%; CCr 30-44 ml/min, reduce dose by 20%; CCr &lt;30 ml/min, reduce dose by 25%</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11801">
						<sec_title>
							<emphasis style="bold">Hepatic dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x11810">
							<label>•</label>
							<sec_title>Adult<route> IV/PO total bilirubin 1.5-3 mg/dl</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11813">
						<sec_title>Available forms:</sec_title>
						<para> Inj 20 mg/ml; 100 mg powder for injection, caps 50 mg</para>
					</section>
					<section type="none" id="sidelem4x11818">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11823">
								<item>
									<label>•</label>
									<para>Antiemetic 30-60 min before product and prn to prevent vomiting</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11831">
							<label>•</label>
							<sec_title>Urate nephropathy</sec_title>
							<para>
								<list id="lidelem4x11831">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Urate nephropathy:</emphasis> Allopurinol, aggressive alkalinization to maintain uric acid levels</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11835">
								<item>
									<label>•</label>
									<para>Antispasmodic, EPINEPHrine, corticosteroids, antihistamines for reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11840">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11844">
									<item>
										<label>•</label>
										<para>Give without regard to food</para>
									</item>
									<item>
										<label>•</label>
										<para>Increase fluid intake to 2-3 L/day to prevent urate deposits, calculi formation</para>
									</item>
									<item>
										<label>•</label>
										<para>Refrigerate oral product; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11860">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x11868">
								<label>•</label>
								<sec_title>
									<route>Do not use acrylic or ABS plastic devices; may crack, leak</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x11871">
							<sec_title>Intermittent IV INFUSION route (etoposide)</sec_title>
							<para>
								<list id="lidelem4x11876">
									<item>
										<label>•</label>
										<para>Use cytotoxic handling procedures, use Luer-Lok fittings to prevent leakage</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x11884">
								<label>•</label>
								<sec_title>
									<route>diluting</route>
								</sec_title>
								<para>
									<list id="lidelem4x11884">
										<item>
											<label>•</label>
											<para>After  5-ml vial with 100 mg/250 ml or more D<emphasis style="inf">5</emphasis>W or NaCl to 0.2-0.4 mg/ml,  over 30-60 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B colloidal, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, famotidine, fenoldopam, fentaNYL, floxuridine, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lansoprazole, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, methohexital, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, nitroglycerin, nitroprusside, norepinephrine, NS, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sargramostim, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
						<section type="none" id="sidelem4x11901">
							<sec_title>Intermittent IV INFUSION route (etoposide phosphate)</sec_title>
							<section type="none" id="sidelem4x11909">
								<label>•</label>
								<sec_title>
									<route>Reconstitute</route>
								</sec_title>
								<para>
									<list id="lidelem4x11909">
										<item>
											<label>•</label>
											<para> each vial with 5 or 10 ml of D<emphasis style="inf">5</emphasis>W, 0.9% NaCl for a concentrations of 20 mg/ml or 10 mg/ml, respectively; may give diluted or undiluted to concentrations of as little as 0.1 mg/ml,  over 5-210 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, ampicillin, ampicillin-sulbactam, anidulafungin, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doripenem, doxacurium, DOXOrubicin, HCL/liposome, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, famotidine, fenoldopam, fentaNYL, floxuridine, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ofloxacin, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, piperacillin-tazobactam, plicamycin, polymyxin B, potassium chloride/phosphates, procainamide, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, riTUXimab, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trastuzumab, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11925">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11928">
					<section type="none" id="sidelem4x11929">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="italic">fever,</emphasis> peripheral neuropathy, paresthesias, confusion, chills, fever</para>
					</section>
					<section type="none" id="sidelem4x11937">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">MI, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11946">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> dyspepsia, diarrhea, constipation</para>
					</section>
					<section type="none" id="sidelem4x11956">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephrotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11963">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11970">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, alopecia,</emphasis> phlebitis at IV site, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11980">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11987">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11994">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-2 hr (initial), terminal 5<emphasis style="sup">1</emphasis>⁄<emphasis style="inf">4</emphasis> hr, metabolized in liver, excreted in urine, feces, crosses placental barrier, protein binding 95%</para>
			</section>
			<section type="interactions" id="sidelem4x12011">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: bone marrow depression—other antineoplastics, radiation, immunosuppressives</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> adverse reactions—live virus vaccines, toxoids</para>
				<para>
					<emphasis alert="lifethreat">Increase: effect of etoposide, toxicity—voriconazole, conivaptan, cycloSPORINE, imatinib, nilotinib, etravirine, telithromycin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk of bleeding—anticoagulants, NSAIDs, platelet inhibitors, thrombolytics, salicylate</para>
				<para>
					<emphasis alert="lifethreat">Decrease: etoposide effect—sargramostim, filgrastim, separate by ≥24 hr</emphasis>
				</para>
				<section type="none" id="sidelem4x12031">
					<section type="none" id="sidelem4x12032">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x12036">
								<item>
									<label>•</label>
									<para>Decreased oral etoposide—grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12042">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, RBC, WBC, neutrophils, Hgb, calcium, phosphate</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12053">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12056">
					<section type="none" id="sidelem4x12057">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow depression:</emphasis> CBC, differential, platelet count weekly; withhold product if WBC is &lt;500 or platelet count is &lt;50,000; notify prescriber, treatment should be delayed</bbw>
						</para>
						<section type="none" id="sidelem4x12076">
							<label>•</label>
							<sec_title>Nephrotoxicity<route> BUN; serum uric acid; urine CCr; electrolytes before, during therapy; I&amp;O ratio; report fall in urine output to &lt;30 ml/hr; check B/P bid, report any significant decrease</route></sec_title>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Infection:</emphasis> Monitor temperature; fever may indicate beginning infection, treat active infection before treatment</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed or monthly</bbw>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bleeding:</emphasis> hematuria, guaiac stools, bruising or petechiae, mucosa or orifices q8hr</bbw>
						</para>
						<para>
							<list id="lidelem4x12117">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12125">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> Jaundice of skin and sclera, dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12128">
								<item>
									<label>•</label>
									<para>B/P q15min during infusion; if systolic reading &lt;90 mm Hg, discontinue infusion, notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12133">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12141">
							<label>•</label>
							<sec_title>Injection-site reaction<route> monitor site closely for infiltration</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12144">
								<item>
									<label>•</label>
									<para>Local irritation, pain, burning, discoloration at inj site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12150">
								<item>
									<para>
										<emphasis alert="nurse">Symptoms indicating severe allergic reaction: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing, restlessness, coughing, difficulty breathing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12158">
							<label>•</label>
							<sec_title>Frequency of stools, characteristics</sec_title>
							<para>
								<list id="lidelem4x12158">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Frequency of stools, characteristics:</emphasis> cramping, acidosis; <emphasis style="bold">signs of dehydration:</emphasis> rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12168">
							<label>•</label>
							<sec_title>Geriatric patients<route> increased alopecia, GI effects, infection, nephrotoxicity, myelosuppression</route></sec_title>
						</section>
						<para>
							<bbw>An experienced clinician knowledgeable in the use of cytotoxic products</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x12181">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12185">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12191">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12196">
								<item>
									<label>•</label>
									<para>To report any changes in breathing or coughing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12201">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12209">
							<para>
								<list id="lidelem4x12209">
									<item>
										<label>•</label>
										<para>That metallic taste may occur
<bbw>
												<emphasis alert="lifethreat">Infection:</emphasis> To report symptoms of infection (fever, sore throat); to avoid crowds, persons with known infections</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12222">
								<item>
									<label>•</label>
									<para>To avoid immunizations</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12230">
							<label>•</label>
							<sec_title>Pregnancy<route> To notify prescriber if pregnancy is planned or suspected pregnancy (D); to use reliable contraception during and for several mo after therapy; to avoid breastfeeding</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12233">
								<item>
									<label>•</label>
									<para>To take as prescribed (PO), not to double dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12238">
								<item>
									<label>•</label>
									<para>To report signs of infection (flu-like symptoms, fever, fatigue, sore throat)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12243">
								<item>
									<label>•</label>
									<para>To take B/P, hypotension occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="58" status="active">
			<mono_name>etravirine (Rx)</mono_name>
			<info>
				<pronunciation>(e-tra′veer-een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x122530">Intelence</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nonnucleoside reverse transcriptase inhibitor (NNRTI)</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x12263">
				<sec_title>Action:</sec_title>
				<para>Binds directly to reverse transcriptase, thus blocking the RNA- and DNA-dependent DNA polymerase action and causing a disruption of the enzyme’s catalytic site</para>
			</section>
			<section type="uses" id="sidelem4x12268">
				<sec_title>Uses:</sec_title>
				<para>In combination with other antiretroviral agents for HIV infection in treatment-experienced patients with evidence of HIV replication despite ongoing antiretroviral therapy</para>
			</section>
			<section type="contra" id="sidelem4x12273">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<section type="none" id="sidelem4x12278">
					<section type="none" id="sidelem4x12279">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), children, geriatric patients, impaired hepatic function, antimicrobial resistance, hepatitis, hypercholesterolemia, hypertriglycerides, immune reconstitution syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12284">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12292">
					<label>•</label>
					<sec_title>Adult/Child/Adolescent ≥6 yr, ≥30 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12292">
							<item>
								<label>•</label>
								<para> 200 mg bid; Child/Adolescent ≥6 yr, 25 to 29 kg: 150 mg bid; Child/Adolescent ≥6 yr, 20 to 24 kg: 125 mg bid; Child/Adolescent ≥6 yr, 16 to 19 kg:100 mg bid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12296">
					<section type="none" id="sidelem4x12297">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 100, 200 mg</para>
					</section>
					<section type="none" id="sidelem4x12302">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12306">
								<item>
									<label>•</label>
									<para>In combination with other antiretrovirals with food or after a meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Tabs may be dispersed in ≥5 ml of water; once dispersed, stir well, give immediately, rinse glass, have patient drink to ensure all medication taken</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment; protect from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12323">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12326">
					<section type="none" id="sidelem4x12327">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia,</emphasis> amnesia, anxiety, confusion, fatigue, nightmares, peripheral neuropathy, <emphasis style="bold">seizures, stroke,</emphasis> tremor</para>
					</section>
					<section type="none" id="sidelem4x12338">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Atrial fibrillation,</emphasis> hypertension, MI</para>
					</section>
					<section type="none" id="sidelem4x12346">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x12351">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, anorexia,</emphasis> abdominal pain, increased AST/ALT, constipation, flatulence, gastritis, GERD, <emphasis style="bold">hematemesis, hepatitis,</emphasis> hepatomegaly, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12364">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12371">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, neutropenia, thrombocytopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12378">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> erythema multiforme, <emphasis style="bold">angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12388">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12395">
						<sec_title>OTHER:</sec_title>
						<para> Diabetes mellitus, gynecomastia, hyperamylasemia, hypercholesterolemia, hyperglycemia, hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x12400">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">bronchospasm</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12407">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">DRESS</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12414">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99.9% plasma protein binding; metabolized by CYP3A4, 2C9, 2C19; half-life 21-61 hr; excreted in feces</para>
			</section>
			<section type="interactions" id="sidelem4x12419">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x12427">
					<label>•</label>
					<sec_title>
						<route>Do not use concurrently with atazanavir, carBAMazepine, delavirdine, fosamprenavir, fosphenytoin, phenytoin, PHENobarbital, rifapentine, rifampin, tipranavir, rilpivirine</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x12430">
						<item>
							<label>•</label>
							<para>Altered effect of cycloSPORINE, tacrolimus, sirolimus</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis—HMG-CoA reductase inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> etravirine levels—CYP3A4 inhibitors (fluconazole, itraconazole, ketoconazole, lopinavir, posaconazole, ritonavir, voriconazole)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> withdrawal symptoms—methadone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of diazepam, rifampin, voriconazole, warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of CYP3A4 inducers (amiodarone, atazanavir, clarithromycin, flecainide, fosamprenavir, lidocaine, mexiletine, propafenone, quiNIDine, sildenafil, tadalafil, vardenafil)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> etravirine levels—darunavir, dexamethasone, disopyramide, efavirenz, nevirapine, ritonavir, saquinavir, tipranavir</para>
				<section type="none" id="sidelem4x12458">
					<section type="none" id="sidelem4x12459">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> etravirine—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12466">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12469">
					<section type="none" id="sidelem4x12470">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12478">
							<label>•</label>
							<sec_title>
								<route>Symptoms of HIV, possible infections; increased temperature</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12482">
								<item>
									<para>
										<emphasis alert="nurse">Fatal hypersensitivity reactions: fever, rash, nausea, vomiting, fatigue, cough, dyspnea, diarrhea, abdominal discomfort; treatment should be discontinued and not restarted; incidence of rash may be worse in women</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12490">
							<label>•</label>
							<sec_title>Blood dyscrasias (anemia, granulocytopenia)<route> bruising, fatigue, bleeding, poor healing</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12496">
							<label>•</label>
							<sec_title>Renal failure<route> BUN, serum uric acid, CCr before, during therapy; may be elevated throughout treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12502">
							<label>•</label>
							<sec_title>Hepatitis/pancreatitis<route> hepatic studies before and during therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12505">
								<item>
									<label>•</label>
									<para>HIV: monitor viral load, CD4 counts, plasma HIV RNA during treatment; watch for decreasing granulocytes, Hgb; if low, therapy may have to be discontinued and restarted after hematologic recovery; blood transfusions may be required; cholesterol/lipid profile</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12510">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12514">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CD4 count, decreased viral load</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12520">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12525">
								<item>
									<label>•</label>
									<para>That product is not a cure but will control symptoms; that patient is still infective, may pass AIDS virus to others</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12534">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of sore throat, swollen lymph nodes, malaise, fever; other infections may occur; to stop product and notify prescriber immediately if skin rash, fever, cough, SOB, GI symptoms occur; to advise all health care providers that allergic reaction has occurred with etravirine</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12537">
								<item>
									<label>•</label>
									<para>That follow-up visits must be continued, since serious toxicity may occur; blood counts must be performed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12545">
							<label>•</label>
							<sec_title>
								<route>To use contraception during treatment; that patient still able to transmit disease</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12548">
								<item>
									<label>•</label>
									<para>About information on medication guide and warning card; discuss points on guide</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12553">
								<item>
									<label>•</label>
									<para>That other products may be necessary to prevent other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12558">
								<item>
									<label>•</label>
									<para>To take medication after a meal</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="59" status="active" ha="yes">
			<mono_name>everolimus (Rx)</mono_name>
			<info>
				<pronunciation>(e-ve-ro′li-mus)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x125702">Afinitor</tradename>
					<tradename id="tnidelem4x125701">Afinitor Disperz</tradename>
					<tradename id="tnidelem4x125700">Zortress</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Immunosuppressant, macrolide</class>
			</info>
			<section type="confusion" id="sidelem4x12580">
				<para>
					<confusion>
						<tradename id="tnidelem4x125800">everolimus</tradename>
						<drug type="generic" refid="idelem4x125800">sirolimus/tacrolimus/temsirolimus</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12584">
				<sec_title>Action:</sec_title>
				<para>Proliferation signal inhibitor that inhibits mammalian target of rapamycin (mTOR); this pathway is dysregulated in cancer</para>
			</section>
			<section type="uses" id="sidelem4x12589">
				<sec_title>Uses:</sec_title>
				<para>Renal cell cancer in those with failed treatment with SORAfenib or SUNItinib kidney transplant rejection prophylaxis with cycloSPORINE, subependymal giant cell astrocytoma, progressive pancreatic neuroendocrine tumor (PNET) with unresectable locally advanced/metastatic disease, breast cancer hormone receptor positive/HER-2 negative, renal angiomyolipoma, tuberous sclerosis complex, liver transplant rejection prophylaxis</para>
			</section>
			<section type="contra" id="sidelem4x12594">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding; hypersensitivity to this product, Rapamune, Torisel, pregnancy (D)</para>
				<section type="none" id="sidelem4x12599">
					<section type="none" id="sidelem4x12600">
						<sec_title>Precautions:</sec_title>
						<para> Children, renal/hepatic disease; diabetes mellitus, hyperlipidemia, pleural effusion</para>
						<para>
							<bbw>lmmunosuppression, infection, renal artery thrombosis, renal impairment, renal vein thrombosis, neoplastic disease, heart transplant</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12615">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12618">
					<section type="none" id="sidelem4x12619">
						<sec_title>Kidney transplant rejection prophylaxis (Zortress)</sec_title>
						<section type="none" id="sidelem4x12627">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12627">
									<item>
										<label>•</label>
										<para> 0.75 mg q12hr with cycloSPORINE in combination with basiliximab, corticosteroids, reduced doses of cycloSPORINE</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12631">
						<sec_title>Liver transplant rejection prophylaxis</sec_title>
						<section type="none" id="sidelem4x12637">
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12637">
									<item>
										<para> 1 mg bid starting at least 30 days after transplant in combination with reduced-dose tacrolimus and corticosteroids</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12641">
						<sec_title>Advanced renal cancer (Afinitor)</sec_title>
						<section type="none" id="sidelem4x12649">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12649">
									<item>
										<label>•</label>
										<para> 10 mg daily as long as clinically beneficial; with strong 3A4 inducers 10 mg daily, then may increase by 5 mg increments to 20 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12653">
						<sec_title>Progressive neuroendocrine tumor (PNET) (Afinitor only)</sec_title>
						<section type="none" id="sidelem4x12661">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12661">
									<item>
										<label>•</label>
										<para> 10 mg daily, reduce dose to 5 mg daily if intolerable adverse reactions occur</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12665">
						<sec_title>Subependymal giant-cell astrocytoma (SEGA) (Afinitor only)</sec_title>
						<section type="none" id="sidelem4x12673">
							<label>•</label>
							<sec_title>Adult/adolescent/child</sec_title>
							<para>
								<list id="lidelem4x12673">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child:</emphasis> 4.5 mg/m<emphasis style="sup">2</emphasis> daily, then titrate to a target trough of 5-15 ng/ml</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12680">
						<sec_title>
							<emphasis style="bold">Hepatic dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x12689">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh A)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12692">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.25, 0.5, 0.75 (Zortess); 2.5, 5, 7.5, 10 mg (Afinitor)</para>
					</section>
					<section type="none" id="sidelem4x12697">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12702">
								<item>
									<label>•</label>
									<para>Follow procedure for proper handling of antineoplastics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12707">
								<item>
									<label>•</label>
									<para>Swallow tabs whole with a full glass of water; do not chew, crush, or break</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12715">
							<label>•</label>
							<sec_title>Afinitor</sec_title>
							<para>
								<list id="lidelem4x12715">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Afinitor:</emphasis> take at same time of day; if unable to swallow, consistently with or without food, disperse in 30 ml of water</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12723">
							<label>•</label>
							<sec_title>Zortress</sec_title>
							<para>
								<list id="lidelem4x12723">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Zortress:</emphasis> must take consistently with/without food, give at same time of day q12hr with cycloSPORINE</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12727">
								<item>
									<label>•</label>
									<para>Store protected from light at room temperature</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12732">
						<sec_title>
							<emphasis style="bold">Afinitor adjustments for toxicity</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x12736">
							<sec_title>
								<emphasis style="bold">Noninfectious pneumonitis</emphasis>
							</sec_title>
							<section type="none" id="sidelem4x12745">
								<label>•</label>
								<sec_title>Grade 1, asymptomatic with radiographic findings only<route> no dosage change</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12751">
								<label>•</label>
								<sec_title>Grade 2, symptomatic but no interference with activities of daily living (ADL)<route> consider withholding therapy, resume Afinitor at a lower dosage when symptoms improve to ≤ grade 1; discontinue Afinitor if symptoms do not improve within 4 wk</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12757">
								<label>•</label>
								<sec_title>Grade 3, symptomatic and interfering with ADL and oxygen therapy indicated<route> hold therapy; consider resuming Afinitor at a lower dosage when symptoms improve to ≤ grade 1; consider discontinuing Afinitor if grade 3 toxicity recurs</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12763">
								<label>•</label>
								<sec_title>Grade 4, life-threatening and ventilator support indicated<route> discontinue therapy</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x12766">
							<sec_title>
								<emphasis style="bold">Stomatitis</emphasis>
							</sec_title>
							<section type="none" id="sidelem4x12775">
								<label>•</label>
								<sec_title>Grade 1, minimum symptoms and normal diet<route> no dosage adjustment required</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12781">
								<label>•</label>
								<sec_title>Grade 2, symptomatic but can eat and swallow modified diet<route> hold therapy until symptoms improve to ≤ grade 1 and resume Afinitor at the same dosage; if grade 2 toxicity recurs, hold therapy and resume Afinitor at a lower dosage when symptoms improve to ≤ grade 1</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12787">
								<label>•</label>
								<sec_title>Grade 3, symptomatic and unable to adequately eat or hydrate orally<route> hold therapy; resume Afinitor at a lower dosage when symptoms improve to ≤ grade 1</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12793">
								<label>•</label>
								<sec_title>Grade 4, symptomatic and life-threatening<route> discontinue therapy</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x12796">
							<sec_title>
								<emphasis style="bold">Other nonhematologic toxicity (excluding metabolic events)</emphasis>
							</sec_title>
							<section type="none" id="sidelem4x12805">
								<label>•</label>
								<sec_title>Grade 1<route> No dosage adjustment required if toxicity is tolerable</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12811">
								<label>•</label>
								<sec_title>Grade 2<route> No dosage adjustment required if toxicity is tolerable; if toxicity is intolerable, hold therapy until symptoms improve to ≤ grade 1 and resume Afinitor at the same dosage; if grade 2 toxicity recurs, hold therapy and resume Afinitor at a lower dosage when symptoms improve to ≤ grade 1</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12817">
								<label>•</label>
								<sec_title>Grade 3<route> Hold therapy; consider resuming Afinitor at a lower dosage when symptoms improve to ≤ grade 1; if grade 3 toxicity recurs, consider discontinuing therapy</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12823">
								<label>•</label>
								<sec_title>Grade 4<route> Discontinue Afinitor therapy</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x12826">
							<sec_title>
								<emphasis style="bold">Metabolic events (hyperglycemia, dyslipidemia)</emphasis>
							</sec_title>
							<section type="none" id="sidelem4x12835">
								<label>•</label>
								<sec_title>Grade 1 or 2<route> No dose adjustment required</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12841">
								<label>•</label>
								<sec_title>Grade 3<route> Temporarily withhold therapy; resume Afinitor at a lower dosage</route></sec_title>
							</section>
							<section type="none" id="sidelem4x12847">
								<label>•</label>
								<sec_title>Grade 4<route> Discontinue Afinitor therapy</route></sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12850">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12853">
					<section type="none" id="sidelem4x12854">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia, paresthesia,</emphasis> chills, fever, seizure, personality changes, insomnia, dizziness</para>
					</section>
					<section type="none" id="sidelem4x12862">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension, CHF, peripheral edema</emphasis>, chest pain</para>
					</section>
					<section type="none" id="sidelem4x12870">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, photophobia, eyelid edema, epistaxis, sinusitis, cataracts, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x12875">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, constipation, stomatitis, anorexia, abdominal pain, dysgeusia, noninfectious hepatitis</para>
					</section>
					<section type="none" id="sidelem4x12880">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure,</emphasis> UTI, <emphasis style="bold">renal tubular necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12890">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, leukopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12897">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, acne</emphasis>, leukocytoclastic vasculitis</para>
					</section>
					<section type="none" id="sidelem4x12905">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, increased creatinine, <emphasis style="italic">hyperlipemia,</emphasis> hypophosphatemia, weight loss</para>
					</section>
					<section type="none" id="sidelem4x12913">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pleural effusion,</emphasis><emphasis style="italic">dyspnea,</emphasis> noninfectious pneumonitis, pulmonary embolism, <emphasis style="bold">pneumonitis</emphasis>, pulmonary alveolar proteinosis</para>
					</section>
					<section type="none" id="sidelem4x12926">
						<sec_title>HEMA:</sec_title>
						<para>
							<emphasis alert="lifethreat">Hemorrhage</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12932">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; peak 1-2 hr; protein binding 74%; extensively metabolized by CYP3A4 enzyme system; half-life 30 hr; reduced by high-fat meal; excreted in feces (80%), urine (5%)</para>
			</section>
			<section type="interactions" id="sidelem4x12937">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> nephrotoxicity—immunosuppressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Everolimus effect—CYP3A4 inhibitors (strong, moderate), antifungals, calcium channel blockers, cimetidine, danazol, erythromycin, cycloSPORINE, HIV-protease inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Decrease: everolimus effect—CYP3A4 inducers, carBAMazepine, PHENobarbital, phenytoin, rifamycin, rifapentine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of live vaccines</para>
				<section type="none" id="sidelem4x12956">
					<section type="none" id="sidelem4x12957">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x12961">
								<item>
									<label>•</label>
									<para>St. John’s wort: may decrease effect of everolimus</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12967">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x12971">
								<item>
									<label>•</label>
									<para>Alters bioavailability; use consistently with/without food; do not use with grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12977">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> bilirubin, calcium, cholesterol, glucose, potassium, lipids, phosphate, triglycerides, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, glucose, potassium, magnesium, phosphate</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12988">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12991">
					<section type="none" id="sidelem4x12992">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x13000">
							<para>
								<list id="lidelem4x13000">
									<item>
										<label>•</label>
										<para>Lipid profile: cholesterol, triglycerides, lipid-lowering agent may be needed; blood glucose
<bbw>
												<emphasis alert="lifethreat">Immunosuppression:</emphasis> CBC with differential during treatment monthly; if leukocytes &lt;3000/mm3 or platelets &lt;100,000/mm3, product should be discontinued or reduced; decreased hemoglobulin level may indicate bone marrow suppression</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13022">
							<para>
								<list id="lidelem4x13022">
									<item>
										<label>•</label>
										<para>Hepatic/renal studies: AST, ALT, amylase, bilirubin, creatinine, phosphate, and for hepatotoxicity: dark urine, jaundice, itching, light-colored stools; product should be discontinued
<bbw>
												<emphasis alert="lifethreat">Infection:</emphasis> bacterial fungal infections can occur and are more common with combination immunosuppression therapy</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13038">
							<label>•</label>
							<sec_title>Renal artery/vein thrombosis (Zortress)</sec_title>
							<para>
								<list id="lidelem4x13038">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal artery/vein thrombosis (Zortress):</emphasis> May result in graft loss within 30 days after transplantation</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13042">
								<item>
									<label>•</label>
									<para>Obtain everolimus blood levels in kidney transplant, hepatic disease, CYP3A4 inducers, inhibitors</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13047">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13051">
								<item>
									<label>•</label>
									<para>Therapeutic response</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13057">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>To report fever, rash, severe diarrhea, chills, sore throat, fatigue; serious infections may occur; to report clay-colored stools, cramping (hepatotoxicity)</bbw>
						</para>
						<para>
							<bbw>To avoid crowds, persons with known infections to reduce risk for infection</bbw>
						</para>
						<section type="none" id="sidelem4x13084">
							<label>•</label>
							<sec_title>Pregnancy<route> to notify prescriber if pregnancy is planned or suspected, pregnancy (D)</route></sec_title>
						</section>
						<section type="none" id="sidelem4x13090">
							<label>•</label>
							<sec_title>
								<route>To use contraception before, during, and 12 wk after product discontinued; to avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13093">
								<item>
									<label>•</label>
									<para>Not to use with grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13098">
								<item>
									<label>•</label>
									<para>To avoid live vaccines; that frequent lab tests are required</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13103">
								<item>
									<label>•</label>
									<para>That product may decrease male, female fertility</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13108">
								<item>
									<label>•</label>
									<para>That drinking alcohol is not recommended</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13113">
								<item>
									<label>•</label>
									<para>To take consistently with or without food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13118">
								<item>
									<label>•</label>
									<para>To report vision changes, weight gain, edema, shortness of breath, impaired wound healing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="60" status="active">
			<mono_name>exemestane (Rx)</mono_name>
			<info>
				<pronunciation>(ex-em′eh-stane)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x131280">Aromasin</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Aromatase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13138">
				<para>
					<confusion>
						<tradename id="tnidelem4x131380">exemestane</tradename>
						<drug type="generic" refid="idelem4x131380">ezetimibe/estramustine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13142">
				<sec_title>Action:</sec_title>
				<para>Lowers serum estradiol concentrations by irreversibly inhibiting aromatase; many breast cancers have strong estrogen receptors</para>
			</section>
			<section type="uses" id="sidelem4x13149">
				<sec_title>Uses:</sec_title>
				<para>Advanced breast carcinoma not responsive to other therapy (postmenopausal), estrogen receptor–positive early breast cancer that has received tamoxifen</para>
			</section>
			<section type="contra" id="sidelem4x13154">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, premenopausal women, hypersensitivity</para>
				<section type="none" id="sidelem4x13159">
					<section type="none" id="sidelem4x13160">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, renal/hepatic disease, osteoporosis, vit D deficiency, hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13165">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13173">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13173">
							<item>
								<label>•</label>
								<para> 25 mg/day after meals; may need 50 mg/day if taken with a potent CYP3A4 inducer</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13177">
					<section type="none" id="sidelem4x13178">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25 mg</para>
					</section>
					<section type="none" id="sidelem4x13183">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13187">
								<item>
									<label>•</label>
									<para>After meals at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13198">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13201">
					<section type="none" id="sidelem4x13202">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, depression, insomnia, anxiety, fatigue, hot flashes, diaphoresis,</emphasis> dizziness, neuropathy</para>
					</section>
					<section type="none" id="sidelem4x13210">
						<sec_title>CV:</sec_title>
						<para> Hypertension, edema, <emphasis style="bold">thromboembolism</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13217">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, constipation, abdominal pain, increased appetite</para>
					</section>
					<section type="none" id="sidelem4x13225">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="italic">Lymphopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13232">
						<sec_title>MS:</sec_title>
						<para> Fracture, bone loss, arthralgia, osteoporosis</para>
					</section>
					<section type="none" id="sidelem4x13237">
						<sec_title>RESP:</sec_title>
						<para> Cough, <emphasis style="italic">dyspnea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13244">
						<sec_title>INTEG: </sec_title>
						<para>Alopecia, hot flashes, sweating</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13249">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 24 hr; excreted in feces, urine</para>
			</section>
			<section type="interactions" id="sidelem4x13254">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> exemestane action—CYP3A4 inducers, estrogens</para>
				<section type="none" id="sidelem4x13261">
					<section type="none" id="sidelem4x13262">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, alk phos, bilirubin, creatinine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13269">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13272">
					<section type="none" id="sidelem4x13273">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13277">
								<item>
									<label>•</label>
									<para>B/P; hypertension may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Bone mineral density, x-ray of thoracic or lumbar spine if bone changes suspected</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13288">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13292">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13298">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x13306">
							<label>•</label>
							<sec_title>
								<route>to immediately report chest pain</route>
							</sec_title>
							<para>
								<list id="lidelem4x13306">
									<item>
										<label>•</label>
										<para>To report any complaints, side effects to prescriber, </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13310">
								<item>
									<label>•</label>
									<para>That hot flashes are reversible after discontinuing treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13318">
							<label>•</label>
							<sec_title>
								<route>To use reliable contraception (pregnancy [X]); not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13321">
								<item>
									<label>•</label>
									<para>That vit D, calcium may be used for bone loss</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="61" status="active" ha="yes">
			<mono_name>exenatide (Rx)</mono_name>
			<info>
				<pronunciation>(ex-en′a-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x133331">Bydureon</tradename>
					<tradename id="tnidelem4x133330">Byetta</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Incretin mimetic</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13343">
				<sec_title>Action:</sec_title>
				<para>Binds and activates known human GLP-1 receptor, mimics natural physiology for self-regulating glycemic control</para>
			</section>
			<section type="uses" id="sidelem4x13348">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus given in combination with metFORMIN, a sulfonylurea, thiazolidinedione, insulin glargine; once-weekly dosing</para>
			</section>
			<section type="contra" id="sidelem4x13353">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (men-2), thyroid cancer</bbw>
				</para>
				<section type="none" id="sidelem4x13368">
					<section type="none" id="sidelem4x13369">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, severe renal/hepatic/GI disease, pancreatitis, vit D deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13374">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13382">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x13382">
							<item>
								<label>•</label>
								<para> 5 mcg bid 1 hr before morning and evening meal; may increase to 10 mcg bid after 1 mo of therapy; ext rel SUBCUT (Bydureon) 2 mg q7days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13386">
					<section type="none" id="sidelem4x13387">
						<sec_title>Available forms:</sec_title>
						<para> Inj 5, 10 mcg pen; ext rel powder for susp for inj 2 mg</para>
					</section>
					<section type="none" id="sidelem4x13393">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13397">
								<item>
									<label>•</label>
									<para>Store in refrigerator for unopened pen; may store at room temperature after opening for up to 30 days</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13403">
							<sec_title>SUBCUT route (regular release—Byetta)</sec_title>
							<para>
								<list id="lidelem4x13408">
									<item>
										<label>•</label>
										<para>May be used as monotherapy or combined with other products</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x13416">
								<label>•</label>
								<sec_title>
									<route>SUBCUT only, do not give IV/IM</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x13419">
									<item>
										<label>•</label>
										<para>Pen needles must be purchased separately, compatible; prime before use; inject into thigh, abdomen, upper arm; rotate sites</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13424">
									<item>
										<label>•</label>
										<para>Product 1 hr before meals, approximately 6 hr apart; if patient is NPO, may need to hold dose to prevent hypoglycemia</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x13429">
									<item>
										<label>•</label>
										<para>If added to insulin glargine, insulin, or detemir, a dosage reduction in these products may be required</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13434">
							<sec_title>SUBCUT route (ext rel—Bydureon)</sec_title>
							<para>
								<list id="lidelem4x13438">
									<item>
										<label>•</label>
										<para>Give every 7 days (weekly); the dose can be given at any time of day without regard to meals</para>
									</item>
									<item>
										<label>•</label>
										<para>Available as a single-dose tray containing a vial of 2 mg, a pre-filled syringe delivering 0.65 ml diluent, a vial connector, and two custom needles (23GX 5/16′) specific to this delivery system (one is a spare needle); do not substitute needles or any other components</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject immediately after the white to off-white powder is suspended in the diluent and transferred to the syringe</para>
									</item>
									<item>
										<label>•</label>
										<para>Inject subcut into the thigh, abdomen, or upper arm, rotate sites to prevent lipodystrophy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13459">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13462">
					<section type="none" id="sidelem4x13463">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Headache, dizziness,</emphasis> feeling jittery, restlessness, weakness</para>
					</section>
					<section type="none" id="sidelem4x13471">
						<sec_title>ENDO:</sec_title>
						<para> <emphasis style="bold">Hypoglycemia,</emphasis> thyroid hyperplasia</para>
					</section>
					<section type="none" id="sidelem4x13479">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, dyspepsia, anorexia, gastroesophageal reflux, weight loss, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13486">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13493">
						<sec_title>INTEG: </sec_title>
						<para>Serious inj-site reactions (cellulitis, abscess, skin necrosis)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13498">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Immediate release: Peak 2.1 hr, elimination by glomerular filtration</para>
				<para>Ext Rel: Peak 2 wk</para>
			</section>
			<section type="interactions" id="sidelem4x13505">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x13510">
						<item>
							<label>•</label>
							<para>May decrease effect of acetaminophen</para>
						</item>
					</list>
				</para>
				<section type="none" id="sidelem4x13518">
					<label>•</label>
					<sec_title>
						<route>Do not use with erythromycin, metoclopramide</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—ACE inhibitors, disopyramide, sulfonylureas, androgens, fibric acid derivatives, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—phenothiazines, corticosteroids, anabolic steroids</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of digoxin, lovastatin, acetaminophen (elixir)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> efficacy—niacin, dextrothyroxine, thiazide diuretics, triamterene, estrogens, progestins, oral contraceptives, MAOIs</para>
			</section>
			<section type="considerations" id="sidelem4x13537">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13540">
					<section type="none" id="sidelem4x13541">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13546">
								<item>
									<label>•</label>
									<para>Fasting blood glucose, A1c levels, postprandial glucose during treatment to determine diabetes control</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13554">
							<label>•</label>
							<sec_title>Pancreatitis<route> severe abdominal pain, with or without vomiting, product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x13560">
							<label>•</label>
							<sec_title>Anaphylaxis, Angioedema<route> product should be discontinued immediately</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x13563">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13568">
								<item>
									<label>•</label>
									<para>Hypo/hyperglycemic reaction that can occur soon after meals; for severe hypoglycemia, give IV D<emphasis style="inf">50</emphasis>W, then IV dextrose solution</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13576">
								<item>
									<label>•</label>
									<para>Nausea, vomiting, diarrhea, ability to tolerate product, may cause dehydration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13581">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13585">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia, clear sensorium, improving A1c, weight; absence of dizziness, stable gait</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13591">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13596">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia, what to do about each; to have glucagon emergency kit available; to carry a glucose source (candy, sugar cube) to treat hypoglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13602">
								<item>
									<label>•</label>
									<para>That product must be continued on a daily or weekly basis (ext rel); about consequences of discontinuing product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13607">
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; product will not cure disease; to carry emergency ID with prescriber and medication information</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13612">
								<item>
									<label>•</label>
									<para>To continue weight control, dietary restrictions, exercise, hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13617">
								<item>
									<label>•</label>
									<para>That regular blood glucose monitoring and A1c testing is needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13622">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant or intending to become pregnant (C)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13627">
								<item>
									<label>•</label>
									<para>About the importance of reading “Information for the Patient” and “Pen User Manual;” about self-injection</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13635">
							<label>•</label>
							<sec_title>Pancreatitis<route> If severe abdominal pain with or without vomiting occurs seek medical attention immediately</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x13638">
								<item>
									<label>•</label>
									<para>To review injection procedure; to store product in refrigerator, room temperature after first use; discard 30 days after first use; do not freeze; protect from light (Byetta)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="62" status="active">
			<mono_name>ezetimibe (Rx)</mono_name>
			<info>
				<pronunciation>(ehz-eh-tim′bee)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x136481">
						<country code="CAN">Ezetrol </country>
					</tradename>
					<tradename id="tnidelem4x136480">Zetia</tradename>
				</tradenames>
				<class type="func"> Antilipemic; cholesterol absorption inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x13657">
				<sec_title>Action:</sec_title>
				<para>Inhibits absorption of cholesterol by the small intestine, causes reduced hepatic cholesterol stores</para>
			</section>
			<section type="uses" id="sidelem4x13662">
				<sec_title>Uses:</sec_title>
				<para>Hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous sitosterolemia</para>
			</section>
			<section type="contra" id="sidelem4x13667">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe hepatic disease</para>
				<section type="none" id="sidelem4x13672">
					<section type="none" id="sidelem4x13673">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13678">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13686">
					<label>•</label>
					<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13686">
							<item>
								<label>•</label>
								<para> 10 mg/day; may be given with HMG-CoA reductase inhibitor at same time; may be given with bile acid sequestrant; give ezetimibe 2 hr before or 4 hr after bile acid sequestrant</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13690">
					<section type="none" id="sidelem4x13691">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg</para>
					</section>
					<section type="none" id="sidelem4x13696">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13700">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13706">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13709">
					<section type="none" id="sidelem4x13710">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x13715">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x13720">
						<sec_title>MISC:</sec_title>
						<para> Chest pain</para>
					</section>
					<section type="none" id="sidelem4x13725">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Myalgias, arthralgias,</emphasis> back pain, <emphasis style="bold">myopathy, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13735">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, sinusitis, cough, <emphasis style="italic">URI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13742">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis, nasopharyngitis</para>
					</section>
					<section type="none" id="sidelem4x13747">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13754">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in small intestine, liver; excreted in feces 78%, urine 11%; peak 4-12 hr; half-life 22 hr</para>
			</section>
			<section type="interactions" id="sidelem4x13759">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of ezetimibe—fibric acid derivatives, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of ezetimibe—antacids, bile acid sequestrants</para>
				<section type="none" id="sidelem4x13770">
					<section type="none" id="sidelem4x13771">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13778">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13781">
					<section type="none" id="sidelem4x13782">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x13790">
							<label>•</label>
							<sec_title>Hypercholestrolemia</sec_title>
							<para>
								<list id="lidelem4x13790">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypercholestrolemia:</emphasis> diet history: fat content, lipid levels (triglycerides, LDL, HDL, cholesterol); LFTs at baseline, periodically during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13797">
							<label>•</label>
							<sec_title>Myopathy/rhabdomyolysis<route> increased CPK, myalgia, muscle cramps, musculoskeletal pain, lethargy, fatigue, fever; more common when combined with statins</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13800">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13804">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased cholesterol, LDL; increased HDL</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13810">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13815">
								<item>
									<label>•</label>
									<para>That compliance is needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13820">
								<item>
									<label>•</label>
									<para>That risk factors should be decreased: high-fat diet, smoking, alcohol consumption, absence of exercise</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13826">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy suspected, planned, or if breastfeeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13834">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if unexplained weakness, muscle pain present</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x13837">
								<item>
									<label>•</label>
									<para>To notify prescriber of dietary/herbal supplements</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="63" status="active">
			<mono_name>ezogabine</mono_name>
			<info>
				<pronunciation>(e-zog′a-been)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x138470">Potiga</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="schedule">Controlled Substance Schedule <schedule num="5">V</schedule></class>
			</info>
			<section type="actions" id="sidelem4x13856">
				<sec_title>Action:</sec_title>
				<para>The exact mechanism of anticonvulsant effects is not fully known; however, studies indicate that the drug enhances transmembrane potassium currents, which may stabilize the resting membrane potential and reduce brain excitability; may also augment GABA-mediated currents</para>
			</section>
			<section type="uses" id="sidelem4x13861">
				<sec_title>Uses:</sec_title>
				<para>Partial seizures</para>
			</section>
			<section type="contra" id="sidelem4x13866">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x13871">
					<section type="none" id="sidelem4x13872">
						<sec_title>Precautions:</sec_title>
						<para> Suicidal ideation/behavior, prostatic hypertrophy, dementia, psychotic disorders, QT prolongation, congestive heart failure, ventricular hypertrophy, hypokalemia, hypomagnesemia, abrupt discontinuation, renal impairment, hepatic disease, geriatric patients, pregnancy category C, breastfeeding, neonates, infants, children, adolescents</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13877">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13885">
					<label>•</label>
					<sec_title>Adult/geriatric patient ≤65 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13885">
							<item>
								<label>•</label>
								<para> initially, 100 mg tid, increase by ≤50 mg tid per day at weekly intervals depending on response, up to a maintenance dose of 200-400 mg tid depending on response; max is 400 mg tid (1200 mg/day)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13892">
					<label>•</label>
					<sec_title>Geriatric patient &gt;65 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13892">
							<item>
								<label>•</label>
								<para> initially, 50 mg tid, increase by ≤50 mg tid per day at weekly intervals depending on response; max 250 mg tid (750 mg/day)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13896">
					<section type="none" id="sidelem4x13897">
						<sec_title>Available forms:</sec_title>
						<para> Film-coated tabs 50, 200, 300, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x13902">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13906">
								<item>
									<label>•</label>
									<para>Tab should be swallowed whole without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Give in 3 equally divided doses</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13917">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13920">
					<section type="none" id="sidelem4x13921">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, drowsiness, memory impairment, tremor, vertigo, abnormal coordination, disturbance in attention, gait disturbance, aphasia, dysarthria, balance disorder, paresthesias, amnesia, dysphagia, myoclonia, hypokinesia, confusion, anxiety, hallucinations, <emphasis style="bold">suicidal thoughts/behaviors,</emphasis> fatigue, asthenia, malaise, euphoria</para>
					</section>
					<section type="none" id="sidelem4x13929">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, blurred vision, retinal pigment change</para>
					</section>
					<section type="none" id="sidelem4x13934">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, dyspepsia, xerostomia, constipation, weight gain, appetite stimulation</para>
					</section>
					<section type="none" id="sidelem4x13939">
						<sec_title>GU:</sec_title>
						<para> Urinary retention, hydronephrosis, dysuria, urinary hesitation, hematuria, chromaturia</para>
					</section>
					<section type="none" id="sidelem4x13944">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13951">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia, blue skin discoloration</para>
					</section>
					<section type="none" id="sidelem4x13956">
						<sec_title>MISC:</sec_title>
						<para> Influenza, dyspnea, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13963">
						<sec_title>MS:</sec_title>
						<para> Muscle spasms, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13968">
				<sec_title>Pharmacokinetics</sec_title>
				<para>80% protein bound; extensively distributed in the body; extensively metabolized by glucuronidation and acetylation; inactive N-glucuronides are the primary metabolites; elimination half-lives of ezogabine and its N-acetyl metabolite are 7 hr and 11 hr, respectively; 36% excreted renally as exogabine, 18% as NAMR, 24% as the N-glururonides of ezogabine and NAMR, 14% fecal excretion; rapidly absorbed, peak 0.5-2 hr, bioavailability 60%; high-fat food increases peak concentrations; increased in hepatic/renal disease, geriatric patients, young adult females</para>
			</section>
			<section type="interactions" id="sidelem4x13974">
				<sec_title>Interactions:</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase:</emphasis>
					<emphasis alert="lifethreat">QT prolongation—arsenic trioxide, chloroquine, chlorproMAZINE, mesoridazine thioridazine, clarithromycin, Class IA antiarrhythmics (disopyramide, procainamide, quiNIDine), Class III antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol), dextromethorphan, dronedarone, droperidol, erythromycin, grepafloxacin, halofantrine, levomethadyl, methadone, pentamidine, pimozide, posaconazole, probucol, propafenone, quiNIDine, saquinavir, sparfloxacin, terfenadine, troleandomycin, ziprasidone</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of ezogabine—carBAMazepine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> urinary retention—antimuscarinics, amantadine, H1-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—anxiolytics, sedatives, hypnotics, buprenorphine, butorphanol, dronabinol, mirtazapine, nabilone, nalbuphine, opiate agonists, pentazocine, pregabalin, skeletal muscle relaxants, traMADol, traZODone, ethanol</para>
				<section type="none" id="sidelem4x14002">
					<section type="none" id="sidelem4x14003">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14010">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14013">
					<section type="none" id="sidelem4x14014">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14020">
								<item>
									<para>
										<emphasis alert="nurse">Seizures: Assess for type, duration, location, activity, presence of aura</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14026">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: Monitor in those with known QT prolongation, congestive heart failure, ventricular hypertrophy, hypokalemia, hypomagnesemia, and in patients receiving medications known to cause QT prolongation; QT prolongation can occur within 3 hr of dose</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14032">
								<item>
									<para>
										<emphasis alert="nurse">Abrupt withdrawal: Withdraw gradually to minimize increased seizure frequency</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14038">
								<item>
									<para>
										<emphasis alert="nurse">Suicidal thoughts/behaviors: Assess for any unusual changes in moods or behaviors, including emotional lability or emerging or worsening depression and suicidal ideation</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14046">
							<label>•</label>
							<sec_title>Vision changes</sec_title>
							<para>
								<list id="lidelem4x14046">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Vision changes:</emphasis> Obtain a baseline eye exam, then periodic eye exams; discontinue if ophthalmic changes occur, unless no other treatment is available</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14050">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14055">
								<item>
									<label>•</label>
									<para>To avoid driving or operating machinery or performing other tasks that require mental alertness until reaction is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14060">
								<item>
									<label>•</label>
									<para>To avoid concurrent use of alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14065">
								<item>
									<label>•</label>
									<para>To avoid abruptly discontinuing this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14071">
								<item>
									<para>
										<emphasis alert="nurse">Suicidal thought/behaviors: Advise patient to notify prescriber immediately of suicidal thought/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14076">
								<item>
									<label>•</label>
									<para>That skin may turn blue; it is unknown if it is reversible</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14085">
							<label>•</label>
							<sec_title>
								<route>To report vision change immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>